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Neuropeptides in dorsal root ganglia (DRG) have been implicated in the
pathogenesis of pain and neurogenic inflammation in experimental and clinical
arthritis. Sensory neuropeptides are released centrally and peripherally on noxious
stimulation and, recently increased levels of substance P (SP) and calcitonin gene-
related peptide (CGRP), confined to innervating DRG, were demonstrated in
adjuvant-mediated monoarthritis. In these studies, the primary afferent neuronal
response to peripheral inflammation with respect to neuropeptide mRNA
expression, and the role of the primary afferent and its neuropeptides in the spread
of arthritis have been examined.
A mild adjuvant-induced arthritis has been adapted from classical polyarthritis in
the rat. Arthritis is induced by adjuvant injection around one tibio-tarsal joint which
causes either a discrete monoarthritis or, with a larger dose of adjuvant, a
monoarthritis spreading to bilateral arthritis involving both tibio-tarsal joints, which
consistently occurs 14 days after adjuvant injection. This model of arthritis thus
enables study of the arthritic process and mechanisms underlying the spread of
inflammation, while reducing animal discomfort and the confounding effects of
systemic illness seen in polyarthritis.
It has been hypothesised that substance P may act upon the peripheral nociceptor
terminals to sensitise them to other inflammatory mediators, and that other
mediators may act through the release of substance P. Exogenous substance P
administered by close arterial injection had no significant effects on C-fibre
nociceptor activity in either monoarthritic or normal anaesthetised rats. Substance P
may exert an effect upon Ad high threshold mechanoreceptors but these fibres were
not studied here.
Analysis of preprotachykinin (PPT, encoding SP), CGRP and somatostatin (SS)
messenger RNAs showed that expression of all three mRNAs are altered in chronic
monoarthritis only in ganglia innervating the affected joint. PPT and CGRP showed
especially dramatic increases during the first 8 hours of inflammation. Somatostatin
mRNA was the only neuropeptide to show contralateral changes 8 hours after
adjuvant injection; this effect being attributable to the injection itself rather than
inflammation. All three mRNAs were also increased in chronic arthritis. In bilateral
arthritis, ganglionic PPT and CGRP levels were elevated bilaterally whereas SS
mRNA increased in ganglia ipsilateral to the adjuvant injection and not in
v
contralateral DRG. Vasoactive intestinal peptide mRNA was not found in DRG
neurons of normal or inflamed animals at any point
Specific perineural capsaicin lesions of C-fibres innervating the joint demonstrated
that capsaicin-sensitive sensory neurons and their neuropeptides are pivotal to both
the maintenance and the spread of arthritis in this model. This lesion attenuated
adjuvant-induced monoarthritis and totally prevented of spread of arthritis. The
inhibition of spread was associated with a reduction in the expression of PPT
mRNA in remaining neurons in contralateral DRG. Neonatal capsaicin, a less
specific neurotoxic lesion of unmyelinated afferents, had no effect on the severity
of arthritis and only delayed the contralateral spread of arthritis, but attenuated
increases in neuropeptide mRNA during arthritis. The central nervous system
plasticity and alterations in dorsal horn excitability following neonatal capsaicin
may be responsible for the lack of effect of this lesion on arthritis.
The regulation of neuropeptide genes in DRG during inflammation is not well
understood. Blockage of the increase in primary afferent spontaneous activity
known to be observed within hours of the onset of inflammation using local
anaesthetic prevented the increase in PPT and CGRP mRNA seen in DRG 8 hours
after adjuvant injection. While endogenous glucocorticoids have been shown to
regulate neuropeptide levels in DRG, adrenalectomy had no effect on the degree or
spread of arthritis and had only subtle effects on the expression of PPT and CGRP
mRNA.
Expression of transcription factors in DRG on noxious stimulation has not been
demonstrated, and this has been substantiated in these experiments as expression of
NGFI-A, NGFI-B and c-jun was not detectable in DRG innervating inflamed or
uninflamed joints. AP-2 mRNA, encoding a transcription factor constitutively
expressed in tissue of neural crest origin, showed a rapid increase in expression one
hour after injection, returning to control levels within 2 hours. The possible
involvement of AP-2 in the regulation of these neuropeptides remains to be
determined.
In conclusion, these data support the hypothesis that polymodal nociceptors and
the neuropeptides they express are closely associated with the maintenance and
spread of arthritis. Changes in neuropeptide mRNA expression may be regulated






Publications arising from this thesis iv
ABSTRACT v
List of Figures xvi
List of Tables xx
List of commonly used abbreviations xxii
SECTION 1. INTRODUCTION 1
1.1. Adjuvant disease as a model of arthritis:clinical and histological
features 1
1.2. The dorsal root ganglion 2
1.3. Neuropeptide content of DRG neurons 3
1.3.1. Substance P and Neurokinin A 3
1.3.2. Calcitonin gene-related peptide 6
1.3.3. Somatostatin 8
1.3.4. Vasoactive intestinal peptide (VIP) 9
1.4. Function of primary afferent neuropeptides 10
1.4.1. Relationship between physiological function and neurochemical
content 10
1.4.2. Neuropeptide involvement in the transmission of nociceptive
information 11
1.4.2.1. Substance P and CGRP 11
1.4.2.2. Somatostatin 12
1.4.2.3. Vasoactive intestinal peptide 13
1.5. A note on the intrathecal administration of neuropeptides 14
1.6. Peptidergic primary afferents and inflammation 14
1.6.1. Neurogenic inflammation 14
1.6.2. Interactions between neuropeptides and the vascular and immune
systems 15
1.6.3. Primary afferents and arthritis 17
1.6.3.1. Primary afferent neuropeptides in rheumatoid arthritis 18
1.6.4. Neuropeptidergic nerves and synovium 21
vii
1.6.5. Location of neurokinin receptors 23
1.7. Capsaicin 24
1.7.1. Systemic administration of capsaicin 25
1.7.1.1. Neuroanatomical effects of systemic capsaicin administration 25
1.7.1.2. Behavioural effects of systemic capsaicin 26
1.7.1.3. Effect on neurochemical markers 26
1.7.1.4. Effect on physiological responses of primary afferent and
dorsal horn neurons 27
1.7.2. Application of capsaicin to peripheral nerves 28
1.7.2.1. Neuroanatomical consequences of perineural capsaicin 28
1.7.2.2. Neurochemical consequences of perineural capsaicin 29
1.7.2.3. Physiological consequences of perineural capsaicin ; 29
1.8. Nerve growth factor 30
1.8.1. Nerve growth factonrole in the prenatal period 30
1.8.2. Role of NGF in the adult animal 31
1.8.3. The significance of NGF in adjuvant arthritis and the expression
of primary afferent neuropeptides 33
1.9. In situ hybridisation 33
1.10. Aims of the thesis 34
SECTION 2. MATERIALS AND METHODS 36
2.1. Induction of arthritis 36
2.1.1. Preparation of adjuvant 36
2.1 . Induction of arthritis 36
2.2. Assessment of inflammation 37
2.2.1. Overt indices of inflammation 37
2.2.2. Histological methods 37
2.2.3. Statistical analysis of data 38
2.3. Neuropharmacology of fine articular afferents 38
2.3.1. In vivo rat preparation 38
2.3.1.1. General preparation 38
2.3.1.2. Identification of articular innervation 39
2.3.2. Recording primary afferent activity 40
2.3.3. Unit identification and stimulation of the receptive field 40
2.3.4. Drug administration 41
2.3.5. Off-line analysis of primary afferent activity 42
viii
2.3.6. Statistical analysis of data 43
2.4. Neurotoxic lesions 43
2.4.1. Perineural capsaicin lesions 43
2.4.2. Neonatal capsaicin lesions 44
2.5. Surgical procedures 44
2.5.1. Adrenalectomy 44
2.6. In situ hybridisation 45
2.6.1. Preparation of solutions 45
2.6.1.1. Solutions for isolation of plasmids and cDNAs 45
2.6.1.2. Solutions for in situ hybridisation 46
2.6.1.3. Gel preparation 46
2.6.2. Preparation of tissue 46
2.6.3. Preparation of slides 47
2.6.4. Preparation of radiolabelled probes 48
2.6.4.1. Preparation of plasmid vectors 48
2.6.4.2 Purification of circular DNA using ethidium bromide-caesium
chloride gradients 50
2.6.4.3. Template DNA 50
2.6.4.4. In vitro transcription of complementary riboprobes 50
2.6.4.5. Verification of probe labelling 51
2.6.5. In situ hybridisation 52
2.6.5.1. Hybridisation and washing 52
2.6.5.2. Positive controls 53
2.6.6. Quantification of mRNA expression 54
f
2.6.7. Calculation of in situ hybridisation results as a percentage of
untreated control expression 55
2.6.8. Statistical analysis of in situ hybridisation data 56
2.7. Subcloning of JUN family cDNA fragments 56
2.7.1. Selection of appropriate cDNA restriction fragments 57
2.7.2. Subcloning of c-jun and jun-D restriction fragments 57
2.7.4. Specificity of subclones 58
2.7.4.1. Northern analysis 59
2.7.4.1A. Extraction of whole brain mRNA 59
2.7.4.IB. RNA electrophoresis and capillary transfer 59
2.7.4.1C. Radiolabelling of cDNAs 60
2.7.4.1D. RNA hybridisation 60
2.7.4.2. In situ hybridisation 61
ix
2.8. Neuropeptide radioimmunoassay 61
2.8.1. Sample preparation 61
2.8.2. Radioimmunoassay 62
2.9. Assessment of chronic stress in arthritis 63
2.9.1. Corticosterone radioimmunoassay 63
2.9.1.1. Preparation of samples 63
2.9.1.2. Corticosterone radioimmunoassay 64
2.9.2. Corticosterone binding globulin assay 64
2.10. Immunohistochemistry 65
2.10.1. Section preparation and solutions 65
2.10.2. Immunohistochemistry method 65
SECTION 3 EVALUATION OF A MODIFIED MODEL OF
ADJUVANT MEDIATED ARTHRITIS IN THE RAT 67
3.1. INTRODUCTION 67
3.1.1. Classical adjuvant-induced polyarthritis in the rat 67
3.1.2. Other models of arthritis.. 68
3.1.3. The arthritic rat as a model of chronic stress 69
3.2 MATERIALS AND METHODS 70
3.2.1. Dose dependency of adjuvant-induced arthritis 70
3.2.2. Measures of chronic stress 71
3.2.3. Statistical procedures 72
3.3. RESULTS 72
3.3.1. Behaviour of animals injected with Mycobacterium tuberculosis.
or vehicle 72
3.3.2. Gross parameters of inflammation 73
3.3.3. Histological features of adjuvant-induced inflammation 76
3.3.4. Relationship between gross parameters and histological features
of inflammation 82
3.3.5. Parameters of chronic stress 83
3.4. DISCUSSION 84
3.4.1. Models of inflammatory arthritis 85
3.4.2. The validity of monoarthritic models 86
3.4.3. The use of gross measurements of inflammation in the
assessment of arthritis 87
3.4.4. The arthritic rat as a model of chronic stress 88
x
3.5. SUMMARY 90
SECTION 4. SUBSTANCE P AND ITS ACTIONS ON
CHEMOSENSITIVE PRIMARY SENSORY FIBRES WITH
ARTICULAR RECEPTORS IN NORMAL AND ARTHRITIC RATS 91
4.1. INTRODUCTION 91
4.1.1. Effects of inflammatory mediators on primary afferent
nociceptors 91
4.1.2. Aims of the study 92
4.2. MATERIALS AND METHODS 92
4.3. RESULTS 93
4.3.1. Effect of close arterial injection of synthetic substance P on
articular nociceptors in normal rats 93
4.3.2. Effect of close arterial injection of substance P on spontaneous
and mechanically evoked activity in arthritic rats 94
4.3.3. Effects on single articular nociceptors 95
4.4. DISCUSSION 97
4.4.1. Effects on single articular afferents and criteria for inclusion in
the analysis 98
4.4.2. The effects of substance P on nociceptive afferents 98
4.5. SUMMARY 100
4.6. CONCLUSION 101
SECTION 5. NEUROPEPTIDE MESSENGER RNA EXPRESSION
IN MALE AND FEMALE RATS WITH MONO- AND BILATERAL
ARTHRITIS 102
5.1. INTRODUCTION 102
5.1.1. Primary afferent neuropeptides in experimental arthritis 102
5.1.2. Male/female differences in adjuvant-induced monoarthritis 103
5.1.3. Aim of the experiments 104
5.2. MATERIALS AND METHODS 105
5.2.1. Neuropeptide mRNA expression in DRG 105




5.3.1. Indices of inflammation during development of monoarthritis 106
5.3.2. Quantification of neuropeptide messenger RNA levels 108
5.3.3. Neuropeptide messenger RNA expression during development of
monoarthritis 110
5.3.4. Effect of paraffin oil injection on neuropeptide mRNA
expression 116
5.3.5. Indices of inflammation during development of bilateral arthritis 117
5.3.6. Neuropeptide messenger RNA expression in bilateral arthritis 118
5.4. DISCUSSION 121
5.4.1. Neuropeptide messenger RNA expression in mono- and bilateral
arthritis 121
5.4.1.1. PPT and CGRP mRNA expression in experimental arthritis 121
5.4.1.2. Numbers of cells expressing PPT and CGRP mRNA 124
5.4.1.3. Somatostatin mRNA changes in mono- and bilateral arthritis 125
5.4.1.4. Vasoactive intestinal peptide in experimental arthritis 127
5.4.2. Male/ female differences in adjuvant-induced monoarthritis 128
5.4.3. Expression of in situ hybridisation results 130
5.4.4. Human versus computer image analysis of in situ hybridisation
silver grain numbers 130
5.5. CONCLUSIONS 133
SECTION 6 THE ROLE OF CAPSAICIN-SENSITIVE PRIMARY
AFFERENTS AND NEUROPEPTIDE mRNA EXPRESSION IN THE
SPREAD OF EXPERIMENTAL ARTHRITIS 134
6.1. INTRODUCTION 134
6.1.1. The peripheral sensory nervous system in articular inflammation 134
6.1.2. The effects of capsaicin on neuropeptides 135
6.1.3. The sympathetic nervous system in inflammation 136
6.1.4. Aims of the studies 137
6.2. MATERIALS AND METHODS 138
6.2.1. Neonatal capsaicin treatment 138
6.2.2. Perineural capsaicin treatment 138
6.2.3. Monitoring of progress of arthritis 139
6.2.4. Efficacy of the perineural capsaicin treatments 139
6.2.5. Expression of in situ hybridisation data 139
6.3. RESULTS 140
xii
6.3.1. Neonatal capsaicin treatment 140
6.3.1.1. Effect of capsaicin on the development of arthritis 140
6.3.1.2. Neuropeptide mRNA expression in monoarthritic rats 144
6.3.1.3. Expression of neuropeptide mRNAs in bilaterally arthritic rats 145
6.3.1.4. Substance P immunoreactivity in DRG from capsaicin-treated
animals 147
6.3.2. Perineural capsaicin treatment 149
6.3.2.1. Efficacy of perineural capsaicin lesions 149
6.3.2.2. Effect of perineural capsaicin on animal behaviour 150
6.3.2.3. Effect of perineural capsaicin on left and right joint inflammation 151
6.3.2.3A. Capsaicin application to the left sciatic nerve (CAPL) 152
6.3.2.3B. Capsaicin application to the right sciatic nerve (CAPR) 153
6.3.2.4. Effect of perineural capsaicin on neuropeptide mRNA
expression 154
6.3.2.4A. Animals with CAPL and arthritis 154
6.3.2.4B. Animals with CAPR and arthritis 154
6.4. DISCUSSION 157
6.4.1. Neonatal capsaicin 157
6.4.1.1. Effects of neonatal capsaicin on the development of related
structures 158
6.4.1.2. Primary afferent neuropeptides following neonatal capsaicin
administration: role in adjuvant arthritis 159
6.4.2. Perineural capsaicin 162
6.4.2.1. Effects of capsaicin treatment of the left sciatic nerve (CAPL) 163
6.4.2.2. Effect of capsaicin treatment of the right sciatic nerve (CAPR) 164
6.4.2.3. Neuropeptide mRNA changes in DRG contralateral to the
capsaicin application 165
6.5. CONCLUSIONS 168
SECTION 7. IN VIVO REGULATION OF NEUROPEPTIDE mRNA
EXPRESSION 169
7.1. INTRODUCTION 169
7.1.1. Regulation of sensory neuropeptides by glucocorticoids 169
7.1.2. Nerve growth factor 171
7.1.3. Regulation of neuropeptide gene expression by other
mechanisms 171
xiii
7.1.4. Aims of the study 172
7.2. MATERIALS AND METHODS 172
7.2.1. Adrenalectomy and induction of arthritis 172
7.2.2. Blockage of action potential conduction 173
7.3. RESULTS 173
7.3.1. Assessment of inflammation 173
7.3.1.1. Effect of adrenalectomy on indices of joint swelling and
inflammation 173
7.3.2. Neuropeptide mRNA expression 176
7.3.2.1. Effect of adrenalectomy on neuropeptide mRNA expression 176
7.3.2.2. Effect of local anaesthetic nerve block on neuropeptide mRNA
expression 180
7.4. DISCUSSION 182
7.4.1. Effect of adrenalectomy on signs of inflammation 182
7.4.2. Effect of adrenalectomy on neuropeptide mRNA expression 183
7.4.3. The influence of neural activity on neuropeptide mRNA
expression 184
7.5. SUMMARY 185
SECTION 8. THE POSSIBLE ROLE OF TRANSCRIPTION
FACTORS IN THE REGULATION OF NEUROPEPTIDE mRNA
EXPRESSION DURING INFLAMMATION 186
8.1. INTRODUCTION 186
8.1.1. Immediate early genes 186
8.1.2. The AP-1 complex 187
8.1.3. Other nerve growth factor inducible transcription factors 188
8.1.4. Activator protein-2 (AP-2) 188
8.1.5. Transcription factors and neuropeptide genes 188
8.1.6. Aim of the experiments 189
8.2. MATERIALS AND METHODS 189
8.3. RESULTS 190
8.3.1. Specificity of the c-jun probe 190
8.3.2. Expression of transcription factors in positive control sections 192
8.3.3. Expression of NGFI-A, -B and c-jun in DRG neurons 192
8.3.4. Expression of AP-2 in DG neurons 192
8.4. DISCUSSION 199
xiv
8.4.1. Expression of c-jun 199
8.4.2. Expression of NGF-induced transcription factors on noxious
stimulation 200
8.4.3. AP-2 mRNA expression 202
SECTION 9. DISCUSSION 203
9.1. The immune system and adjuvant-induced arthritis 203
9.2. Contralateral spread of arthritis 204
9.3. The role of primary afferent neuropeptides 205
9.4. The central nervous system 207
9.5. The relevance of the observations to arthritis 208




APPENDIX 1. PUBLICATIONS 245
xv
List Qf figures
Figure 1.1. Amino acid sequences of three members of the tachykinin
family 3
Figure 1.2. Primary structure and alternative splicing of the
preprotachykinin-A gene 5
Figure 1.3. Amino acid sequence of rat a- and B-CGRP, and post-
transcriptional splicing of the calcitonin gene 7
Figure 1.4 Amino acid sequence of somatostatin-14 8
Figure 1.5 Amino acid sequence of rat vasoactive intestinal peptide 9
Figure 1.6. The structure of capsaicin 24
Figure 3.1. Mean body weights of adjuvant injected rats 73
Figure 3.2. Mean left joint circumferences during the development of
arthritis 74
Figure 3.3. Mean left and right joint circumferences in rats 69 days
after injection of 150)ig p. M. Tub 75
Figure 3.4. Mean right joint circumferences of rats 76
Figure 3.5. Histological appearance of subdermal infiltrate from an
animal injected with 50|ig M.tub 77
Figure 3.6. Photomicrographs showing the left and right tibio-tarsal
joints from a rat injected around the left tibio-tarsal joint
with \50[ig M.tub 78
Figure 3.7. Photomicrographs of left and right tibio-tarsal joints from a
rat injected around the left tibio-tarsal joint with 250pg
M.tub., 79
Figure 3.8. Photomicrographs showing some features of adjuvant-
induced arthritis 80
Figure 3.9. Photomicrographs of left and right tibio-tarsal joints 70
days after injection of 150pg M.tub 81
Figure 3.10. Morning and evening plasma corticosterone levels in
mono- and bilaterally arthritic rats during the development
of inflammation 84
Figure 4.1. Mechanically evoked responses of articular nociceptors in
normal rats 94
xvi
Figure 4.2. Normalised spontaneous activity of articular nociceptors in
normal rats 95
Figure 4.3. Mechanically evoked responses in arthritic rats 96
Figure 4.4. Effect of i.a. injection of substance P on spontaneous
activity in articular nociceptors in arthritic rats 96
Figure 4.5. Activity in a single nociceptor from an arthritic rat 97
Figure 5.1 Increase in left and right joints circumferences in
monoarthritic male and female rats during the development
of monoarthritis 107
Figure 5.2. Linear regression curves for eye against computerised
silver grain counts 109
Figure 5.3. PPT mRNA expression during development of
monoarthritis 111
Figure 5.4. Neuropeptide mRNA expression in DRG of monoarthritic
female rats 112
Figure 5.5. CGRP mRNA expression in DRG of monoarthritic rats 113
Figure 5.6. Dark field photomicrographs showing PPT mRNA
and CGRP mRNA expressing neurons 8h after injection 114
Figure 5.7. Dark field photomicrographs showing PPT mRNA (top)
and CGRP mRNA expressing neurons 14d after injection 115
Figure 5.8. Somatostatin mRNA expression in DRG of monoarthritic
rats 116
Figure 5.9. Increase in left and right ankle joint circumferences during
development of bilateral arthritis in male rats 118
Figure 5.10. Neuropeptide mRNA expression in DRG of bilaterally
arthritic rats 119
Figure 5.11. Light field photomicrograph showing VIP mRNA
expression in control section through the suprachiasmatic
nucleus 120
Figure 5.12. Dark field photomicrograph showing neurons expressing
PPT mRNA 132
Figure 6.1. Mean body weight of monoarthritic rats treated neonatally
with either capsaicin or vehicle 140
Figure 6.2. Increase in weight during development of arthritis in
capsaicin and vehicle treated bilaterally arthritic rats 141
xvii
Figure 6.3. Increase in left and right joint circumferences in
monoarthritic rats treated neonatally with either
capsaicin or vehicle 142
Figure 6.4. Increase in left and right joint circumferences in bilaterally
arthritic rats treated neonatally with either capsaicin or
vehicle 143
Figure 6.5. Expression of PPT, CGRP and somatostatin in left DRG
from control animals , and animals treated neonatally with
either capsaicin or vehicle 145
Figure 6.6. Neuropeptide mRNA expression in DRG from rats treated
neonatally with either capsaicin or vehicle 147
Figure 6.7. Light field photomicrographs of DRG neurons expressing
substance P-like immunoreactivity 148
Figure 6.8. Increase in weight of bilaterally arthritic, CAPL, CAPR and
arthritic rats following sciatic nerve exposure during
development of arthritis 150
Figure 6.9. Increase in left joint circumferences in bilaterally arthritic
and sciatic nerve exposed, CAPL and CAPR rats 151
Figure 6.10. Increase in right joint circumferences in bilaterally arthritic
and sciatic nerve exposed, CAPL and CAPR rats 152
Figure 6.11. Neuropeptide mRNA expression in DRG of bilaterally
arthritic, CAPL and CAPR animals 15 days after injection
of adjuvant 155
Figure 6.12. Dark field photomicrographs of PPT mRNA in L5 DRG 156
Figure 7.1. Left and right joint circumferences from ADX and sham
operated rats during the development of monoarthritis 174
Figure 7.2. Weight gain during development of monoarthritis in ADX
and sham operated rats 174
Figure 7.3. Increase in left and right joint circumferences in bilaterally
arthritic ADX and sham operated rats 175
Figure 7.4. Mean increase in body weight of bilaterally arthritic ADX
and sham operated rats during development of arthritis 176
Figure 7.5. Somatostatin mRNA expression in DRG from ADX or
sham operated bilaterally arthritic rats 177
Figure 7.6A PPT mRNA expression in monoarthritic ADX and sham
operated rats 178
xviii
Figure 7.6B PPT mRNA expression in bilaterally arthritic ADX and
sham operated rats 178
Figure 7.7A. CGRP mRNA expression in DRG from monoarthritic ADX
or sham operated rats 179
Figure 7.7B. CGRP mRNA expression in DRG from bilaterally arthritic
ADX or sham operated rats 180
Figure 7.8. Effect of lidocaine nerve block on expression of PPT,
CGRP and somatostatin mRNAs 182
Figure 8.1. Northern blot of whole rat brain mRNA 190
Figure 8.2. Autoradiographs of coronal rat brain sections through
anterior hippocampus 191
Figure 8.3. Basal expression of NGFI-A mRNA in rat hippocampus 193
Figure 8.4. Basal expression of NGFI-B mRNA in rat hippocampus 194
Figure 8.5. Basal expression of AP-2 mRNA in rat hippocampus 195
Figure 8.6. Expression of AP-2 mRNA during the first eight hours after
adjuvant injection around the left tibio-tarsal joint 196
Figure 8.7. Dark field photomicrographs showing expression of AP2
mRNA in DRG neurons 197
Figure 8.8. Populations of small DRG neurons expressing AP2 mRNA




Table 1.1 Neuro-immune interactions 17
Table 1.2. Substance P- and tachykinin-like immunoreactivity in
synovial fluid of patients with rheumatoid arthritis 19
Table 1.3. Other peptides found in synovial fluid of patients with
rheumatoid arthritis 21
Table 1.4. Half-maximal effective concentrations (EC50) of
tachykinins on receptor subtypes 23
Table 2.1 cDNAs used for in preparation of riboprobes by in vitro
transcription 48
Table 2.2. Restriction enzymes used for plasmid linearisation, RNA
polymerase and riboprobe length for the mRNAs under
study 52
Table 2.3. Restriction fragments and vector cloning sites for jun
family subclones 57
Table 2.4. Antibody cross-reactivity and coefficients of variance for
neuropeptide radioimmunoassay 63
Table 3.1. Histological scores for left and right tibio-tarsal joints 82
Table 3.2 Thymic, adrenal and splenic weights and CBG in arthritic
rats 83
Table 5.1 Inflammation scores in female and male monoarthritic and
bilaterally arthritic rats 108
Table 5.2. Neuropeptide messenger RNA expression in response to
intradermal injection of 0.15ml sterile paraffin oil 117
Table 6.1. Histological scores for capsaicin and vehicle treated
bilaterally arthritic rats 143
Table 6.2. Expression of neuropeptide mRNAs in monoarthritic rats
treated at postnatal day 2 with either capsaicin or vehicle 144
Table 6.3. Expression of PPT, CGRP and somatostatin mRNAs in L5
DRG of bilaterally arthritic rats treated neonatally with
either capsaicin or vehicle 146
Table 6.4. Neuropeptide content of L4/5 DRG in normal and CAPL
animals 149
Table 6.5. Inflammation scores for right and left joints from
bilaterally arthritic, CAPL and CAPR rats 153
xx
Table 6.6. Histological scores of bilaterally arthritic, CAPL and
CAPR animals 153
Table 6.7. Neuropeptide mRNA expression in DRG of bilaterally
arthritic, CAPL and CAPR animals 157
Table 7.1. Neuropeptide mRNA levels in left DRG following
adjuvant injection with and without nerve block with 2%
lidocaine solution 181
xxi
List of commonly used abbreviations
AA adjuvant arthritis





cAMP cyclic adenosine monophosphate
CAPL perineural capsaicin application to the
left sciatic nerve
CAPR capsaicin application to the right
sciatic nerve
CBG corticosterone binding globulin
CGRP calcitonin gene-related peptide
CRE cAMP response element










ISH in situ hybridisation
kg kilogram













PACR primary articulocutaneous ramus







r.p.m. revolutions per minute
s second





VIP vasoactive intestinal (poly)peptide
I, INTRODUCTION
1.1 Adjuvant disease as a model of arthritis: clinical and histological features
Adjuvant arthritis (AA) has been widely used as a model of human disease as the
pathological and biochemical features closely resemble human rheumatoid disease.
AA is thought to be initiated by a delayed hypersensitivity reaction, as overt
pathology does not become apparent until 11-16 days post-injection of adjuvant.
Some evidence that the disease has an immunological basis was presented by
Wakesman et al, (1960), who showed that whole body irradiation prior to adjuvant
injection delayed the appearance of joint swelling. However, these studies did not
exclude the possibility of the involvement of other systems in the pathogenesis of
adjuvant disease. In the classical model, a disease of the whole animal develops
following intradermal injection of a mycobacterial suspension in mineral oil,
resulting in reduced weight gain (Pearson and Wood, 1959; Sarlis et al., 1992;
Colpaert, 1987), reduced mobility (de Castro Costa et al., 1987), increased
vocalisation and irritability (Colpaert et al., 1982) and hyperventilation (Colpaert and
Van den Hoogen, 1983).
Gross lesions in animals with adjuvant disease are oedematous swellings of
multiple joints, particularly the tarsal joints of the hind paws. As the disease
progresses, periarticular swellings develop in the hind limbs and tail adjacent to the
intervertebral discs (Pearson and Wood, 1959). The disease follows a relapsing and
remitting course after the initial two weeks, and may persist for several months,
eventually resulting in chronic joint deformation (Pearson, 1963).
Detailed examination of the histological and histochemical features of AA have
been made by numerous workers (Pearson and Wood, 1959; Jones and Ward, 1963;
Nusbickel and Troyer; 1976; Rainsford, 1982). Microscopic features of arthritis
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appear before the gross manifestations, and progress to a suppurative arthritis and
periarthritis. As AA progresses there are signs of joint destruction, new bone
formation, and fibrous and bony ankyloses. Inflammatory changes are seen in
synovium and synovial spaces, periarticular tissues and bone marrow (Jones and
Ward, 1963). Histochemical changes indicative of chondrocytic hypertrophy,
calcification, and loss of glycosaminoglycans from arthritic cartilage are seen
(Nusbickel and Troyer, 1976). Similarities between AA and rheumatoid disease in
humans have been summarised by Rainsford (1982). In general AA shares many
pathological features with RA, with the exception of the presence of circulating
rheumatoid factor, but differs in the gross skin, genital and vascular lesions seen in
AA but not in RA.
1.2 The dorsal root ganglion
Primary sensory neurons are the first stage in the relay of peripheral sensory
information to the central nervous system. These neurons have a simple anatomical
structure, being pseudounipolar neurons with their somata in dorsal root ganglia,
located either just inside (rat) or outside (human) the vertebral column, peripheral
axons ending in receptor structures, and central processes synapsing in the dorsal
hom of the spinal cord. Primary afferents have been classified by their conduction
velocity, the modality of stimulus to which they respond, morphometric,
ultrastructural and cytochemical criteria (Carr and Nagy, 1993). The cell bodies of
sensory neurons have been divided into two populations on the basis of Nissl
staining, and, more recently neurofilament content, into large light, and small dark
neurons. In general, large, myelinated fibres have large somata and mediate
innocuous stimuli, whereas fine myelinated afferents are either nociceptive or non-
nociceptive and unmyelinated afferents mediate noxious information. However, in
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terms of both sensory modality and neurochemical content, the dorsal root ganglion
represents an extremely heterogeneous population of neurons.
1.3. Neuropeptide content of DRG neurons
A large number of neuropeptides, enzymes and other marker substances have been
localised in DRG, usually restricted to a subpopulation of the total (Carr and Nagy,
1993). The subpopulations of DRG neurons expressing SP and CGRP are discussed
further in Section 5.4.3.3. Due to the large number of different neurochemical
markers found in DRG it is perhaps not surprising that there is a considerable degree
of colocalisation between peptides, enzymes and others.
1.3.1. Substance P and Neurokinin A
Substance P (SP) neurokinin A (NKA) and neurokinin B (NKB) all belong to the
tachykinin family of peptides which share a common C terminus sequence (Figure
Figure 1.1. Amino acid sequences of three members of the tachykinin family.
Common amino acid sequences are in bold.
Substance P and NKA are translated from the same gene, preprotachykinin A, by
alternative RNA splicing and neurokinin B from a second gene, PPT-B. The two








evolved from a common ancestor gene by duplication events (Kotani et al., 1986).
Two further members of the tachykinin family, neuropeptide K and neuropeptide y,
are also encoded by the PPT-A gene. The primary structure, alternative mRNA
splicing of the PPT-A gene and the neuropeptides produced from each mRNA
species was initially determined for the bovine mRNA species and is shown below
in Figure 1.2. Similar structures have been demonstrated in the rat (Carter and
Krause, 1990; Krause et al., 1987; Harmar et al., 1990) where a-PPT levels are
extremely low and y- and (3-PPT comprise 80, and 20% of the mRNA respectively
(Krause et al., 1987)
Thus all the splicing variants of the PPT-A primary transcripts encode substance P,
and y-PPT also encode neurokinin A. Additionally neuropeptides K and y can be
produced through post-translational processing of the relevant RNA species.
Neurokinin B is thought to be the only tachykinin encoded by the PPT-B gene. It
has two transcripts, both very similar and both encoding NKB. It is clear from this
that the tachykinin family achieves a large diversity through gene diversity,
alternative RNA slicing and post-translational processing.
The tachykinins also exhibit tissue specific expression, even to the extent of
expression restricted to subpopulations of DRG neurons (see Section 5); however the
promoter sequences responsible for this have not yet been identified. A construct
containing 3.3kb of 5' promoter sequence plus the first intron from the rat PPT-A
gene directing the expression of the reporter gene beta-galactosidase ((3-GAL)
microinjected into cultured DRG neurons appears to be selective for neuronal
expression of PPT-p-GAL. Unfortunately this region of the gene does not seem to
direct the expression to a specific subset of DRG neurons as seen in vivo, as the
reporter gene marker was observed in neurons which did not show endogenous SP-
like immunoreactivity, in addition to neurons which expressed SP endogenously
(Mulderry et al., 1993a).
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Figure 1.2. Primary structure and alternative splicing of the preprotachykinin-A
gene encoding substance P, neurokinin A, neuropeptides K and y. Open boxes
represent exons as numbered.
PPT-A gene
Primary structure
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Substance P is found in many areas of the central nervous system (Cuello et al.,
1982), in the dorsal horn of the spinal cord and in a subpopulation of DRG neurons
(see Section 5). This consists of 20-25% of the total neuronal number when either
immunoreactivity (Hokfelt et al., 1980; McCarthy and Lawson, 1989) or mRNA is
measured (Henken et al., 1988; Warden and Young, 1988; Henken et al., 1990); the
populations showing PPT mRNA and substance P immunoreactivity being identical
(Henken et al., 1988). Using radioimmunoasssay, while both substance P and
neurokinin A are present in significant amounts in DRG and peripheral nerve,
neurokinin B is either present in low amounts or is undetectable (Moussaoui et al.,
1992 ; Ogawa et al., 1985).
1.3.2. Calcitonin gene-related peptide
Calcitonin gene-related peptide (CGRP), a 37 amino acid peptide (sequence below),
is produced by alternative RNA splicing of the calcitonin gene in neuronal tissues.
This was first described by Amara and colleagues (Amara et al., 1982; Rosenfeld et
al., 1983) in rat nervous tissue and later in human (Nelkin et al., 1984).
Subsequently a second gene encoding a related peptide called p-CGRP, was also
identified in rat (Amara et al., 1985) and human (Steenburgh et al., 1985) and the
peptide products were found to differ from a-CGRP by 1 and 3 amino acids
respectively. The calcitonin gene and production of CGRP by tissue-specific
alternative splicing has been extensively studied. The primary transcript of the
calcitonin gene is spliced in different tissues according to the schematic diagram
below (Figure 1.3), which is adapted from Emeson et al. (1992). The gene encoding
P-CGRP has five exons and only one transcript, (Bennett and Amara, 1992),
however this gene does have a "potential" splice site and a segment similar to the
calcitonin exon, suggesting a possible gene duplication as in the case of the
tachykinin family.
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Figure 1.3. Amino acid sequence of rat a- andJl- CGRP (single amino acid
difference above sequence in bold) and post-transcriptional splicing of the calcitonin
gene. Open andfdled boxes represent exons as numbered: (calcitonin specific exon;
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CGRP is also found in many areas of the central nervous system (Ishida-Yamamoto
and Toyama, 1989) and the spinal cord and DRG of several species including rat and
human where it is found in approximately 50% of neuronal somata by either
immunohistochemistry (Skofitsch and Jacobowitz, 1985a; Gibson et al., 1984) or in
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situ hybridisation (Rethelyi et al., 1989) (see also Section 5). CGRP is known to
coexist with a large number of other peptides and enzymes particularly substance P
(Cameron et al., 1988; Gibbins et al., 1987; Ju et al., 1987; Lee et al., 1985;
Skofitsch and Jacobowitz, 1985b), but also somatostatin, dynorphin,
cholescystokinin, bombesin, galanin and fluoride resistant acid phosphatase (FRAP:
Carr and Nagy, 1993). Colocalised neuropeptides are known to be contained in the
same secretory granules (Merighi et al., 1988) and interact in the dorsal horn
(Wiesenfeld-Hallin et al., 1984; see also below). Some neuropeptide populations are
thought to be discrete e.g. SP and somatostatin, suggesting that these may represent
functionally different populations (see below).
1.3.3. Somatostatin
Somatostatin exists in two forms in mammalian tissues, somatostatin-14 and an
amino-terminally extended form, somatostatin-28 encoded by the same gene (Shen,
1982; Tavianini et al., 1984). The amino acid sequence of somatostatin is depicted
below (Figure 1.4). The rat and human genes are very similar and consist of two
introns, the second encoding somatostatin-14 and -28 (Shen et al., 1982).
Somatostatin exerts its effects through high affinity G-protein coupled receptors
which have been cloned and found in both mouse and human brain (Yamada et al.,
1992).
Figure 1.4 Amino acid sequence ofsomatostatin-14
Met-Ala-Gly-Cvs-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cvs-COOH
L s— s 1
Somatostatin has been detected in 8-10% of DRG neurons (Heppleman et al., 1993;
Henken et al., 1988). It is often stated that somatostatin and SP exist in separate
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populations of DRG neurons (Carr and Nagy, 1993) even though some workers have
found a variable degree of tachykinin and somatostatin colocalisation in neurons
(Cameron et al., 1988; Ju et ah, 1987) and even in the same secretory granules
(Merighi et ah, 1988). Somatostatin has been shown to be expressed in 8-10% of
DRG neurons when localised by either immunohistochemistry or in situ
hybridisation (Henken et ah, 1988; Heppleman et ah, 1993).
1.3.4, Vasoactive intestinal peptide fYIP)
The VIP gene has been cloned from rat, mouse and human (Gozes, 1988; Lamperti
et ah, 1991) and has been shown to give rise to a single precursor transcript encoding
both vasoactive intestinal peptide and peptide histidine isoleucine (PHI) (Nishizawa
et ah, 1985; Lamperti et ah, 1991). There is no evidence to suggest that RNA
splicing produces separate mRNAs encoding these two peptides; therefore
differential tissue distributions of VIP and PHI have been attributed to post-
translational processing (Lamperti et ah, 1991). The gene consists of seven exons,
the fourth encoding PHI and the fifth, VIP (Giladi et al., 1990), giving rise to PHI
which differs from the human peptide by 4 amino acids, and an identical VIP to that
in both human and mouse (Gozes, 1988; Lamperti et ah, 1991).
The amino acid sequence of rat VIP is shown in Figure 1.5
Figure 1.5 Amino acid sequence of rat vasoactive intestinal peptide
His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-
Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-COOH
VIP has also been colocalised with substance P in autonomic nerve fibres in the cat
airway (Dey, 1992). VIP is not usually expressed under normal conditions in
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sensory ganglia (Noguchi et al., 1989; Nielsch and Keen, 1989; Ju et al., 1987), but
is potently induced following nerve injury (Atkinson and Shehab, 1986) by an
increase in VIP mRNA content of the DRG (Nielsch and Keen, 1989), whereas
tachykinins are decreased. It is not known whether VIP expression occurs in
neurons previously expressing other neuropeptides or in a new population, however
some colocalisation of CGRP and VIP after axotomy has been reported (Ju et al.,
1987).
1,4 Function of primary afferent neuropeptides
1.4.1. Relationship between physiological function and neurochemical content
Recently there have been attempts to find a neurochemical marker for functionally
defined groups of afferents, particularly nociceptors. The colocalisation of
neurochemical markers has given rise to the suggestion that these populations of
neurons may each represent a functional subset of primary afferents. Neuropeptide
content and neuronal size studies showed that neuropeptide-containing somata all
belonged to the small ganglion cell population (CGRP was not studied: Kummer and
Heym, 1986). Combined electrophysiological and immunohistochemical studies
have found that while substance P and CGRP are not confined to either C- or A-
fibres, approximately 50% of C-fibres contain substance P, 50% contain CGRP,
whereas somatostatin-immunoreactivity is only found in neurons with axons
conducting in the C-fibre range (Lawson et al., 1993; McCarthy and Lawson, 1989;
McCarthy and Lawson, 1990). Substance P is also found in A-fibres, thought to be
Ad afferents as the conduction velocity of substance P-immunoreactive neurons did
not exceed 10ms~* (McCarthy and Lawson, 1989). Unsurprisingly, due to the range
of size of soma in which CGRP immunoreactivity is found, 50% of all CGRP-
immunoreactive neurons were found to belong to the A-fibre category (Lawson et
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al., 1993). A correlation between neuropeptide expression and functional modality
has, however, proved to be elusive (Leah et al., 1985).
Recent work has suggested that nociceptors may be the only functional modality of
primary afferents which will respond to exogenous nerve growth factor in the adult
animal (Lewin and Mendell, 1993); it remains to be seen whether the expression of
the high affinity nerve growth factor receptor is indeed limited to this population of
neurons (see below).
1.4.2. Neuropeptide involvement in the transmission of nociceptive information
There is now strong evidence that some neuropeptides, particularly substance P, act
as transmitters in the spinal dorsal horn in the transmission of nociceptive
information.
1.4.2.1. Substance P and CGRP
The postulated involvement of substance P in the central transmission of
nociceptive stimuli is based upon behavioural and electrophysiological data.
Intrathecal substance P elicits caudally directed scratching and biting behaviours
which have been taken to be indicative of pain (Hylden and Wilcox, 1981).
Substance P, neurokinin A and CGRP are known to be released in the dorsal horn on
capsaicin application (Zhao et al., 1992; Gamse et al., 1979), in response to
inflammatory mediators (Andreeva and Rang, 1993), by noxious stimuli (Yaksh et
al., 1980; Klein et al., 1990; Morton and Hutchison, 1989) and in acute and chronic
arthritis, (Duggan et al., 1987; Oku et al., 1987b; Duggan et ah, 1988; Morton et al.,
1989; Duggan et al., 1990; Schaible et al., 1990; Garry and Hargreaves, 1992; Collin
et al., 1993). Substance P causes prolonged depolarisation in dorsal horn neurons in
vivo, and has been shown to excite those neurons which respond to noxious
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stimulation (Otsuka and Yoshioka, 1993). Neurokinin A and CGRP also exert direct
excitatory effects on dorsal horn neurons and are increased upon noxious stimulation
and in arthritis (Otsuka and Yoshioka, 1993). Spinal cord nociceptive transmission
in the formalin test is also mediated through release of substance P and can be
blocked by a specific NKi antagonist (Chapman and Dickenson, 1993).
Increases in expression of tachykinins and CGRP also occur in nociceptive second
order projection neurons in the central nervous system during inflammation
(Noguchi and Ruda, 1992; Sluka et al., 1992; Minami et ah, 1989).
Additionally studies using immunoneutralisation ( Louis et ah, 1990; Elliot et ah,
1989; Louis et ah, 1989; Kawamura et ah, 1989; Kuraishi et al., 1988), agonists
(Mjellem-Joly et ah, 1992; Kuraishi et ah, 1991; Hylden and Wilcox, 1981) and
specific antagonists (Chapman and Dickenson, 1993; Yamamoto and Yaksh, 1992;
Murray et ah, 1991; Yamamoto and Yaksh, 1991) have revealed an excitatory role
for tachykinins and CGRP which interact with many other spinal systems such as
excitatory amino acids (Nagy et ah, 1993; Murray et ah, 1991; Smullin et al., 1990)
and prostanoids (Malmberg and Yaksh, 1992) in the spinal processing of nociceptive
information.
L4.2.2. Somatostatin
In the central nervous system, somatostatin is a potent inhibitor of growth hormone
release (Berne and Levy, 1990), inhibits the release of substance P from primary
afferent terminals (Gazelius et ah, 1981) along with other spinal systems such as
opioids (Aimone and Yaksh, 1989) and inhibits the responses of dorsal horn neurons
(Otsuka and Yoshioka, 1993). Somatostatin has been postulated to mediate the
spinal transmission of thermal noxious information as it was found not be released
by other noxious or innocuous stimuli (Morton et ah, 1989). Intrathecal
administration of somatostatin and anti-somatostatin antisera have further supported
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the hypothesis that this neuropeptide is involved in thermal and not mechanical
nociceptive processes (Ohno et al., 1988; Wiesenfeld-Hallin, 1986). However
somatostatin and its stable analogue, sandostatin (Octreotide, Sandoz), have also
been shown to inhibit both phases of the formalin test (Chapman and Dickenson,
1992), whereas somatostatin antiserum also inhibits the second phase (Ohkubo et al.,
1990). The identical actions of the agonists and the antiserum indicate that the role
of somatostatin in nociceptive transmission is not as simple as previously thought.
These studies may well be complicated by the known neurotoxic effects of
somatostatin, and the problems associated with intrathecal drug administration (see
below).
1.4.2.3. Vasoactive intestinal peptide
Vasoactive intestinal peptide is expressed in various nuclei in the central nervous
system, particularly the suprachiasmatic nucleus of the hypothalamus where it may
be involved in the mediation of the light-dark regulation of the circadian pacemaker
(Shinohara et al., 1993). VIP levels are unchanged in the spinal cord of polyarthritic
rats (Chery-Croze et al., 1985), and while there are VIP containing systems in the
lumbar spinal cord, it is probable that these represent the central terminals of primary
afferent nerves from visceral afferents (Anand et al., 1983). As with somatostatin,
the role of VIP in nociceptive processing is unclear, as although it is not normally
expressed in primary afferents, VIP is known to excite dorsal horn neurons when
applied directly to both intact spinal cord and slice preparations (Jeftinija et al.,
1982) and causes analgesia in the tail flick test when used intrathecally (Komisaruk
et al., 1992).
1.5. A note on the intrathecal administration of neuropeptides
A large number of studies have used the behavioural responses following
intrathecal neuropeptides as a measure of their involvement in nociceptive
transmission. It must always be borne in mind that many intrathecally administered
neuropeptides are neurotoxic to motoneurons and therefore behavioural analysis may
be confounded by the impairment of motor activity (Gaumann et al., 1990;
Mollenholt et al., 1990). In the case of somatostatin, sham operations have also been
shown to affect the effectiveness of the drug (Dirkson et al., 1990).
1.6. Peptidergic primary afferents and inflammation
1.6.1 Neurogenic inflammation
Neurogenic inflammation is the term coined to describe the effects of vasodilation
and plasma extravasation seen on antidromic stimulation of sensory nerves, and is
thought to result from the release of active substances from peripheral sensory nerve
terminals. This has been rigorously reviewed recently (Holzer, 1988). The
involvement of the sensory nervous system in inflammatory responses was first
proposed by Lewis in his experiments on the axon reflex (1959). Antidromic
electrical stimulation or application of substances such as mustard oil to the skin,
which directly activates sensory nerves, results in local vasodilatation and
extravasation of plasma. That this effect was directly dependent upon an intact
sensory nervous system was elegantly shown by Jancso et al. (1967), who also
showed that the effect was mediated primarily through capsaicin-sensitive primary
afferents, i.e. unmyelinated polymodal C-fibres. Recently Ad fibres have also been
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shown to mediate neurogenic vasodilation (Janig and Lisney, 1989). Neurogenic
inflammation is only evident two weeks postnatally, which has been postulated to be
due to a delay in development of either the sensory or postganglionic sympathetic
nervous systems (Fitzgerald and Gibson, 1984; Gonzales et al., 1991). Lewis again
suggested that this effect was due to the release of various substances from the
terminals of sensory nerves. This was based on Dale's principle (1935) that the same
mediators should be released from both the central and peripheral terminals of
sensory neurons, and is supported by the finding that 90% of substance P translated
in DRG is transported to the periphery (Harmar and Keen, 1982). There is now
strong evidence for the release of many neuropeptides from primary afferent
neurons, including substance P, CGRP, somatostatin, neurokinin A, VIP and
adenosine triphosphate, by both antidromic stimulation and the action of other
inflammatory mediators such as bradykinin, 5-HT and histamine on nerve terminals
(Holzer, 1988; Geppetti et ah, 1990; Hua and Yaksh, 1993).
1.6.2. Interactions between neuropeptides and the vascular and immune systems
Many neuropeptides, particularly substance P and CGRP, have been shown to
interact in the production of vasodilatation and plasma extravasation. Substance P
and CGRP are both known to be potent vasodilators in their own right (Gazelius et
al., 1981; Brain et al., 1985; Pernow, 1985), and neurokinins A and B also cause
transient vasodilatation in the rat knee joint (Lam and Ferrell, 1993b). While CGRP
does not cause plasma extravasation independently, unlike substance P (Louis et al.,
1989), it can potentiate that caused by substance P in both the skin (Gamse and
Saria, 1985; Newbold and Brain, 1993) and the joint (Cambridge and Brain, 1992;
Cruwys et ah, 1992). This is mediated through a combination of inhibition of SP
degradation in both the periphery and the spinal cord (le Greves et ah, 1985; Mao et
al., 1992) and potentiation of SP release (Oku et ah, 1987a) by CGRP. Somatostatin
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and galanin can abolish the extravasation produced by capsaicin, possibly acting
presynaptically to inhibit release of pro-inflammatory mediators such as substance P
and CGRP (Green et al., 1992). In joints, various models of acute inflammation
have been shown to have a neurogenic component (Lam and Ferrell, 1991) with only
a slight contribution from the sympathetic nervous system; acute inflammation may
even attenuate sympathetic and enhance neuropeptide-mediated vascular effects in
the joint (Lam and Ferrell, 1993a). Vascular effects in the knee joint induced by
electrical antidromic nerve stimulation and carrageenen-induced inflammation can
both be blocked by a substance P antagonist, further implicating neuropeptides in
inflammation (Lam and Ferrell, 1989; Khoshbaten and Ferrell, 1990). In chronic
adjuvant-induced arthritis both myelinated and unmyelinated afferents have been
implicated (Levine et al., 1985a; 1985b; 1985c; Levine et al., 1986) together with
postganglionic sympathetic efferents.. The role of the sympathetic nervous system
in inflammatory processes is further discussed in Section 6.
Neuropeptides are also known to have potent trophic effects, and may also play a
role in wound healing (Holzer, 1988). The effects of the four neuropeptides under
study here on various arms of the immune system are summarised in Table 1.1.
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Table 1.1 Neuro-immune interactions
Neuropeptide Effect Reference




t neutrophil adherence, 5
t histamine release, 6
t phagocytosis 3
CGRP T Neutrophil adherence, 5
activation 8
Somatostatin I lymphocyte 1
proliferation,
17- PMN migration 4,7
-I macrophage cAMP 6
accumulation




References: 1. Tang et al., 1992; 2. Kavelaars et al., 1993; 3. O'Dorisio et al., 1985;
4. Partsch and Marucci-Cerinic, 1992; 5. Zimmerman et ah, 1992; 6. Krumins and
Broomfield, 1993; 7. Kolasinski et ah, 1992; 8. Richter et al., 1992.
1.6.3. Primary afferents and arthritis
Following the identification of the interactions between the nervous, vascular and
immune systems detailed above, an interest in the possible neuronal involvement in
arthritis has developed. The observation that patients with disruption of the
innervation of a limb due to poliomyelitis (Glick, 1967) or stroke (Thompson and
Bywaters, 1962) did not develop rheumatoid arthritis in the affected limb has
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concentrated investigation on the peripheral nervous system. Since the work of
Levine and colleagues in the mid 1980s there has been a growing recognition of the
involvement of specific primary afferent modalities and some of the neuropeptides
they synthesise, in the maintenance and exacerbation of inflammatory arthritis, and
numerous hypotheses on the nervous system and arthritis have been suggested
(Green et al., 1993a; Garrett et al., 1992; Kidd et al., 1990; Kidd et al., 1989b;
Fitzgerald, 1989; Levine et al., 1985b; 1985c). A recent report of a hemiplegic
patient with a sparing of the paralysed limb from psoriatic arthritis combined with
substance P levels in synovial fluid increased and those in synovium decreased only
in the affected knee, further supports a role for primary afferent neuropeptides in
clinical inflammatory arthritis (Veale et al., 1993; see also below).
1.6.3.1. Primary afferent neuropeptides in rheumatoid arthritis
A number of the speculations on the involvement of primary afferent neuropeptides
have arisen as a result of the discovery of various neuropeptides in the synovial fluid
of patients with rheumatoid arthritis. Substance P has been found to be elevated in
the majority of studies, but the absolute levels found in both control and rheumatoid
patients varies enormously (Table 1.2) which may be due to differing antibody
specificities and cross-reaction with other tachykinins. There is a gradient in patients
with rheumatoid arthritis between the synovial fluid and synovial tissue, suggesting
that there is active release of this neuropeptide into the joint cavity (Menkes et al.,
1993).
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Table 1.2. Substance P- and tachykinin-like immunoreactivity in synovial fluid
from patients with rheumatoid arthritis. Amounts have been converted to pglml
where necessary and are shown as means ±S.E.M. (n). Controls are all patients
with osteoarthritis exceptfor Larsson et al., where traumatic arthritis was used. ND
= not detectable.
Reference Control Rheumatoid arthritis
Marshall et al., 1990 1034±117 (15) 947 ± 830 (24)
Larsson etal., 1991 (SP) ND (13) ND (18)
Larsson et al., 1991 (NKA) 6+0.8(13) 4 ±0.9 (18)
Marabini et al., 1991 16171±1751(12) 57947± 13206 (8)*
Aloe et al., 1992a 70 ± 10 (6) 135 ±23 (8)*
Hernanz et al., 1993 70 ± 4 (20) 120 ± 11 (40)*
Matucci-Cerinic et al., 1993 12 ± 13 (10) 43 ± 17 (26)*
Menkes et al., 1993 52 ± 9 (9) 157 ±15(19)
CGRP, VIP and somatostatin have been investigated to a lesser extent and also
show variation in the levels found by different groups. CGRP is the only peptide
apart from substance P to show a consistent rise, however it has only been examined
in two groups of patients (Table 1.3). Hernanz et al., (1993) have recently shown a
strong positive correlation between the CGRP and substance P content in synovial
fluid, as would be expected from their frequent colocalisation. Interestingly, there
was also a strong correlation between the ratio of CGRP and substance P and the
Mallya index, an index of rheumatoid disease activity analysing morning stiffness,
pain, grip strength, articular index (involvement), haemoglobin and erythrocyte
sedimentation rate (Mallya et al., 1982). Larsson et al. (1991) also found a
correlation, in this instance negative, between CGRP and neurokinin A content of
synovial fluid. Recently one of the enzymes involved in the degradation of
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substance P, neutral endopeptidase (3.4.24.11) (NEP) has also been found to be
elevated in both the plasma and synovial fluid of patients with rheumatoid arthritis
(Matucci-Cerinic et al., 1993; Appelboom et al., 1991) compared to patients with
osteoarthritis. It has been speculated that the levels of this enzyme may be a marker
of the inflammatory process per se, rather than directly linked to the levels of
substance P in the synovial fluid as angiotensin converting enzyme, also known to
degrade substance P was unaltered in either the plasma or synovial fluid of patients
with RA (Matucci-Cerinic et al., 1993). The localisation and activity of NEP is of
increasing interest as it is also known to have a potent degrading action on
enkephalins (Hughes et al., 1975), consequently the relative proportions of algesic
and analgesic neuromodulators may be, in part determined by the activity of NEP.
The finding of increased NEP levels in synovial fluid suggests that the high levels of
substance P found in the synovial fluid is not a result of impaired enzymatic
degradation in RA contributing to the severity of arthritis but rather due to an active
secretion (Menkes et al., 1993)
The origin of the substances found in the synovial fluid of patients with RA, shown
in Tables 1.2 and 1.3 is as yet unclear. Neuropeptides are thought to be of sensory
origin as neuropeptide containing nerves are found in synovium (see below) and
bone (Bjurholm et al., 1988) and are known to be released in the periphery (Holzer,
1988). This is a local effect as plasma neuropeptides are, in general, unaltered in
these patients (Lygren et al., 1986; Matucci-Cerinic et al., 1993; Hernanz et al.,
1993; Menkes et al., 1993; but see also Marshall et al., 1990). NEP is produced by
fibroblasts, and in RA its probable source are fibroblast-like synoviocytes or
chondrocytes (Matucci-Cerinic et al., 1993) whereas NGF is produced by
perivascular cells and lymphocytes in synovitis (Aloe et al., 1992a)
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Table 1.3. Other peptides found in synovial fluid ofpatients with rheumatoid
arthritis. Units are as in Table 1.2 exceptfor neutral endopeptidase (NEP;
pmollmllmin) and expressed as means ±S.E.M. except Lygren et al., 1986 which are
medians (range). ND = not detectable; NGF = nerve growth factor.
Reference Peptide Control RA
Lygren et al., 1986 VIP 33 (8-173) 296 (56-565)*
Somatostatin 66 (0-229) 90 (0-147)
Larsson et al., 1991 VIP 0.7 ±0.6 0.8 ±0.6
CGRP 59 ±10 144 ±7
Marabini et al., 1991 Somatostatin 22275±7698 37344±2293*
Aloe et al., 1992b NGF ND 4000±1000
Hernanz et al., 1993 VIP 16 ± 2 30 ±3*
CGRP 76 ± 11 152±19*
Matucci-Cerinic et al., 1993 NEP 15 ± 11 134 ±32*
The significance of the changes in neuropeptide content of synovial fluid in patients
with rheumatoid arthritis is as yet unclear; however as outlined above and below
these neuropeptides can have potent effects on the immune system and synovium
and may therefore interact to exacerbate inflammation or promote repair, depending
on the relative proportions of agents present.
1.6.4. Neuropeptidergic nerves and synovium
It has been recently stated (Mapp et al., 1990) that the innervation of human
synovium has been poorly demonstrated. However, in a comprehensive review of
the joint from Gardner (1950) using serial sectioning of the human foetus, there is a
clear description of innervation of various regions of the joint capsule, the
infrapatellar fat pad and numerous blood vessels. More particularly, innervation of
the synovium and epiphyses is also noted. In the experimental animal
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neuropeptidergic nerves have been localised to the synovial lining and sublining
tissue, periosteum, marrow and epiphyseal growth plates in the normal rat
(Hukkanen et al., 1992) and mouse (Buma et al., 1992). That these nerves, or rather
a proportion thereof, contain neuropeptides was first described by Gronblad et al.,
(1988) and this study also suggested an increased release of these peptides in
rheumatoid disease as manifest by decreased staining intensity compared to
osteoarthritic and normal controls. Neuropeptide containing nerves appear to be
located primarily around synovial blood vessels, perhaps reflecting the potent effects
of neuropeptides on the vasculature (vide supra). This has also been seen in the
joints of rats with adjuvant arthritis in a study which demonstrated additionally that
levels of both substance P and CGRP are raised in arthritic joints when compared to
controls (Ahmed et al., 1993). Subsequently, studies involving both animal models
and human rheumatoid synovium have demonstrated a loss of neuropeptide
containing nerves in inflamed synovium. Initially this was attributed, as above, to an
increased release of the peptides in these inflammatory conditions, however using
double staining techniques for neural proteins and neuropeptides it was shown that
there was an actual loss of fine nerve terminals in the superficial synovium (Mapp et
al., 1990; Pereira da Silva and Carmo-Fonseca, 1990; Konttinen et al., 1990). The
destruction of these nerve terminals may be attributable to the local production of
proteolytic enzymes by inflammatory cells which are known to be in close proximity
to neuropeptide immunoreactive nerves in normal synovium (Konttinen et al., 1992;
Hukkanen et al., 1991). This has lead to the suggestion that rheumatoid synovium
has a disturbed neural control (Pereira da Silva and Carmo-Fonseca, 1990) which is
supported by the observation that synovial cells from patients with rheumatoid
arthritis behave differently in culture than those from controls, spontaneously
releasing interleukin 16 and prostaglandin E2 (Goto et al., 1990). There have,
naturally been studies to elucidate the role of neuropeptides in synovium and as
usual, the most studied neuropeptide is substance P which has been shown to cause
synoviocyte proliferation (Lotz et al., 1987) and stimulate collagenase production
from synoviocytes (Partsch et al., 1991; Lotz et al., 1987) and monocytes (Lotz et
al., 1988).
1.6.5. Location of neurokinin receptors
There has recently been a rationalisation of the nomenclature used for the receptors
for the tachykinins, which are termed NKi, NK2 and nk3 on the basis of their
affinities for SP, NKA and NKB. These are summarised in Table 1.4.
It can be seen from these values that substance P has a greater affinity for the NKi
receptor, NKB has a much higher affinity for nk3 receptor and NKA has equal
affinities for the NKi and NK2 receptors., but a greater affinity for the NK2 than
substance P.
There have been numerous studies of the localisation of the tachykinin receptors in
the central nervous system and in peripheral tissues using autoradiographic binding
studies and mRNA localisation.
Table 1.4. Half-maximal effective concentrations (EC50) of tachykinins on receptor
subtypes expressedfrom recombinantmRNA inXenopus oocytes (taken from Otsuka
and Yoshioka, 1993; refs. 875,1206,1442).
EC5Q. M
Receptor subtype Substance P Neurokinin A Neurokinin B
nki 3x10-9 5x10-8 3.6x10-7
nk2 8.7xl0-6 6x10-8 3.4x10-7
nk3 1.9x10-7 2.9x10-8 4.2X10"10
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The NK3 receptor is the only one not found in peripheral tissues. The NKi receptor
is more widely distributed than the NK2 (Otsuka and Yoshioka, 1993), and is the
only receptor found in skin. Substance P binding sites showing characteristics of the
NKi receptor have been localised to perivascular sites in human synovium (Walsh et
al., 1992) and under inflammatory conditions, the NKi receptor is increased in
vascular sites and lymph nodes (Mantyh et al., 1989) and in rheumatoid synovium
(Garrett et al., 1992).
1.7. Capsaicin
Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a natural extract which is the
pungent element of the capsicum family. Its structure is shown in Figure 1.6.
Figure 1.6. The structure of capsaicin
It has been known for some time that this substance has neurotoxic effects on
peripheral sensory neurons . There have been few reports of an action of capsaicin
upon the central nervous system (Buck and Burks, 1986; Fitzgerald, 1983; Sivam
and Krause, 1992). Indirect pharmacological evidence has suggested that capsaicin
acts through a specific receptor (Holzer, 1988; Szallasi and Blumberg, 1989) to
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cause intracellular calcium accumulation through which it is thought to exert its
many actions. Both the route of administration of capsaicin, and age of the animal is
of importance to the action of capsaicin (Fitzgerald, 1983) and the extent of the
lesion caused. Capsaicin has been administered systemically either to the neonate or
the adult, intrathecally, or directly onto the peripheral nerve or its target e.g. skin.
The action of capsaicin upon the nervous system when injected subcutaneously in
the neonate, or applied directly to peripheral nerve are the only methods of
administration used in this thesis, and therefore are the two routes which will be
considered in detail here.
1.7.1. Systemic administration of capsaicin
1.7.1.1. Neuroanatomical effects of systemic capsaicin administration
Systemic administration in the neonatal rat (postnatal day 2; 50mg/kg) results in a
loss of up to 95% of C-fibres (Jancso et al., 1977); lower doses cause axon terminal
degeneration. Higher doses are thought to cause loss of Ad fibres also; this effect
varies between workers (Wall et ah, 1982b; Lawson and Nickels, 1980; Nagy and
Hunt, 1983). However all workers report a small percentage (~5%) of C-fibres
which are capsaicin-insensitive. Systemic administration in the adult causes no
peripheral sensory neuronal degeneration (Joo et ah, 1969), however there is a
reduction in the numbers of primary afferent neurons expressing these neuropeptides
(Lynn, 1987). This effect has also been observed in ORG cell culture following
capsaicin (Jeftinija et al., 1992). Administration in the adult has also been reported
to result in damage to the hypothalamus (Jancso-Gabor et al, 1970; Szolcsanyi et 1.
1971).
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1.7.1.2, Behavioural effects of systemic capsaicin
One of the reasons why capsaicin has become such a popular pharmacological tool
was an initial report of its ability to impart analgesia when neonatal rats were treated
systemically with 50mg/kg capsaicin (Holzer et al., 1979). However subsequent
investigations of the effect of neonatal and adult capsaicin treatments on nociceptive
thresholds have proved inconclusive, with some groups finding capsaicin analgesic
in thermal tests (Nagy et al., 1980; Holzer et al., 1979) and others finding effects
only on mechanical thresholds (Hayes et al., 1981; Cervero and McRichie, 1981).
Subsequent work by Nagy (1983) showed a variable response to different
nociceptive stimuli and also to the dose of capsaicin used, with the dose needed to
produce thermal analgesia being higher than that required for mechanical analgesia.
1.7.1.3. Effect on neurochemical markers
Originally, there were reports that capsaicin had specific effects upon neuronal
substance P, as neonatal treatment of rats causes a marked reduction in Substance P
immunoreactivity in the dorsal horn and the trigeminal nucleus (Buck et al., 1982;
Hayes et al., 1980; Meller et al., 1992), and in many non-neuronal sites such as skin
(Holzer et al., 1982) and joint (Levine et al., 1986). The reported dorsal hom
reduction is in SP rather variable, but ranges between 30-80% (Buck et al., 1982;
Hayes and Tyers, 1980; Gamse et al., 1981). However, it has become more apparent
that systemic capsaicin affects other primary afferent neuropeptides as well as
substance P. Jancso and colleagues (1981) have shown depletion of cholecystokinin
(CCK), somatostatin, fluoride resistant acid phosphatase (FRAP) and vasoactive
intestinal peptide VIP) in dorsal horn and dorsal root ganglia, and this has been
confirmed by others (Nagy et al., 1981; Singer et al., 1982). Calcitonin gene-related
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peptide (CGRP) has also been shown to be depleted in laminae I, II and V of the
dorsal hom (Hammond and Ruda, 1991) and in DRG (Kashiba et al., 1990). This
neuropeptide depletion is considered to be permanent as effects on substance P
persist for up to 7 months (Cuello et al., 1981); however there is a suggestion that
there may be a recovery of primary afferent neuropeptide content in the adult rat
treated neonatally with capsaicin, particularly in those afferents expressing CGRP
and FRAP (Hammond and Ruda, 1991). Dorsal hom peptides of non-primary
afferent origin such as enkephalin, dynorphin (Sivam and Krause, 1992), neurotensin
or 5-hydroxytryptamine are not affected by neonatal capsaicin (Jancso et al., 1981;
Singer et al., 1982).
Systemic treatment in the adult results in an immediate fall in primary afferent
substance P followed by a rise, probably due to increased synthesis in response to
the insult. Higher doses of capsaicin cause depletions of SP in dorsal hom which do
not recover even after 9 months, although DRG peptide levels recover much more
quickly, in 4 months (Gamse et al., 1981).
1.7.1.4, Effect on physiological responses of primary afferent and dorsal hom
neurons
Capsaicin is an acute excitant of particular peripheral primary afferents, and will
result in excitation of polymodal nociceptors in many mammalian species including
the rat (Renins, 1982; Szolcsanyi et al., 1988). Occasionally specific Ad modalities
may be excited (mechano-heat nociceptors; Szolcsanyi et al., 1988). Capsaicin also
causes depolarisation of DRG neurons (Heyman and Rang, 1985).
In neonatally treated animals the majority of the C-fibres have been destroyed;
consequently there is a loss of the C-fibre component to the action potential when
recorded from peripheral nerve (Wall 1982b). The capsaicin-insensitive C-fibres
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remaining show a normal distribution of modality and normal stimulus thresholds
(Carpenter and Lynn, 1981)
The afferent denervation caused by neonatal capsaicin administration, while having
no direct effect on somatosensory cells in the central nervous system, does have an
indirect one on their physiological properties. It is known that neonatal C-fibre
denervation leads to aberrant innervation of the superficial dorsal hom with
remaining primary afferents (Nagy and Hunt, 1983; Rethelyi et al., 1986; Beal and
Knight, 1987; Shortland et al., 1990). Treatment of the neonate with capsaicin
reduces the number of dorsal horn neurons, from both deep and superficial layers,
responsive to C-fibre stimulation (Cervero et al., 1984). This reduction is somewhat
less than the total reduction in C-fibres seen following this lesion, being less than
50% rather than 90%. This study also showed decreased responsivity of dorsal hom
neurons showing "wind-up", that is an increase in C-fibre response following
repetitive stimulation, and a shift of the neurons which did show "wind-up" to those
with smaller receptive fields and those responding to nociceptive stimuli. These
neurons do not usually show "wind-up" in the normal animal (Schouenborg and
Sjolund, 1982). Dorsal horn neurons are less responsive to noxious thermal
stimulation, as are those in the trigeminal system (Fitzgerald, 1983), but show
unaltered responses to noxious mechanical stimuli (Cervero et al., 1984).
1.7.2. Application of capsaicin to peripheral nerves
1.7.2.1. Neuroanatomical consequences of perineural capsaicin
As with the majority of early work on the actions of capsaicin, Jancso and
colleagues first showed that capsaicin could have a direct action upon axons to affect
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the sensory function of the nerve (Jancso et al., 1980). The morphological
consequences of perineural capsaicin were originally thought to be brief and
reversible, resulting in no overall loss of primary afferents (Fitzgerald, 1983). More
recent studies, using the capsaicin gap technique (Jancso and Lawson, 1990),
however, have shown that perineural capsaicin will cause degeneration of 12-14% of
small sized L4 DRG neurons, and that this results in profound transganglionic
changes in the dorsal horn (Jancso, 1992). This treatment also causes a reduction of
30-40% in the numbers of C-fibre axons, but not A-fibres, in treated nerves (Pini et
al., 1990) and an abolition of neurogenic inflammation (Pini and Lynn, 1990).
Discrepancies between cell and axon counts could arise due to branching of C-fibres
in the axon (McCarthy et ah, 1993).
I.7.2.2. Neurochemical consequences of perineural capsaicin
The degeneration of primary afferents does not seem to be restricted to one
particular neurochemical population, as substance P, somatostatin, FRAP and CGRP
containing neurons in DRG are reduced by 61%, 46%, 37% and 23% respectively
(Holzer, 1991). These peptides are also markedly depleted in the areas of primary
afferent termination in the dorsal hom (Ainsworth et ah, 1981) and skin (Pini and
Lynn, 1990). The changes observed by Gibson and colleagues (1982) in substance P
and CCK staining in dorsal hom and skin were found to be maximal after 14 days
and to persist for 4-5 months.
L8.2.3. Physiological consequences of perineural capsaicin
The actions of capsaicin upon the function of the sensory nerve have been divided
into acute and chronic effects. Acute application of 1% capsaicin solution to a nerve
trunk initially causes depolarisation and action potential discharge (Holzer, 1988).
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Following this acute depolarisation capsaicin causes block of the C-fibre conduction
which recovers, if not completely, on removal of the solution (Wall and Fitzgerald,
1981), and, in the intermediate term, results in a reduced conduction velocity in these
fibres.
After two weeks, there is a large reduction in the numbers of C-fibres responding to
strong heat or pressure stimulation (Pini and Lynn, 1990). Electrophysiological
experiments have demonstrated that the action of capsaicin applied directly to a
nerve is purely restricted to polymodal nociceptors (Pini and Lynn, 1990) and it was
observed that the responses of polymodal nociceptors to electrical or heat
stimulation, were invariably blocked by the application of capsaicin (Petsche et al.,
1983). This effect is associated with a reduction in neurogenic inflammation in areas
innervated by the treated nerve and neuropeptide levels in the skin (Pini and Lynn,
1990) and significant increases in thermal nociceptive thresholds without effect on
mechanical thresholds (Fitzgerald, 1983; Jancso, 1992).
Dorsal horn neurons responses to noxious heat and C-fibre stimulation are both
affected, beginning 24 hours after capsaicin application. There is a marked
reduction in the number of deep and superficial dorsal horn neurons which respond
to either noxious heat or peripheral C-fibre stimulation (Fitzgerald, 1982; McMahon
et al., 1984).
1.8. Nerve growth factor
1.8.1. Nerve growth factor: role in the prenatal period
Nerve growth factor (NGF) was the first of a family of neurotrophic factors
including brain-derived neurotrophic factor (BDNF), neurotrophin-3, -4 and -5 (NT-
3, NT-4, NT-5). Nerve growth factor is required for the survival of postganglionic
sympathetic neurons as immunoneutralisation of NGF in the neonatal rat results in
the destruction of sympathetic ganglia (Korsching, 1993). NGF is also crucial for
the survival of a sub-population of primary sensory neurons during embryonic
development; if endogenous NGF is neutralised in embryonic rats by sensitisation of
the mother, up to 85% of DRG neurons are lost, in addition to all the sympathetic
neurons. Initially, nerve growth factor was thought to be necessary for the
development of substance P-containing neurons (Otten et al., 1980) although NGF
deprivation has been shown to have effects on the ganglionic content of various
primary afferent neurochemical markers including somatostatin, FRAP and VIP
(Goedert et al., 1984; Otten, 1984). Augmentation of endogenous NGF levels by
administration of exogenous NGF will prevent the naturally occurring cell death
normally seen in sensory neurons around birth and increase neurotransmitter levels
in DRG (Otten et al., 1980; Vedder et al., 1993) without increasing neuronal
numbers. The fact that a large number of neurochemical^ different primary
afferents appear to be dependent upon NGF during embryogenesis suggests that the
effects on the neuropeptides described above are related to the direct effects of NGF
on the neurons rather than an effect on the expression of the neuropeptide per se. It
is possible that the population of primary afferent neurons which are dependent on
NGF are those which are capsaicin-sensitive, as NGF is known to reverse the effects
of neonatal capsaicin administration (Otten et al., 1983).
1.8.2. Role of NGF in the adult animal
In the adult animal, chronic systemic deprivation of NGF does not result in cell
death although neuropeptide levels are decreased (Schwartz et al., 1982). Chronic
nerve section or crush does however result in the loss of approximately 20% of the
axotomised neurons (Johnson and Yip, 1985) and this can be reversed by exogenous
nerve growth factor (Fitzgerald et al., 1985). Postnatal deprivation of NGF results in
the loss of one sensory modality, the A3 high-threshold mechanoreceptor, by
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conversion to D-hair afferents (Ritter et al., 1991; Lewin et al., 1992a; 1992b) and
increased NGF available in the periphery results in increased spinal cord
responsivity to nerve simulation (Lewin et al., 1992c). Using administration of both
anti-NGF and NGF (albeit in high doses) Ritter and colleagues have suggested that
NGF exerts its effects specifically upon nociceptive afferents and does not affect
other sensory modalities (Ritter et al., 1993). Intraperitoneal injections of NGF have
also been shown to result in a profound thermal and mechanical hyperalgesia (Lewin
and Mendell, 1993); these results however have been criticised for the extremely
large doses of NGF used (lmg/kg).
NGF has also been investigated with regard to its role in the regulation of
neuropeptide expression. Both in vitro and in vivo, NGF has been shown to increase
substance P, neurokinin A (Vedder et al., 1993; MacLean et al., 1991), CGRP
(Delree et al., 1992; Lindsay et al., 1989) and mRNA levels encoding these
neuropeptides (Lindsay and Harmar, 1989). NGF has no effect on the expression of
somatostatin, whereas BDNF appears to regulate the levels of both somatostatin and
its mRNA in cortical neurons (Nawa et al., 1993). Following nerve injury, levels of
substance P are reduced whereas VIP is increased (Anand et al., 1991; Noguchi et
al., 1989; Atkinson and Shehab, 1986). It was initially suggested that this was a
reciprocal regulation through NGF (Nielsch and Keen, 1989); subsequently the
increase in VIP expression in culture has been shown to be independent of NGF
(Mulderry and Lindsay, 1990). However injured nerve is known to express NGF
and other neurotrophins (Andeev et al., 1993), and interleukin -1 (Rotshenker et al.,
1992) which may induce NGF synthesis in this situation as in inflammation (see
below).
The effect of NGF on substance P expression is thought to be mediated through
direct regulation of gene transcription through NGF responsive regions in the PPT
promoter region (Gilchrist et al., 1991; Helke et al., 1990). This may also be the
case for CGRP as there is a sequence similar to that found to be responsive to NGF
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in the PPT gene in the CGRP promoter region (Gilchrist et al., 1991). NGF may
also exert regulatory effects through the induction of other transcription factors such
as c-fos, c-jun, NGFI-A or NGFI-B, all of which are known to be induced by NGF in
rat pheochromocytoma cell lines (see Section 8). The possible role of these
immediate early genes and other transcription factors in the regulation of primary
afferent neuropeptide expression is discussed in Section 8.
1.8.3. Tire significance of NGF in adjuvant arthritis and the expression of primary
afferent neuropeptides.
Nerve growth factor is of interest in inflammatory processes as neuropeptide
expression is known to be altered in inflammatory states. Inflammatory mediators
such as tumour necrosis factor and interleukin-113 stimulate the production of NGF
(Hattori et al., 1993; Lewin and Mendell, 1993), retrograde transport of NGF is
increased in the sciatic nerve during the first 2 days of adjuvant inflammation
(Donnerer et al., 1992), and NGF levels are increased in joints in both experimental
and rheumatoid arthritis (Aloe et al., 1992a; 1992b). The increased content of
substance P and CGRP in sensory nerves innervating inflamed tissue has been
attributed to increased levels of NGF (Donnerer et al., 1992)
1.9. In situ hybridisation; advantages of the technique
In situ hybridisation (ISH) is a potent molecular biological tool for the
quantification of DNA and RNA in tissue sections rather than immobilised on solid
supports (as in Northern blotting) or in solution, as ISH allows DNA or mRNA to be
precisely localised to the cellular site of transcription (Hofler, 1990). This is of
particular use in studying heterogeneous cell populations such as exist in the dorsal
root ganglion. This technique was first developed approximately 25 years ago and
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has been extensively used to localise DNA, and more recently mRNA to individual
cells. Use of radioisotopically labelled probes and computer-aided analysis systems
in ISH has also provided a reliable method of quantification of mRNA levels in
individual cells either compared to RNA standards, or as in the studies described
here, to basal expression in normal animals, and has shown an excellent correlation
with the estimation of mRNA levels as assessed by Northern analysis with other
mRNAs (Segerson et al., 1987).
1.10. Aims of the thesis
Previous work has identified a possible role for the primary afferent neuron and
neuropeptides in both the maintenance and spread of clinical and experimental
arthritides. However, these studies have been complicated by the use of the
polyarthritic rat model which suffers profound systemic immune stimulation and
subsequent illness as described in Section 1.1. While a number of studies have
shown increased DRG content of neuropeptides in this model, it is difficult to
attribute these changes to the arthritic process per se. Using a modified adjuvant-
induced monoarthritis, increases in SP and CGRP were found only in innervating
DRG (Smith et al., 1992). However this study and others examining peptide content
have not identified whether the observed changes are attributable to increased
synthesis, or decreased axonal transport and/or peripheral release. Additionally the
mechanisms through which neuropeptide gene expression is regulated during
inflammation are poorly understood.
The aims of this thesis were:-
1. To develop and characterise a mild modified adjuvant-induced arthritis in the rat
for use in the study of primary afferent involvement in the arthritic process without
the complicating effects of systemic illness. This model has also been used to
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determine whether spread of arthritis is an inevitable consequence of monoarthritis
and study the possible mechanisms through which spread of inflammation occurs.
2. To determine the effect of exogenous substance P on both the spontaneous and
mechanically evoked activity in primary afferent nociceptors with receptors in the
ankle joint in normal and monoarthritic rats.
3. To examine the expression of four neuropeptide messenger RNAs,
preprotachykinin, calcitonin gene-related peptide, somatostatin and vasoactive
intestinal peptide, during the development of monoarthritis and in established
bilateral arthritis of the hind limbs in order to determine whether changes in
neuropeptide levels are reflected in changes at the level of the mRNA.
4. To identify the contribution of the primary afferent neuron and signals from the
periphery in the regulation of any observed changes in neuropeptide mRNA
expression during inflammation.
5. To determine the possible role of transcription factors including immediate early
genes and glucocorticoid hormone receptors in the possible regulation of these
mRNA species during inflammation.
35
SECTION 2. MATERIALS AND METHODS
2,1 Induction of arthritis
2.1.1. Preparation of adjuvant
Adjuvant used for the induction of symmetrical arthritis was prepared using
attenuated Mycobacterium tuberculosis (MAFF) suspended in paraffin oil.
Suspensions of 5mg/ml or 3mg/ml were prepared and dispersed in a warm ultrasonic
water bath for 30 minutes. Suspensions were well mixed before injection into the
animals.
2.1 2 Induction of arthritis
Han Wistar rats (male; 7 weeks; 200-250g) were used in all experiments except
those involving neurotoxic lesions when younger animals were used (see section 2.4)
and for the comparisons between male and females. All groups of animals were age
matched. Arthritis was induced under 4% halothane anaesthesia by intradermal
injection of adjuvant administered at two sites around the left tibio-tarsal joint.
Monoarthritis was induced with either 0.15ml of Freund's Complete Adjuvant
(lmg/ml; Sigma) or 0.05ml adjuvant prepared as described above (3mg/ml).
Animals showed no difference in reaction to either adjuvant preparation.
Symmetrical arthritis was induced using 0.05ml of 5mg/ml adjuvant prepared as
above. Control animals were left untreated. Additional controls for vehicle itself
were made by injecting 0 15ml sterile paraffin oil.
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2.2 Assessment of inflammation
2.2.1 Overt indices of inflammation
Animals were weighed throughout each experiment as an assessment of general
health. The joint circumference was measured using a loop of dressmakers tape
three times per week for the duration of each experiment and inflammation was
scored according to the overt signs discernible around the joint as follows;
0=normal, l=mild redness, 2=moderate redness and swelling, 3=severe
swelling/lesions over the joint. At the termination of each experiment, when animals
were killed, left and right tibio tarsal joints were removed and processed for
histological assessment of arthritis.
2.2.2 Histological methods
Animals were either anaesthetised with sodium pentabarbitone and killed by
cervical dislocation, or were decapitated if tissue was also being collected for in situ
hybridisation. For initial studies on joint histology, hind limbs were fixed by
perfusion with heparinised saline (10ml; 500 Units/kg) followed by 50-100ml formal
saline (0.9g NaCl; 10ml 40% formaldehyde solution; 90ml distilled water) via a
cannula inserted anterogradely in the abdominal aorta until the hind limbs were
fixed. Hind limbs were removed by section of tibia and fibula, post-fixed in 10%
formal saline for 2 weeks. In studies where fresh frozen tissue was required for in
situ hybridisation, hind limbs were removed and immersion-fixed for at least 4
weeks in formal saline. Tissues were then decalcified in Gooding and Stewart's
solution (15% formic acid; 5% formaldehyde; 80% distilled water) for at least two
weeks. After decalcification, tissues were trimmed closely around the tibio tarsal
joint and placed in 5% gelatin overnight at 37°C. Blocks for sectioning were made
37
in 10% gelatin and frozen in Arcton 12 (BOC) cooled to -70°C with liquid nitrogen.
20(im sections were cut from each joint using a cryostat (SLEE), mounted on glass
slides, counterstained with haematoxylin and eosin and sealed with glass coverslips.
The histological inflammation was assessed microscopically and scored for
histological inflammation for both left and right limbs (classified as:- 0=normal,
l=subdermal inflammatory infiltrate, 2=mild synovitis, 3-moderate
synovitis/arthritis, 4=severe arthritis; scores >3 were taken as indicative of arthritis).
2.2.3. Statistical analysis of data
Body weights and limb circumferences were compared using 1 or 2 factor analysis
of variance (ANOVA) followed by Dunnetts post hoc test (Lewis, 1971; Phillips,
1971). Analogue scales such as those used for inflammation or histology were
compared using Mann Whitney U test (between groups) and Wilcoxon signed rank
test (paired data, within groups; Pipkin, 1984). The Null Hypothesis was rejected at
the 5% probability level.
2.3 Neuropharmacology of fine articular afferents
2.3.1. In vivo rat preparation
2.3.1.1 General preparation
Male Han-Wistar rats (250-300g) were used for all in vivo experiments. Both
normal, untreated animals and monoarthric rats were used in these experiments.
Rats were irreversibly anaesthetised by i.p. injection of 0.6ml/100g body weight
urethane (ethyl carbamate, 25% w/v in distilled water). Tracheal and left carotid
cannulae (external diameter 0.75mm) were inserted via a midline incision in the
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ventral aspect of the neck. The tracheal cannula was inserted immediately below the
larynx and secured with a suture. The carotid artery was closed with a ligature just
proximal to the bifurcation of the common carotid artery, the cannula inserted
retrogradely proximal to the ligature and secured in position with two sutures. The
carotid cannula was connected to a pressure transducer (Bell and Howell, 4-442) and
arterial blood pressure was monitored following signal amplification and displayed
on a chart recorder (Devices M4).
The right femoral artery and vein were exposed through a mid thigh level incision
on the ventral surface of the right hind limb. A cannula (external diameter 0.63mm)
was inserted retrogradely into the femoral artery following distal ligation of the
vessel and advanced approximately 4cm so that the tip lay at the iliac bifurcation.
Positioning of the tip of the cannula was routinely checked at the end of each
experiment.
Body temperature was monitored continuously via a rectal probe and maintained at
37±1°C by an electronic heating blanket (Harvard Apparatus Ltd).
2,3.1.2 Identification of articular innervation
The primary articulo-cutaneous ramus (PACR; the branch of the medial plantar
nerve which innervates the ankle joint in the rat) was identified from the tibial nerve.
The tibial nerve was exposed through a longitudinal incision in the medial aspect of
the left leg from the knee to a position over the ankle joint. The musculature
overlying the tibial nerve, that is semitendinosis, semimembranosis, biceps femoris
and medial gastrocnemius muscles, was removed and the PACR identified where it
leaves with the medial plantar nerve (Guilbaud et al., 1985). The skin around the
incision was dissected from underlying connective tissues; a pool was then created
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by suturing the skin flaps to a copper loop and filling the space thus created with
paraffin oil at 37°C. This dissection of the surrounding skin also served to rupture
any cutaneous fibres around the joint ensuring that recordings made from the PACR
were from units innervating the joint capsule, adjacent fascia and skin on the medial
aspect of the heel.
2,3.2 Recording primary afferent activity
The PACR was dissected free from surrounding tissues, cleaned of attached fat and
desheathed. Afferent activity in the PACR was recorded extracellularly either from
the intact PACR or from dissected filaments of the ramus. The tibial nerve was
routinely cut proximally to abolish efferent activity in the PACR. Activity was
recorded via bipolar platinum-iridium wire electrodes mounted on a
micromanipulator, in close contact with the undersurface of the PACR. Single
afferent unit receptive fields were identified by manual probing with a smooth
perspex probe, tip diameter approximately 1mm, over the medial aspect of the joint
capsule while recording electrically from the PACR. The electrical signal was
amplified (xlOOO) and displayed on a storage oscilloscope (Tektronix 5113). The
signal was also digitised via a digital audio processor (Sony PCM 701-ES) and
stored on a videotape recorder (Sony Betamax SL-HF100 UB) for subsequent off¬
line data analysis. Output from the amplifier was also relayed to a loudspeaker.
2.3.3. Unit identification and stimulation of the receptive field
All units were identified as C-fibres by measurement of conduction velocities. The
receptive field was electrically stimulated using a mechanical transducer probe
consisting of a silver wire core isolated from a metal cylinder casing and action
potentials recorded with the bipolar electrodes. The tip of the transducer probe was
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smooth, sealed with plastic resin and approximately 1mm in diameter. Conduction
velocity was calculated from the conduction distance (d) as measured in situ in
centimetres, and the conduction time in seconds (t) for the action potential to travel
from the stimulating to the recording electrodes, measured from the oscilloscope as
below.
Conduction velocity (v) = d/t (ms"1)
For all units studied, v ranged from 0.4-2.5 ms"*. Only slowly adapting units were
used in these experiments. All units were tested for their chemoresponsivity to
capsaicin immediately before termination of each experiment.
Receptive fields were stimulated mechanically using the same mechanical
transducer probe. The tip of the probe was placed over the receptive field and
mechanical stimuli delivered using an electromechanical indentation generator
(Somedic, Sweden). A ramp stimulus waveform of maximum displacement 600|im
and duration 2 seconds was used routinely. Stimuli were applied at two minute
intervals to minimise receptor fatigue. Both mechanically evoked and background
activity in the units were analysed.
2.3.4 Drug administration
Drugs were administered in a bolus by close arterial injection via the femoral
cannula in a total volume of 0.1ml and washed in with 0.1ml normal saline (0.9%
w/v NaCl in distilled water), 15s before a mechanical stimulus. Injections were
completed within 1 second. As the tachykinins are known to induce tachyphylaxis, a
period of at least 10 minutes was left between injections. Injections of 0.1ml saline
were used as a control of the effect of injection alone on primary afferent activity,
were made before the injection of drug and repeated throughout an experiment.
All drugs were dissolved in 0.9% saline except for capsaicin (8-methyl-N-vanillyl-
6-nonenamide; Sigma) which was dissolved in 10% Tween 80
(polyoxyethylenesorbitan monooleate; Sigma); 10% ethanol; 80% 0.9% saline, and
were equilibrated to room temperature before injection.
2,3.5 Off-line analysis of primary afferent activity
The electrical recording stored on videotape was passed through an amplifier and
CED 1401 filter module and fed through a WPI window discriminator This allowed
the counting of selected action potentials by appropriate positioning of a window
discriminator. Each action potential falling in the window generated a pulse of 1ms
duration. The number of impulses occurring in 0.1s intervals was collected and
stored using a personal computer and software designed to collect over a period of
up to 900 seconds (software written and kindly supplied by Dr M. Dutia, Dept.
Physiology, University of Edinburgh). The point of saline or drug injection was
indicated with a marker. Collected data were stored on floppy disc for analysis
using the same software.
Action potential discharge frequency as a function of time was displayed as a
computer-generated plot. Discharge was analysed in the control (pre-injection)
period (defined as the 10-60s period immediately prior to injection), and in defined
periods after drug injection. Mechanically evoked activity was defined as the
number of action potentials produced per stimulus and were analysed for 1 stimulus
prior to, and three stimuli after the injection. Background activity was analysed over
the first 15 seconds post-injection and in 1 minute periods thereafter for 5 minutes
after drug injection. These periods of time were defined using a moving cursor on
the plot.
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2.3.6 Statistical analysis of data
All data was normalised with pre-injection activity expressed as 100%. Each dose
of substance P activity was compared to saline injection and also to baseline activity
with respect to time using 2 factor ANOVA (Lewis, 1971).
2,4 Neurotoxic lesions
2,4,1 Perineural capsaicin lesions
A 1.5% capsaicin solution was prepared as in section 2.3.4. Capsaicin was applied
perineurally to the exposed sciatic nerve according to the method of Ainsworth et al.
(1981) under aseptic conditions. Male rats (Han Wistar, 150g) were anaesthetised
with 4% halothane and either right or left sciatic nerves exposed at the mid-thigh.
The nerve was carefully separated from the surrounding tissues and approximately
lcm cleaned of attached fascia and fat. Cotton wool soaked in 1.5% capsaicin
solution was applied to the nerve trunk for 15 min while anaesthesia was maintained.
Exposed tissue was covered in saline-soaked gauze to prevent dehydration. Cotton
wool and excess solution were then removed, muscle and skin closed and the
animals allowed to recover. Since Tween/ethanol/saline vehicle itself has effects on
the physiological characteristics of primary afferents (Petsche et al., 1983), sciatic
nerve exposure was used as a control for the surgery; additional controls were
untreated. After 2 weeks, animals were re-anaesthetised with 4% halothane in
oxygen and symmetrical arthritis induced by injection of 250|ig M.tub. as outlined in
section 2.2.1.
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2,4.2 Neonatal capsaicin lesions
Capsaicin solution was prepared at a concentration of lOmg/ml in
Tween/ethanol/saline vehicle as described above. Vehicle solution alone was also
prepared. Neonatal male rats (2-4 days postnatal) were anaesthetised with 4%
halothane in oxygen. Capsaicin or vehicle was injected subcutaneously in the dorsal
cervical region while anaesthesia was maintained. Parent animals were also treated
topically with capsaicin or vehicle to their nose and mouth; this desensitises the
parents to the taste of capsaicin and prevents cannibalism of the litter. On recovery
from the anaesthesia, the neonatal rats were returned to the mother until weaning. At
seven weeks of age, the rats were re-anaesthetised with 4% halothane and either
mono- or symmetrical arthritis induced as described previously in section 2.2.1.
2,5 Surgical procedures .
2.5.1 Adrenalectomy
All adrenalectomies were kindly performed by June Noble and Keith Chalmers.
Adrenalectomy was performed under 4% halothane anaesthesia and aseptic
conditions. An incision was made in the flank immediately over each kidney, the
adrenals located and removed. Sham operated animals served as controls; adrenals
were located but left in situ. All adrenalectomised animals received 0.9% saline for
drinking. Animals were allowed to recover for five days before being re-
anaesthetised for induction of mono- or symmetrical arthritis (Section 2.2.1).
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2.6 In situ hybridisation
2.6.1 Preparation of solutions
2.6.1.1 Solutions for isolation of plasmids and cDNAs
Luria Broth: lOg bacto-tryptone (BDH); lOg NaCl (Sigma); 5g bacto-yeast
extract (BDH) per litre distilled water. pH of solution = 7. Sterilise by autoclaving
(20 minutes @ 121°C and 151b/in2 pressure).
Glucose/Tris/EDTA buffer (GTE): 50mM glucose (BDH); 25mM Trisma base
(pH8; Sigma); lOmM ethylenediaminetetraacetic acid (EDTA; pH8; Sigma).
Sterilise by autoclaving.
5M potassium acetate solution: 60ml 5M potassium acetate; 11.5ml acetic
acid; 28.5ml distilled water. Sterilise by autoclaving.
Tris/EDTA (TE) buffer: lOmM Tris (pH8); ImM EDTA (pH8). SteriUse by
autoclaving.
2.6.1.2. Solutions for in situ hybridisation
Diethyl pyrocarbonate (DEP) treated water: 0.02% DEP in distilled water.
Leave to stand for at least 2 hours and sterilise by autoclaving.
4% paraformaldehyde in 0.1M phosphate buffer:
20mM NaH2P04 (BDH); 80mM Na2HP04 (BDH); 40g paraformaldehyde
(BDH) in 1 litre DEP water.
20xSSC (sodium-saline citrate): 3M NaCl (Sigma); 0.3M trisodium citrate
(Sigma).
2xSSC (for postfixation rinsing): Dilute 50ml sterilised DEP treated 20xSSC or
sodium saline citrate solution (Sigma) in 450ml DEP water.
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2xHybridisation buffer: 1,2M NaCl; 20 mM Tris-Cl (pH 7.5); 0.04% Ficoll;
0.04% polyvinylpyrrolidone; 0.2% BSA; 2 mM EDTA; 0.2 mg denatured salmon
sperm DNA; 0.1 ing/ml total yeast RNA; 20% dextran sulphate (w:v) and 20 mM
dithiothreitol in DEP water.
Box buffer (for hybridisation): 50% deionised formamide; 20% 20xSSC; 30%
DEP water.
RNase buffer: 0.5M NaCl; 0.01M Tris; 0.0ImM EDTA.
2.6.1.3. Gel preparation
lOxTris/borate/EDTA buffer (TBE) 108g Trisma base; 55g boric acid
(Sigma); 40ml 0.5M EDTA (pH8).
Agarose gel: 1-1.5% agarose powder (Gibco); lxTBE buffer; lp.l/25ml ethidium
bromide solution (lOmg/ml; Sigma) in distilled water. Heat to melt.
4% polyacrylamide mini-gel: 4.2g urea (Sigma), 1ml 40% acrylamide
solution (Sigma), 1ml lOxTBE. Make up to 10ml with distilled water. Polymerise
acrylamide with lOOpl 10% ammonium persulphate (Sigma) solution and lOfJ.1
TEMED (N,N,N',n'-tetramethylethylenediamine; Sigma). Pour immediately.
2,6.2 Preparation of tissue
All in situ hybridisation experiments were performed on primary afferent neurons
whose cell bodies are located in dorsal root ganglia, which are sited adjacent to the
spinal cord. For the time course experiments, animals were decapitated at various
times after adjuvant injection, ranging from 30 minutes to 8 hours for the
transcription factor studies, and 8 hours to 14 days for studies on neuropeptide
mRNA expression. The efficacy of perineural capsaicin lesions was assessed using
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tissue taken two weeks after lesioning was performed. In all other experiments,
animals were killed by decapitation fourteen or fifteen days after the induction of
arthritis. Control tissue was taken from untreated animals.
Following decapitation lumbar L4/L5 dorsal root ganglia were removed by
performing a laminectomy, and were rapidly frozen on dry ice. Tissue was then
mounted in Ml embedding medium (Bright) on cork squares and stored at -80°C
until sectioning.
2.6.3 Preparation of slides
Glass microscope slides with frosted ends were treated for 3 minutes in each of
0.2M HC1 in DEP treated water, DEP treated water and acetone before thorough
drying in an oven at 60°C. Slides were then subbed in 0.15% gelatin, 0.03% sodium
azide solution in DEP treated water for five minutes and dried overnight at 60°C.
Finally slides were dipped in poly-L-lysine (Sigma) solution (100mg/500ml DEP
water) for 2x10 seconds, rinsed in DEP water for 10 minutes and dried at 60°C.
Sections of DRG were cut at 10)im thickness, following equilibration of the tissue
to -20°C, in a Cryostat (Bright). Sections were then mounted on poly-L-lysine
subbed slides and stored at -80°C until processed for in situ hybridisation. All slides
with DRG sections were coded when sectioned. All subsequent analysis was
performed blind to experimental group until all analysis of in situ hybridisation data
was complete.
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2,6.4 Preparation of radiolabeled probes
2.6.4.1 Preparation of plasmid vectors
cDNAs for the appropriate neuropeptides and immediate early genes under study
were obtained from the sources listed below:-
(3-PPT, Dr A.J. Harmar; a-CGRP, Dr S. Amara; somatostatin and VIP; Dr R.
Goodman; AP-2; Dr P. Mitchell; NGFI-A and -B, Dr J. Milbrandt; c-jun, Dr M.
Seckl and jun-D, Dr J. Quinn. The cDNA, vector and appropriate references are
detailed in Table 2.1.
Table 2.1 cDNAs usedfor in preparation of riboprobes by in vitro transcription
Neuropeptides Vector Reference
(3-PPT pGEM3 Harmar et al., 1990
a-CGRP pSP64 Amara et al., 1985
Somatostatin pSP65 Shen et al., 1982
VIP pSP64 Nishizawa et al., 1985
Transcription factors
c-jun pGEM3 Hattori et ah, 1988
jun D pGEM3 Ryder et ah, 1989
NGFI-A Bluescript KS Milbrandt, 1987
NGFI-B Bluescript KS Milbrandt, 1988
AP-2 Bluescript SK+ Mitchell et ah, 1991
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Competent E.coli. (HB101) were prepared using the calcium chloride method
(Sambrook et al., 1989). A colony of HB101 was transferred to 50ml of Luria Broth
(LB) medium and grown for 2-3 hours at 37°C with vigorous shaking. Cells were
then cooled rapidly on ice, transferred to a sterile centrifuge tube and spun for 5
minutes @ 4000 r.p.m at 4°C. The medium was drained and the pellet resuspended
in 10ml ice cold 0.1M calcium chloride solution. The solution was left to stand on
ice for 10 minutes, respun @ 4000 r.p.m. at 4°C, the calcium chloride drained and
the pellet resuspended in 2ml of fresh calcium chloride. The competent cells were
then stored on ice until transformed with the appropriate plasmid containing the
required cDNA and an ampicillin resistance gene.
Transformation was carried out using a heat shock method adapted from Sambrook
et al. (1989). 100pl of cells were placed in each eppendorf tube and either the
plasmid containing the required cDNA or a control plasmid vector with no cDNA
were added. The mixture was stored on ice for 20 minutes, heat shocked in a water
bath at 42°C for exactly 90 seconds and stored on ice. The cells were then plated out
onto LB agar plates (15g/L LB) containing 100|ig/ml ampicillin (Sigma). Plates
were grown overnight at 37°C.
A single colony containing the plasmid vector and cDNA was then used to
innoculate a 500ml culture of LB medium containing 100(ig/ml ampicillin and
grown overnight at 37°C with vigorous shaking. Plasmids were then isolated
according to Sambrook et al., 1989. Cultures were spun (4000 r.p.m.; 15 mins; 4°C)
and the pellet resuspended in 18ml glucose/Tris/EDTA buffer (pH8). Cells were
lysed with 2ml lysozyme (lOmg/ml in lOmM Tris pH8) and 40ml 1%SDS/ 0.2M
sodium hydroxide solution, and then neutralised with 5M potassium acetate solution.
Following centrifugation and filtration to remove the precipitate of bacterial
proteins/SDS complexes, chromosomal DNA and high molecular weight RNA,
plasmid DNA was precipitated using 0.6 volumes of isopropanol (BDH). Following
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centrifugation (5000 r.p.m.; 15 min; room temp.), the DNA pellet was rinsed in 70%
ethanol and allowed to dry before dissolving in 3ml of Tris. EDTA buffer (pH8).
2.6.4.2 Purification of circular DNA using ethidium bromide-caesium chloride
gradients
Plasmid DNA was purified according to the method of Sambrook et al. (1989).
lmg/ml of caesium chloride (Boeringer Mannheim) and 0.8ml/10ml ethidium
bromide (Sigma; lOmg/ml) were added to the Tris/DNA solution, sealed in Beckman
Quickseal ultracentrifuge tubes and centrifuged overnight at 70 000 r.p.m. at 20°C.
Plasmid DNA bands were then recovered from the centrifuge tube, and ethidium
bromide extracted using equal volumes of water saturated butanol. Plasmid DNA
was then precipitated with 3 volumes of 70% ethanol, spun at 10 000 r.p.m. for 15
mins at 4°C, rinsed in 70% ethanol, air dried and resuspended in Tris/EDTA buffer.
Concentration of DNA was determined spectrophotometrically at 260nm.
2.6.4.3 Template DNA
Plasmid dissolved in Tris.EDTA buffer (pH8) was digested with the appropriate
restriction enzyme as in Table 2.2. Digests were performed in a total volume of 20jil
in DEP treated eppendorf tubes with 2(il lOx restriction buffer, 1 unit of restriction
enzyme and 17|il plasmid solution. l|il of digested plasmid was electrophoresed on
a 1% agarose gel to verify linearisation.
2.6.4.4 In vitro transcription of complementary riboprobes
Probes were transcribed in vitro from linearised plasmid constructs containing
cDNAs encoding the neuropeptides and immediate early genes. Linearised plasmids
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were incubated in a total volume of 10pl containing [35S]-UTP (800 Ci/mmol,
Amersham International, UK ) and "cold" UTP to a total concentration of 20(iM.
CTP, ATP and GTP were also present in excess. The reaction mixture also
contained lxlO'^M dithiothreitol (Sigma), RNase inhibitor (Gibco) and the
appropriate polymerase as summarised in Table 2. After incubation at 37°C or 40°C
for 60 minutes, transcription was halted by incubation with 1 unit DNase I (RNase
free, GIBCO) for 10 minutes at 37°C. Probes were then extracted in phenol:
chloroform: isoamyl alcohol and RNA precipitated using glycogen, ammonium
acetate and 100% ethanol at -80°C for 10 minutes. Following centrifugation @
14000 r.p.m., pellets were dried under vacuum and resuspended in DEP water.
Neuropeptide probes were labelled to a specific activity of 3-5x108 Ci/mmol and
immediate early genes to a specific activity 6-10xl08 Ci/mmol depending upon
probe length. The length, appropriate restriction enzymes and RNA polymerases for
each of the riboprobes is detailed in Table 2.2.
2.6.4.5. Verification of probe labelling
1 p.1 of RNA solution was counted in 5ml scintillation fluid in a beta counter to
estimate the total activity of the probe. l|il of RNA was also electrophoresed on a
vertical 4% polyacrylamide denaturing gel, and exposed against B-max film
(Amersham International) for 3-16 hours to check for incorporation of nucleotide
and any degradation of the probe. The remaining RNA was stored at -20°C in
hybridisation buffer.
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Table 2.2. Restriction enzyme usedfor plasmid linearisation, RNA polymerase and






(3-PPT 441 EcoRl SP6
a-CGRP 450 EcoRl SP6
Somatostatin 450 Hindlll SP6
VIP 350 PvuII SP6
Transcription
factors
c-jun 732 SphI T7
junD 404 EcoRl SP6
NGFI-A 230 EcoRl T7
NGFI-B 160 Smal T7
AP-2 240 EcoRl T3
2,6.5 In situ hybridisation
2.6.5.1 Hybridisation and washing
Sections were removed from the -80°C freezer and immediately postfixed in 4%
paraformaldehyde in 0.1M phosphate buffered saline solution for 10 min and rinsed
three times in 2xSSC. All solutions were treated with diethylpyrocarbonate (0.02%).
[35S]-labelled cRNA probes in hybridisation buffer were denatured by heating at
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70°C and added to hybridisation mix (50% deionised formamide, 0.6 M NaCl , 10
mM Tris-Cl (pH 7.5), 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.1% BSA, 1 mM
EDTA, 0.1 mg denatured salmon sperm DNA, 0.05 mg/ml total yeast RNA, 0.05
mg/ml yeast tRNA, 10% dextran sulphate and 10 mM dithiothreitol) to give lOxlO6
counts/ml. Hybridisation mix (200 |il) was added to each slide and hybridisation
was carried out overnight in sealed humid chambers at 45 or 50°C, humidified with
box buffer (Section 2.6.1.2). After hybridisation slides were rinsed in 2xSSC and
treated with RNase A (30 [ig/ml) for 60 min at 37°C in boxes humidified with buffer
(Section 2.6.1.2). Washes consisted of 2xSSC at room temperature and O.lxSSC at
50-55°C for 60 minutes for all probes. Sections were then dehydrated in 50,70 and
90% ethanols in 0.3 M sodium acetate, air dried overnight and dipped in K5 nuclear
emulsion (Ilford, UK) diluted 1:1 with distilled water at 42°C. Sections were
exposed at 4°C for 2-4 weeks, developed, counterstained with haematoxylin and
eosin and coverslipped with DPX mountant (BDH). Control sections were
pretreated with RNase A (100 (ig/ml) for 60 min at 37°C prior to hybridisation.
Positive control brain sections were exposed to B-max film (Amersham) for 3-10
days before dipping in emulsion.
2.6.5.2 Positive controls
As VIP and some of the immediate early genes are not basally expressed in DRG
neurons, positive control sections of brain tissue were used in these in situ
hybridisations.
Sections through the hypothalamic suprachiasmatic nucleus were used as positive
controls for VIP expression and hippocampal and cerebellar sections used for
positive control of NGFI-A, NGFT-B, the JUN family and AP2 expression.
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2.6.6 Quantification of mRNA expression
All neurons studied belonged to the class of small, dark neurons i.e. with neuronal
cell bodies of less than 30 Jim diameter, which are those thought to belong to the
polymodal nociceptor class involved in neurogenic inflammation.
In the initial time course experiments mRNA levels were quantified by direct visual
counting of the silver grains overlying individual cells expressing neuropeptide
mRNAs. Expression of mRNA was later quantified using computer image analysis
(Seescan, Cambridge) of sections. Neuropeptide in situ hybridisation (which gives a
high silver grain density) was assessed using software which identifies single grains
and clumps independently. Immediate early gene in situ hybridisation was
quantified using the software which identifies only single grains (identical to that in
the first stage of neuropeptide mRNA assessment). A correlation between analysis
by eye and computer was also performed. The relative advantages/disadvantages of
the two methods of analysis are discussed in Chapter 5.
A positive cell was classified as one which showed a hybridisation signal to
background ratio of at least 4:1. In the time course experiments, four representative
cells and four equal areas of background expression in each of three separate
sections of each DRG were counted for each animal. In all other experiments a
greater number of neurons was analysed due to the increased speed of counting with
the computer-aided system. Background values were subtracted from cell counts




Equation 2.1. X = xtynzbn)
l
n
where:- n = the total number of cells counted
y = the number of silver grains overlying a cell
b = the number of silver grains overlying an equal area of background
L5 DRG mRNA expression from experimental animals was expressed as a
percentage of L5 DRG mRNA expression from untreated controls to eliminate
variability in silver grains due to probe specific activity, emulsion layer thickness
and time of exposure. The method of calculation of the percentage of control
expression is described below and discussed in Chapter 5.
2.6.7. Calculation of in situ hybridisation results as a percentage of untreated
control expression
In situ hybridisation results are all expressed as a percentage of the expression of
each messenger RNA in L5 DRG sections taken from a group of normal male Han
Wistar rats. Control sections are hybridised, exposed to emulsion and developed at
the same time as the experimental sections.
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The mean for each group is then calculated using Equation 2.2
Equation 2.2 % control = 100 * T, IYXp) /££Xc / iv)l
ne
where:- X = mean number of silver grains per cell in an animal
e denotes the experimental group
c denotes the control group
n is the number of animals per group
2,6.8. Statistical analysis of in situ hybridisation data
Data from in situ hybridisation experiments were compared using ANOVA
followed by Dunnetts post hoc test. The Null Hypothesis was rejected at the 5%
probability level.
2.7 Subcloning of JUN family cDNA fragments
A Sal I- Bgl II human genomic c-jun cDNA fragment cloned into GEM, was kindly
given by Dr. M. Seckl. The full length mouse jun-D cDNA cloned into pGEM2 was
generously supplied by Dr J. Quinn.
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2.7.1 Selection of appropriate cDNA restriction fragments
Restriction fragments specific for c-jun and jun-D were identified from 3'
untranslated sequences of a c-jun human genomic DNA Sal I- Bglll fragment
(Hattori et al., 1988) and the mouse jun-D cDNA (Ryder et al., 1989).
The restriction fragments were digested with the appropriate restriction enzymes as
detailed in Table 2.3 (Northumbria Biochemicals Ltd) at 37°C for 1 hour and
purified by size electrophoresis on 1.5% low melting point agarose gel. Bands were
cut from the gel, melted at 70°C and extracted with 1:1 phenohchlorofonn/isoamyl
alcohol (24:1), ethanol precipitated and centrifuged at 14000 r.p.m. for 10 minutes.
The pellet was air dried and resuspended in 10[il sterile distilled water. Recovery of
the fragment was checked using horizontal agarose gel electrophoresis on a 1.5%
agarose gel.





c-jun Hae III Hinc II 732 (2747-3479)
jun D Hinc II- Dra I Hinc II 404(1154-1558)
2.1.2 Subcloning of c-iun and iun-D restriction fragments
The fragments were ligated into the Hinc II site of linearised pGEM3 vector using
T4 DNA ligase (NBL), lOmM ATP in ligase buffer, and two different ratios of insert
to vector in order to optimise conditions. pGEM vector was religated as a control.
Ligations were incubated at room temperature for at least 4 hours. The ligation
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mixture was then digested with Sal I (NBL) which shares the restriction site with
Hinc n, to linearise any religated vector and the ligation mixtures were then used to
transform competent E.coli. (HB101) as described in section 2.6.3.1.
Individual colonies transformed with ligation mixtures were cultured overnight in
3ml Luria Broth and DNA extracted according to the method of Sambrook et al.,
1989. Bacterial pellets were centrifuged in eppendorf tubes for 30 seconds, drained
of medium and resuspended in glucose/Tris/EDTA buffer (200|il). Bacterial cells
were lysed with NaOH/SDS (lOOpl) solution and neutralised with acetate solution
(150|ll). Tubes were centrifuged to remove protein/SDS/ high molecular weight
RNA and the supernatent removed. DNA was precipitated with 2 volumes of 100%
ethanol, centrifuged for 10 minutes at 14000 r.p.m., the pellet air dried and
resuspended in 50pl TE buffer and 20|ig/ml RNase A. Aliquots of DNA were then
double digested with EcoRI and Hindlll to cut out the entire polylinker region plus
insert if present. Digests were then electrophoresed on 1% agarose gels to determine
whether the insert was present.
2,7.4 Specificity of subclones
Specificity of the jun subclones was determined by in situ hybridisation in control




2.7.4,1A Extraction of whole brain mRNA
Total messenger RNA was extracted from whole brain by the guanidium
thiocyanate method (Chomczynski and Sacchi, 1987).
Whole brain was homogenised in 1ml denaturing solution (0.025M sodium citrate,
0.5% sarcosyl, 4M guanidium thiocyanate, 0.1M (3-mercaptoethanol in DEP water)
in sterile glass/glass homogenisers and 500|il aliquots transferred to DEP treated
eppendorf tubes. DNA was precipitated with 50|il 2M sodium acetate solution, and
extracted using citrate saturated phenol and chloroform/isoamyl alcohol (49:1).
After centrifugation for 20 minutes at 4°C and 14000 r.p.m. the aqueous phase was
transferred to a DEP eppendorf and precipitated with isopropanol at -20°C
overnight.
The RNA was recovered by and resuspended in 60|il denaturing solution. The
RNA was then re-precipitated with 1 volume isopropanol and precipitated for 4
hours at -20°C. RNA was then recovered by centrifugation for 20 minutes at 4 °C
and 14000 r.p.m, washed in 75% ethanol, dried in vacuo and resuspended in 5-20|il
DEP water depending on pellet size.
2.7.4.1B. RNA electrophoresis and capillary transfer
Total brain RNA samples were denatured in 12.5% MOPS buffer, 12.5%
formaldehyde and 50% formamide at 65°C for 15 minutes and electrophoresed on a
submerged horizontal denaturing agarose gel (lxMOPS buffer, 0.5% formaldehyde,
1% agarose in DEP water). The gel was photographed under ultraviolet trans¬
illumination to check for RNA degradation and blotted overnight by capillary
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transfer onto nylon membranes (Amersham International). The gel was placed on a
3MM paper wick over an upturned gel plate in a reservoir of sterile 20xSSC
solution. The nylon membrane, cut to exactly the same size as the gel, was placed in
direct contact with the gel. Three layers of 3MM paper were placed on top of the
filter, and covered with a 5cm thickness of absorbent paper. A weight was placed on
top of the paper and the blot left overnight. RNA was then crosslinked to the nylon
membrane by baking at 80°C for 3 hours.
2.7.4.1C. Radiolabelling of cDNAs
The jun cDNA fragment was isolated from the vectors by digestion with EcoRI and
Hindlll and gel purified on a low melting point agarose gel as described in section
2.7.2. The cDNA fragments were then diluted in 2 volumes TE buffer and melted at
65°C. The cDNAs were labelled using a random priming kit (Boehringer
Mannheim). 25ng DNA was incubated at 37°C for 30 minutes with 32P labelled
dCTP, unlabelled deoxynucleotides and Klenow enzyme. The reaction was stopped
by the addition of 2(il 0.25M EDTA, pH 8. Labelled probe was then precipitated
using 1/20 volumes 5M NaCl and 2 volumes absolute ethanol and incubating for 10
minutes at -80°C. The DNA was recovered by centrifugation, air dried briefly and
resuspended in 50pl DEP H2O.
2.7.4.1D. RNA hybridisation
Filters were prehybridised in 10ml hybridisation buffer at 42°C for at least 2 hours
in a Hybaid hybridisation oven. The buffer was then removed, probe added to the
buffer and then replaced in the hybridisation tube, and the filter hybridised overnight
at 42°C. Following hybridisation, filters were washed in 2xSSC, 0.1% SDS (sodium
lauryl sulphate; Sigma) at 42°C for 30 minutes. Stringent washes consisted of 2
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consecutive washes in 0.2xSSC, 0.1% SDS at 50°C for up to 1 hour each. Filters
were then covered in Saran wrap and exposed to X-AR film (Amersham
International) in cassettes with intensifying filters, for 1-5 days.
Films were developed for 2.5 minutes in D19 developer (Kodak) and fixed for 3
minutes in Amfix high speed fixer (Champion Photochemistry).
2.7.4.2. In situ hybridisation
Messenger RNA distribution for c-jun and jun-D was determined in control rat
brain sections through the hippocampus using the same protocol as described in
Section 2.6. Distribution of mRNAs was determined by film autoradiography for 10
days (Hyperfilm, (3-max; Amersham International).
2,8 Neuropeptide radioimmunoassay
All neuropeptide radioimmunoassays were kindly performed by John Bennie and
Sheena Carroll (MRC Brain Metabolism Unit, Royal Edinburgh Hospital,
Edinburgh).
Sample preparation and radioimmunoassay were performed as described previously
(Pierotti and Harmar, 1984; Smith et al., 1991)
2.8.1. Sample preparation
Animals were killed by decapitation and a laminectomy performed to expose the
lumber enlargement. The sciatic nerve was exposed, L4 and L5 DRG identified and
dissected free from the dura. DRG were rapidly frozen on dry ice and stored at
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-20°C prior to peptide extraction. Left and right L4 and L5 DRG respectively, were
pooled to assess peptide levels from left (lesioned) or right (unlesioned) DRG. DRG
were homogenised on ice in lOOjil 2M acetic acid, homogenates centrifuged at 14
000 r.p.m. to remove insoluble material and supernatents were assayed for SP,
CGRP and SS.
2,8.2 Radioimmunoassay
Samples were evaporated to dryness in a vacuum oven (45°C, 700 mmHg) and
resuspended in assay buffer (0.1M PO4, pH 7.6, lg bovine serum albumin/1).
For SP assay, standards (0-500 pg/ml) and samples were prepared in a volume of
200j.il in duplicate. Standards and samples were incubated at 4°C for 16 hours with
200jll of 1:80 000 dilution of rabbit anti-SP antiserum and 5000 cpm in lOOjil of 125I
labelled SP. Bound radiolabel was separated from free by precipitation with donkey
anti-rabbit gamma globulin antiserum (Scottish Antibody Production Unit, Carluke,
UK, SAPU).
For CGRP assay, standards (human CGRP 0-5000 pg/ml, Peninsula; 200|il/tube) 0r
samples were incubated for 16 hours at 4°C with lOOpl of 1:2000 dilution of rabbit
anti-human CGRP antiserum (Amersham International) and 5000 cpm 2-
[,25I]iodohistidyl CGRP (human, Amersham International)in lOOjil assay buffer.
Bound radiolabel was separated from free by precipitation with donkey anti-rabbit
gamma globulin antiserum (SAPU).
For SS assay, standards containing SS-14 (0-120 fmol) or samples diluted to 200JJ.1
in assay buffer were incubated with 200)il 12<5I SS-14 (5000 cpm) and 200|il
antiserum (1:250 000 dilution; antiserum directed against SS-14) for 20-24 hours at
4°C. Charcoal suspension (0.2 ml; 25g/l in 0.1M PO4 buffer pH 7.6 containing 10g/l
bovine serum albumin) and 0.8ml phosphate buffer were added and the tubes
incubated in ice for 20 minutes before centrifugation. The radioactivity of the
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supematent was counted. The antiserum detected SS-14, SS-28 and higher
molecular weight forms of SS.
Cross-reactivity between peptide antibodies, inter- and intra assay coefficients of
variance and assay sensitivity are summarised in Table 2.4.
Table 2.4. Antibody cross-reactivity and coefficients ofvariance for neuropeptide
radioimmunoassay
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2.9 Assessment of chronic stress in arthritis
2.9.1 Corticosterone radioimmunoassay
2.9.1.1 Preparation of samples
Whole blood samples (500-1000pl) were taken from adult male Han Wistar rats
with both mono- and symmetrical arthritis by tail nicks, morning and evening (2
hours after lights on/off), three times per week during the development of arthritis
Samples were taken in tubes containing anticoagulant, kept on ice until spun and
plasma samples collected and kept at -20°C until assayed for corticosterone.
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Animals were killed by decapitation in the morning of day 15 after adjuvant
injection, trunk blood collected into lithium chloride tubes and stored on ice. Blood
samples were spun and plasma samples stored at -20°C until assayed for
corticosterone.
2.9.1.2 Corticosterone radioimmunoassay
Rat plasma samples diluted 1:25 in assay buffer were incubated for 30 minutes at
75-80°C. Samples (50|il) or corticosterone standards (0.005-6.4 pmol/50|il) in
sodium borate assay buffer were incubated in duplicate with 100|il of 1:5000
specific anti-corticosterone antiserum and 50(il (15 000 c.p.m.) [3H] corticosterone
overnight at 4°C. Bound and unbound fractions were separated on ice by addition of
dextran-coated charcoal suspension (0.5g activated charcoal; 0.05g Dextran T-70;
50mg bovine serum albumin/ 100ml sodium borate buffer) and centrifugation at 4°C
for 30 minutes at 3000g. The supernatent was removed into scintillation vials
containing 5ml Picofluor 40 scintillant and counted in a (3-counter.
Standard curve plots and sample calculations were calculated using computer
software (Assayzap).
2.9.2 Corticosterone binding globulin assay
Corticosterone binding globulin (CBG) assays were kindly performed by Isobel
Forbes.
Plasma samples from morning trunk bloods were assayed for CBG as previously
described (Martin et al., 1977). Endogenous steroids were removed from plasma by
running samples through a Sephadex LH-20 column (10 x 1cm). Plasma samples
were diluted 1:50 with TEGMD buffer, pH7.4 (30mM Tris, ImM EDTA, lOmM
64
sodium molybdate, 10% glycerol, ImM dithiothreitol) and incubated overnight at
4°C with 200nM solution of [3H] corticosterone in TEGMD to give total binding.
Non-specific binding was determined by incubation with excess (0.1M) cold
corticosterone. Separation of bound from free corticosterone was achieved on
Sephadex LH-20 columns as described above. CGB levels were expressed as pmol
[3H] corticosterone bound/mg protein.
2.10 Immunohistochemistrv
2.10.1. Section preparation and solutions
Parallel fresh frozen DRG tissue sections to those used for in situ hybridisation
were mounted on gelatin/poly-L-lysine subbed slides and processed for
immunohistochemical localisation of SP-like immunoreactivity.
4% paraformaldehyde in 0.1M PB pH7.4 as described in section 2.4 except the
water is not DEP treated.
0.1M phosphate buffer (PB): 20mM NaH2P04 (BDH); 80mM Na2HP04
(BDH); in 1 litre distilled water.
0.1M phosphate buffer (PB)+ 0.3% Triton X-100 (Sigma): 3ml TX-100 per
litre 0.1MPB
Tris buffered saline (TBS) 0.05M, pH 7.6; 9g NaCl; 6.05g Trizma base; per litre
distilled water.
2.10.2. Immunohistochemistrv method
The anti-SP antiserum used was that also used for SP radioimmunoassay (Section
2.8; a generous gift from Dr Tony Harmar). Slide mounted fresh frozen tissue
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sections were postfixed in 4% paraformaldehyde in 0.1M phosphate buffer (0.1M
PB), pH 7.4 for 30 minutes, and then washed thoroughly in 0.1M phosphate
buffer/0.3% Triton X-100 (TX-100; Sigma). Non-specific binding was blocked by
incubation of the tissue sections, in a humid box, with 10% normal sheep serum
(NSS; SAPU) in 0.1M PB + 0.3% TX-100 for twenty minutes at room temperature.
Slides were then drained and incubated overnight at 4°C in a humid box with
primary anti-SP antiserum diluted 1:1000 in 0.1M PB/0.3% TX-100/1% NSS. After
primary incubation, slides were thoroughly washed in 0.1M PB/1% NSS/0.3% TX-
100 before incubation for 90 minutes with a 1:400 dilution of sheep anti-rabbit IgG-
biotin conjugate (Boehringer Mannheim) in 0.1M PB/1% NSS. Tissue was then
thoroughly washed in 0.1 PB and incubated in avidin-peroxidase complex
(Vectorstain Elite, Vector Laboratories) for 1 hour. After rinsing in 0.1 PB, antibody
binding was localised using diaminobenzidene (0.3ml 5mg/ml diaminobenzidene in
TBS; 1.2ml TBS; 0.02% hydrogen peroxide). Following the peroxidase reaction
(approx. 5 minutes) tissue sections were counterstained with methyl green for 15
seconds, dehydated through 70% and absolute ethanol and coverslipped with DPX
mountant. Control for the specificity of the signal was omission of the primary
antiserum.
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SECTION 3 EVALUATION OF A MODIFIED MODEL OF ADJUVANT
MEPIATEP-ABTHRITIS IN THE.RAX
3.1 INTRODUCTION
3.1.1 Classical adjuvant-induced polyarthritis in the rat
Arthritis in the rat was originally described in 1959 by Pearson and Wood as a
reproducible polyarthritis induced by intradermal injection of heat-attenuated
mycobacteria suspended in mineral oil into the tailbase or footpad. The reaction is
generally one of systemic illness, with inflammatory involvement of peripheral
joints, particularly of the hind limbs. After eleven to sixteen days a severe
polyarthritis of the tarsal, carpal, phalangeal and spinal joints develops, accompanied
by lesions to the eyes, ears, nose, skin and genitals as well as anorexia and profound
weight loss. (Pearson and Wood 1959; Rainsford, 1982) Adjuvant arthritis (AA)
shows similar histological features to rheumatoid arthritis in humans and is therefore
useful in studies of the chronic pain and inflammation of this condition. AA has
been widely accepted as a model of chronic pain as rats show an increased self
administration of both non-steroidal anti-inflammatory drugs and opiate analgesics
when compared to normal animals (Colpaert et al., 1980; Colpaert et al., 1982).
Adjuvant arthritis has been widely exploited in the study of all aspects of arthritic
disease including neurophysiology, peptide biochemistry and immunology
(Guilbaud 1991; Ohno et al., 1990; Kuraishi et al., 1989). However, the widespread
and severe disease induced makes it difficult to attribute changes observed to the
arthritic processes per se.
It is extremely difficult to study the pathophysiology of inflammation and arthritis
in vitro as the interactions between joint, immune system, vasculature and sensory
and sympathetic nervous systems are disrupted. Therefore whole animal models
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which facilitate the study of inflammation and arthritis are continually being
evaluated.
3.1.2. Other models of arthritis
In the light of the severity of AA, and the ethical problems involved in the care of
such severely affected animals, there have been numerous attempts to modify AA or
develop other animal models of chronic pain or inflammation. With such a severe
disease process, it is obviously more difficult to attribute observed changes
specifically to the arthritic process. There have been several attempts to develop
models which show milder disease than the classical AA.
The injection of urate crystals directly into the joint space of either cats (Okuda et
al., 1984) or rats (Otsuki et al., 1986; Coderre and Wall, 1987) has been suggested as
an alternative to adjuvant arthritis. This intervention gives rise to an inflammatory
process peaking at 24 hours and resolving after approximately 1 week, which is
milder than adjuvant disease. Intra-articular urate crystals do not result in arthritic
changes, but joints show tissue oedema and polymorphonuclear leucocytic
infiltration.
Injection of adjuvant into the footpad of the rat has been suggested as a way of
limiting AA to one paw (Millan et al., 1988) but this has long been recognised as a
very effective site of injection for the induction of polyarthritis (Waksman et al.,
1960;Ward and Jones, 1962) and indeed the article proposing this model did
describe significant contralateral paw swelling after 21 days (Millan et al., 1988).
A localised adjuvant-induced monoarthritis which shows no behavioural or
histological evidence of contralateral effects, where arthritis is induced by
periarticular injection of adjuvant, has been extensively used in the study of joint
receptors in the intact animal (Grubb et al., 1988; Grubb et al., 1991; McQueen et
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al., 1991) and has been adapted to produce a limited adjuvant induced monoarthritis
which is stable for six weeks (Butler et al., 1992).
In these studies, the monoarthritis described by Grubb et al. (1988) has been further
evaluated in view of recent hypotheses that ipsilateral inflammation necessarily
results in contralateral changes indicative of inflammation (Levine et al., 1985b;
1985c; Kidd et al, 1989a). Preliminary studies showed that localised or more distant
inflammation may be dependent upon the total injected dose of Mycobacterium
species. Therefore the effect of increasing amounts of Mycobacterium tuberculosis
suspended in paraffin oil on the arthritis induced by periarticular injection of
adjuvant have been further investigated. The relationship between measures of
inflammation and the histological appearance of the joint was also studied to
determine whether use of these common indices is valid as such "blind" assessments
have been criticised (Rainsford 1982). Rheumatoid arthritis is thought to have a
diumal variation, being more severe in the mornings (Chowdrey and Lightman,
1993); therefore measurements of joint swelling and inflammation were routinely
performed at the same time of the day to prevent the possibility of bias due to this
effect.
3.1.3. The arthritic rat as a model of chronic stress
Chronic inflammatory polyarthritis in the rat was first proposed as a model of
chronic stress by the authors of some of the original evaluations of the model
(Colpaert, 1987; Colpaert and Van den Hoogen, 1983; Colpaert et al., 1882).
However, these studies were primarily concerned with the arthritic rat as a model of
chronic pain, and therefore did not seek to establish any changes in the activity of the
hypothalamo-pituitary-adrenal axis in these animals. More recent work has shown
that there is a chronic hypothalamic-pituitary-adrenal stimulation in these animals,
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with a loss of diurnal rhythm of both adrenocorticotropin releasing hormone
(ACTH) and corticosterone (Sarlis et al., 1992). These animals also show a
disturbance of the normal circadian rhythm of motor activity seen in rats.
Susceptibility to AA in the inbred Lewis rat has been postulated to be due to a
defective HPA axis response to inflammatory stimuli (Sternberg et al., 1989).
However, this ineffective HPA axis response may not be not an absolute requirement
for susceptibility to AA as strains which show a vigorous HPA response have been
shown to be susceptible to AA (Harbuz et al., 1993) and AA has been studied in a
variety of different strains of rat (Waksman et al., 1960; Jones and Ward, 1963;
Vernon-Roberts et al., 1976; Nusbickel and Troyer, 1976). However it has also been
postulated that an underlying defect in hypothalamic responses may contribute to the
aetiopathogenesis of human rheumatoid disease (Chikanza et al., 1992). It was,
therefore, of interest to examine the corticosteroid status of these arthritic animals to
assess whether this model also represents a chronic stressor.
3.2 MATERIALS AND METHODS
3.2.1 Dose dependency of adjuvant-induced arthritis
Male Wistar rats (200-250 g) were allocated to groups (n=5 per group). Animals,
under halothane anaesthesia (5% in oxygen), were injected intradermally with either
paraffin oil or Freund's Complete adjuvant containing 50 pg, 150 pg or 250 pg
attenuated Mycobacterium tuberculosis (M. tub.; MAFF, UK) suspended in 0.05 ml
paraffin oil, divided between two injection sites around the left tarsal joint. Controls
were untreated.
Before induction of arthritis and twice weekly thereafter, the animals were weighed,
their left and right tarsal joint circumferences measured, and left tarsal joints scored
for inflammation and response to a mild noxious stimulus. Nociceptive threshold
70
was determined by the pressure required to elicit limb withdrawal was measured
either subjectively and scored on an analogue scale 0-3 (0=intense pressure, 3=slight
pressure), or objectively using an electrical meter connected to a pressure transducer
and scored 0-8 based on the meter reading (0=very slight pressure, 8=intense
pressure). All measurements were performed blind to treatment by the same
experienced operator.
Preliminary histological studies demonstrated chronic monoarthritis 14 days after
adjuvant injection. Therefore, 15 days after injection, animals were deeply
anaesthetised with sodium pentabarbitone (60 mg/kg i.p.) and perfused through the
descending aorta with heparinised saline (500 U/kg, 10 ml) followed by 10% formal
saline (~50 ml) until the hind limbs were fixed. An additional group of animals
injected with 150(ig M. Tub. was killed after 69 days to determine whether bilateral
arthritis would eventually develop and joints were also assessed histologically. Both
hind limbs were removed and processed for histological examination as detailed in
Section 2. Each section was scored blind for histological evidence for the presence
and degree of joint inflammation; assessed on the following histological features;
inflammatory cell infiltrate, synovial proliferation, articular cartilage breakdown and
new bone formation and classified as:- 0=normal, l=subdermal inflammation,
2=mild, 3=moderate and 4=severe joint inflammation; scores >3 were taken as
indicative of arthritis.
3.2.2 Measures of chronic stress
Groups of male Han Wistar rats (200-250g; n=5 per group) were induced for study
of either mono- or bilateral arthritis. Tail blood samples were taken three times per
week (morning and evening, 2 hours after lights on/off) during the development of
chronic arthritis, collected and stored on ice until centrifuged to obtain plasma
samples. On day 15 post-injection, animals were killed in the morning by
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decapitation, and trunk blood collected. Thymus, spleen and adrenals were also
collected and weighed. Control tissue from age-matched untreated animals was also
taken. Plasma samples were stored at -20°C until assayed for corticosterone and
CBG as outlined in Section 2.9.
3.2,3. Statistical procedures
Statistical analysis was by ANOVA (factorial or repeated measures as appropriate)
followed by Dunnett's post hoc test. Spearman Rank correlation coefficient was
used to determine correlations between the histological arthritis and gross measures
of inflammation, joint circumference, nociceptive threshold and inflammation
scores. Values are means± S.E.M. The Null Hypothesis was rejected at the 5%
probability level.
3.3.1. Behaviour of animals injected with Mycobacterium tuberculosis, or vehicle
During development of inflammation, animals showed little or no apparent
discomfort and locomotor activity was near normal, with only occasional guarding
of the affected limb. Only in the group receiving the highest dose of M.tub. (250 pig)
was the left hind limb not used for walking, and then only occasionally, fourteen
days post-injection.
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3.3.2. Gross parameters of inflammation
The normal gain in weight was not affected by any treatment although the group
receiving the largest amount ofM. Tub. showed a non-significant drop in weight on
day 15 (Figure 3.1).
Figure 3.1
-2 0 2 4 6 8 1012 14 16 18
day after injection
Figure 3.1. Mean body weights of rats injected around left ankle with 150fig, and
250/J.g M. Tub. and untreated controls during the course of the study. Only the
group injected with 250pg M. Tub. show a non-significant alteration in the normal
weight gain seen in rats of this age. (Data from paraffin and 50pg groups not
shown; not significantly different from untreated controls).
Animals injected with M. tub. showed a dose-related increase in left (injected) joint
circumference, redness and swelling, and histological inflammation score. Injection
of 50 fig M. tub. or paraffin oil alone caused slight, non-significant increases in left
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tarsal joint circumference which remained constant for 15 d. By contrast, injection
of 150 fig or 250 jig M.tub. caused acute inflammation and significant swelling of
the left tarsal joint within 24 hours, reaching an initial peak 4 days post-injection
(p<0.01). This initial swelling partially resolved at days 8-11 (although remaining































Figure 3.2. Mean left joint circumferences during the development ofarthritis in
rats injected around the left ankle joint with either M. Tub., paraffin, or untreated.
*p<0.05 compared to untreated control animals.
The group of rats injected with 150jig M.tub. and killed after 69 days showed
swelling of the left tibio-tarsal joint with no effect on right joint circumference up to
69 days post adjuvant injection (Figure 3.3). Histological assessment of the right
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and left joints verified that inflammation remained confined to the left (injected)
limb (see Section 3.3.3, Figure 3.9 and Table 3.1).
Figure 3.3
Figure 3.3. Mean increase in left and right joint circumferences in rats 69 days
after injection of 150/ug /J. M. Tub. around the left ankle joint showing joint swelling
affecting the joint only on the injected side.
Animals treated with the 250 (ig dose showed redness and swelling of the
contralateral tarsal joint at 14 days post-injection. Those receiving 250 (ig only
occasionally showed mild forepaw swelling, nose and eye inflammation Only
animals injected with 250 pg of M. tub. showed a statistically significant increase in
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Figure 3.4 Mean right joint circumferences of rats injected around left ankle joint
with either M. Tub., paraffin oil or untreated. *p<0.05 compared with untreated
controls.
3.3.3. Histological features of adjuvant-induced inflammation
Animals receiving no treatment, paraffin, or 50 jig M.tub. showed no histological
evidence of arthritis of the left tarsal joint, although an inflammatory infiltrate in
overlying subcutaneous tissues was evident in the latter group (Figure 3.5). The
histological features in the left (injected) joint from an animal injected with 150fig
M.tub. are illustrated in Figure 3.6. Similar histopathology was also seen in the right
(uninjected) ankle joint of animals receiving 250 (ig M. Tub. and is shown in Figure
3.7. Histopathological features seen in the joints of these animals were mononuclear
cell infiltration, synovial hyperplasia and oedema, pannus formation and
subchondral bone resoiption and are illustrated in Figure 3.8. Neither gross nor
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Figure 3.5. Histological appearance ofsubdermal infiltrate from an animal
injected with 50pg M.tub. which showed no other signs ofjoint inflammation.
11
Figure 3.6. Photomicrographs showing the left (top) and right (bottom) tibio-tarsal
joints from a rat injected around the left tibio-tarsal joint with 150jig M.tub.,
showing arthritis limited to the left (injected) joint.
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Figure 3.7. Photomicrographs of left (top) and right (bottom) tibio-tarsal joints
from a rat injected around the left tibio-tarsal joint with 250pg M.tub., 14 days after
adjuvant injection, showing arthritis affecting both joints.
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Figure 3.8. Photomicrographs showing some features ofadjuvant-induced
arthritis; inflammatory infiltration of synovium and joint cavity (top) and pannus
invasion ofsubchondral bone (bottom). Original magnification xlO.
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Figure 3.9. Photomicrographs of left (top) and right (bottom) tibio-tarsal joints 70
days after injection of 150jig M.tub. around the left tibio-tarsal joint showing
arthritis affecting only the left (injected) joint.
histopathological changes indicative of arthritis were seen in the right joints of
animals injected with 150|ig M. Tub. at either 15 (Figure 3.6) or 69 days (Figure 3.9)
post-adjuvant injection, agreeing with and extending the observations of Grubb et al.
(1988). Histological scores are summarised in Table 3.1.
Table 3.1. Histological scores for left and right tibio-tarsal joints in the five
treatment groups of rats at day 15 after adjuvant injection of the left limb. Median




Paraffin oil 1 (0-1) 0(0-1)
50|ig M. Tub. 1 (0-2) 0 (0-1)
150pg M. Tub. 3.5 (3-4)** 1 (1-2)
250pg M. Tub. 4 (2-4)** 2 (1-4)**
150|lg M. Tub. (70 days) 3 (3)* 0.5 (0-1)
3.3.4. Relationship between gross parameters and histological features of
inflammation
There was a significant correlation between the histological score and (i) the
increase in joint circumference (n=37, r=0.71, p<0.0005) and (ii) the inflammation
score (n=25,1-0.86, p<0.0005). The response to a subjectively scored mild noxious
stimulus (squeeze) did not correlate significantly with joint histology (n=23, r=0.36,
p>0.05), whereas when this parameter was subsequently assessed objectively, a
highly significant correlation was seen (n=30, r= -0.699, p<0.0001).
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3.3.5. Parameters of chronic stress
Thymus, adrenal and splenic weights and final CBG values for each group are
summarised in Table 3.2. There were no significant differences in any of these
parameters between controls, mono- and bilaterally arthritic rats.
Table 3.2 Thymic, adrenal and splenic weights and CBG values in control, mono-
and bilaterally arthritic male rats. CBG levels are expressed as pmol. 3Hlmg
protein. All values are mean ±S.E.M.
Group Thymus Adrenal Splenic CBG
weight (g) weight (g) weight (g)
Control 0.58+0.057 0.077+0.004 0.903+0.035 13.2+2
Monoarthritic 0.523±0.04 0.065+0.006 0.941+0.074 16.8+2
Bilaterally 0.539+0.015 0.079+0.008 1.057+0.065 10.7+2
arthritic
None of these measures, which are known to be sensitive to increased levels of
circulating corticosterone were significantly different from control animals.
The morning and evening corticosterone levels in both groups of arthritic rats are
shown in Figure 3.10. Control basal corticosterone levels are usually below
50nmol/L and maximal control evening levels are represented by the dashed line at
approximately 500 nmol/L. It can be seen from this graph that circulating
corticosterone levels are generally raised in both monoarthritic and bilaterally
arthritic rats showing levels indicative of stress. Importantly the normal diurnal
variation in corticosterone secretion is lost from the onset of inflammation
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Figure 3.10 Morning and evening plasma corticosterone levels in mono- and
bilaterally arthritic rats during the development of inflammation. The dashed line
shows the maximal evening corticosterone levels in control rats (Dr. M. Holmes,
personal communication).
These results show that adjuvant injected periarticularly can be used to induce
either a monoarthritis which remains confined to one joint for up to 69 days, or, with
a small increase in the dose of M. Tub used, can produce a bilateral arthritis of the
hind limbs, assessed by histological features of arthritis. It has also been shown that
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the gross assessment of arthritis by measurement of joint swelling shows a high
correlation with the histological assessment of arthritis.
3.4.1. Models of inflammatory arthritis
There are other models of arthritic disease commonly used in experimental animals,
in addition to adjuvant polyarthritis as described by Pearson and Wood (1959). The
subcutaneous injection of sterile air in the rat results in a pouch granuloma, the
lining cells of which have many similarities with synovial lining cells (Edwards et
al., 1981). The study of cartilage breakdown has been facilitated by an adaptation of
the air pouch model (Da Silva et al., 1993).
Many models involve the sensitisation of an animal to an antigen such as collagen
and bacterial cell wall components for example, collagen induced arthritis in either
rats or mice which is induced by two injections of native Type II collagen (Trentham
et al., 1977). Cell mediated immunity to collagen has been reported in patients with
rheumatoid arthritis (Stuart et al., 1980). Streptococcal cell wall induced arthritis in
rats, first described by Cromartie et al. (1977) induces symmetrical synovitis in all
animals treated. Both of these models affect all peripheral joints and are of use in
the study of the immune reactions involved in this disease as they are T-cell
dependent (Taurog et al., 1983; Trentham et al., 1977; Ridge et al., 1985). Like
adjuvant-induced arthritis, collagen and streptococcal cell wall arthritis show many
similarities to rheumatoid arthritis clinically, histologically and radiologically. All
show involvement of peripheral joints, chronic proliferative synovitis, pannus
formation and marginal destruction of joints (Cromartie et al., 1977; Pearson and
Wood 1959). Obviously a major difference between all these animal models and
human rheumatoid arthritis is the absence of circulating rheumatoid factor in
experimental models.
There are also two models of spontaneous arthritis both affecting mice. MRL/Mpj-
lpr/lpr mice spontaneously develop polyarthritis by five months of age, particularly
involving the hind limbs (Hang et ah, 1982). This is associated with an increase in
circulating levels of rheumatoid factors and is therefore useful in the study of the
aetiology of rheumatoid disease. The second model involving spontaneous
development involves a transgenic mouse expressing human tumour necrosis factor.
This mouse shows gross and histological evidence of arthritis with associated weight
loss, at around 3-4 weeks of age, increasing in severity up to 9-10 weeks when
complete loss of hind limb movement occurs (Keffer et ah, 1991). This model was
not initially developed as a model of arthritis and is proposed as a model suitable for
the study of the treatment and pathogenesis of arthritis. While this model would be
useful for the study of treatments of arthritic disease, and is strongly indicative of a
role for tumour necrosis factor in the pathology of arthritis, its use in the evaluation
of the pathogenesis of arthritis is complicated by the overexpression of a human
protein in an experimental mouse.
3.4,2. The validity of monoarthritic models
There has been some debate about the validity of models of monoarthritis as many
models which are initially confined to one limb eventually become more widespread
(Millan et al., 1988), and some workers have documented contralateral effects
following a very mild ipsilateral stimulus (Levine et al., 1985a; Denko and
Petricevic, 1978; Kidd et al., 1989a). The model described here (monoarthritis) has
been utilised for a number of years as a model of monoarthritis; animals have been
kept for up to 70 days after the injection of adjuvant and contralateral evidence of
inflammation has been extremely rare. Another unilateral model of arthritis induced
by adjuvant injected intra-articularly (Butler et al., 1992) also did not show any
contralateral effects when the animals were followed for six weeks. It could,
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therefore, be hypothesised that adjuvant represents a stimulus which can be graded to
produce arthritis which is either localised to the immediate area of adjuvant injection
or more widespread.
3.4.3. The use of gross measurements of inflammation in the assessment of
arthritis.
Hind-limb swelling or diameter has been widely used in the assessment of arthritic
inflammation (de Castro Costa et ah, 1981; Coderre and Wall, 1987; Butler et al.,
1992) but has been criticised (Rainsford, 1982), who states that" hind-paw swelling
.... is admittedly a convenient measure ... but tells absolutely nothing about what is
happening in the joints that are affected with the disease". The strong positive
correlations shown here between the histopathology and the hind paw swelling show
that, in this model, this statement is incorrect. The fact that inflammation scores
(when performed blind by the same experienced operator) and the response to a
noxious stimulus also correlate highly with joint pathology confirms that
complicated methods of assessment of joint destruction are not always necessary.
Rainsford also maintains that in addition to radiological studies, only complex
biochemical investigations can give an accurate picture of the state of joint
pathology. The changes seen in classical polyarthritis, and the model adapted by
Butler et al. (1992) can be assessed by radiological examination as the bony joint
destruction is marked. However, many models, including that described here have
been purposefully developed to give a milder arthritis. It has not been established
whether the histological features seen in this adapted model are too mild to show
obvious changes on radiographic analysis but total joint destruction with joint
ankylosis, as seen in more severe models, is never seen in the model described here.
In addition, it is not always possible for workers to gain access to the facilities for
radiography and complex biochemical analysis regarded as necessary by Rainsford.
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Therefore the correlations here should enable use of this model without the need of
recourse to complicated assessment of joint pathology.
3.4.4 The arthritic rat as a model of chronic stress.
The circulating corticosterone in both mono- and bilaterally arthritic rats shows
both elevated overall levels and a loss of diurnal rhythm throughout the fourteen
days of study. However, none of the other measures documented to change under
conditions of chronic stress (Sarlis et al., 1992) such as CBG levels and thymus,
spleen and adrenal weight, show any significant differences in arthritic rats
compared to controls. The thymus is particularly sensitive to increased
corticosterone and involution would be expected to occur over this period of time. It
is unclear why these parameters are unaltered in the face of raised corticosterone,
however as this arthritis is immunologically mediated, the immune stimulus may
counteract the effects of raised corticosterone on the thymus gland. In addition this
model may represent an intermittent stress, as animal discomfort may only occur
when the animal moves, and this is then reflected in raised corticosterone levels with
no alteration in any of the other parameters under study.
The particularly striking feature of corticosterone secretion in these animals is the
obvious loss of diurnal variation, due to an apparent increase in morning values.
Control values used for comparison in the studies presented here were kindly
provided by Dr. M. Holmes and were obtained from trunk blood samples in
untreated control rats of the same strain (Han-Wistar). Concurrent samples were not
taken from control animals during the fifteen days of the development of arthritis
due to the problems of obtaining unstressed control blood samples and this obviously
limits the interpretation of the data presented. It has proved difficult to obtain
control corticosterone levels in the animal facility used due to the conditions of
housing. The control data provided by Dr. Holmes were obtained using careful
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housing and handling conditions and provide a guide as to the unstressed
corticosterone levels in this strain. It is more difficult to interpret this data as a
result; however it is unlikely that the method of sampling i.e. tail nicks is
complicating the data. Tail nicks are an accepted method of sampling blood from
animals without the effects of handling producing a rise in circulating corticosterone
in itself, as the sample is taken too rapidly for circulating steroids to be altered in tail
blood. Other authors have shown a loss of diurnal rhythm in corticosterone in
polyarthritic rats (Sarlis et al., 1992) where morning corticosterone levels were
raised to control evening levels and above, whereas evening corticosterone secretion
remained unaltered until 14 days after adjuvant injection. These authors postulate
that this may be due to increased HPA activation in response to chronic stress. This
phenomenon is also apparent in other models of chronic stress (Bhatnagar et al. in
press) and certain clinical conditions such as Cushing's syndrome and depression,
where the most notable feature is a loss of the evening nadir in Cortisol secretion
(Wilson and Foster, 1992). However, the significance of the altered secretion is
unexplained as these animals show none of the features seen in conditions
characterised by a loss in diurnal Cortisol secretion in humans. As has already been
stated in Section 3.3.1., the ambulatory and exploratory behaviour and weight gain in
these rats are all normal. Interleukin 1 (IL-1), known to be produced in
inflammatory states (Dinarello et al., 1986), is thought to have stimulatory effects on
the HPA axis (Harbuz and Lightman, 1992) and therefore increased circulating IL-1
levels in these animals may underlie the loss of diurnal rhythm in these animals.
In human rheumatoid arthritis (RA), Cortisol diurnal variation was found to be
normal compared to normal and osteoarthritic controls, and patients with
osteomyelitis by Chikanza et al. (1992). However the Cortisol levels were at the
lower limit of normal and were inappropriately low for the degree of active joint
inflammation in the patients. Patients with osteomyelitis had Cortisol levels at the
high normal level which would be expected in severe inflammation (Chikanza et al.,
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1992). However others have reported both abnormally high and low circulating
Cortisol levels in active RA (Chowdrey and Lightman, 1993). It is therefore unclear
how the disturbances in corticosterone secretion in the arthritic rat relate to the
situation in the human disease.
15xSUMMARY
It can be seen that this model of adjuvant-induced arthritis in the rat has several
advantages over the classical model as described by Pearson and Wood. Slight
manipulations in the concentration of Mycobacterium tuberculosis used in the
induction of the disease can result in either a discrete monoarthritis, or a bilateral
arthritis, the point at which contralateral spread occurs being easily predicted. The
monoarthritis remains confined to a single joint for up to seventy days post-injection.
The animals used do not suffer profound systemic disease, unlike other models, so
changes observed are more likely to be directly attributable to the inflammatory
process per se. The inflammation has been shown to be arthritic in nature, with
severe synovitis but only mild destruction of hard tissues, thereby reducing the
discomfort of the animals as ankylosis and joint deformation do not occur. There is
a strong correlation between easily measured parameters of inflammation and the
histological arthritis present, which facilitates the assessment of disease progression
by non-invasive means.
In general these animals show significantly elevated corticosterone levels and a
marked loss of the diurnal corticosterone secretion, however there are no significant
changes in other parameters sensitive to corticosterone. This loss of diurnal
variation may be attributable to increased endogenous cytokines. This model may
therefore represent a mild form of chronic or intermittent stress, with the only
evident change in "stress parameters" being a loss of diurnal variation in
corticosterone.
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SECTION 4, SUBSJANCE P AND ITS ACTIONS ON CHEMQSENSITIVE
PRIMARY SENSORY FIBRES WITH ARTICULAR RECEPTORS IN
NORMAL AND ARTHRITIC RATS.
4.1. INTRODUCTION
Substance P, synthesised in dorsal root ganglion neurons, has long been postulated
to be a neurotransmitter, as outlined in Section 1. The Dale principle suggested that
the chemical transmitter released from the peripheral terminal of a neuron might be
the same as that released centrally. This appears to be the case with the tachykinins
and CGRP, which have been shown to be released from peripheral nerve terminals
following antidromic nerve stimulation, capsaicin application or in inflammatory
joint diseases (Holzer, 1988), and also in the dorsal horn on noxious stimulation.
4.1.1. Effects of inflammatory mediators on primary afferent nociceptors
High threshold articular afferents innervating an acutely inflamed joint are known
to become spontaneously active and to begin to respond to normally innocuous
stimuli and movements within the working range of the joint (Schaible and Schmidt,
1985). In rats with chronic adjuvant arthritis, lowered mechanical thresholds have
been shown in joint nociceptors (Guilbaud et al., 1985). This activation and
sensitisation of nociceptors is mediated through the action of inflammatory
mediators on nociceptors and has been thought to be responsible for inflammatory
pain and hyperalgesia. Various products of immune cells, the peripheral vasculature
and sympathetic nerves have been shown to exert effects on peripheral nociceptors.
Among these are 5-hydroxytryptamine (5-HT; Grubb et al., 1988; Herbert and
Schmidt, 1992), prostanoids and other arachadonic acid metabolites (Cohen and
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Perl, 1990; Grubb et al., 1991; McQueen et al., 1991; Birrell et al., 1991), bradykinin
(Koltzenburg et al., 1992), platelet activating factor and low pH. The interaction of
these mediators was recently discussed at a symposium on Inflammatory Mediators
which was reported on by Dray and Bevan (1993).
It has been hypothesised that substance P may act upon the peripheral nociceptor
terminals to sensitise them to other mediators, and that in turn other mediators may
act through the release of substance P (Nakamura-Craig and Smith, 1989). CGRP,
another neuropeptide which may be involved in the activation or sensitisation of
peripheral nociceptors is known to be released from afferent nerves by the action of
known inflammatory mediators bradykinin and histamine (Hua and Yaksh, 1993).
4.1,2. Aims of the study
In view of the effects of neuropeptides on trigeminal ganglion and second order
sensory neurons, and the fact that neuropeptides are released in the periphery, it was
of interest to examine the effects of substance P on primary afferent terminals in
normal and arthritic rats. The effect of close arterial injection of synthetic substance
P on both noxious mechanical and spontaneous activity in normal and arthritic rats
was studied to examine:-
1. whether substance P directly excites, or sensitises articular nociceptors in the
normal state, and
2. whether substance P contributes to the increased activity observed in afferents
supplying the inflamed joint.
4.2. MATERIALS AND METHODS
The in vivo monoarthritis preparation, neural recording and off-line analysis has
been described in detail in Section 2 (Materials and Methods).
92
Briefly, the trachea, external carotid artery, and right femoral artery and veins of
urethane anaesthetised male rats (Han Wistar, 200-250g) were cannulated. Blood
pressure was monitored throughout the experiments. Drugs were administered by
close arterial injection through the femoral arterial cannula. Extracellular recording
was performed using a bipolar platinum electrode from the PACR which supplies the
tibio-tarsal joint in the rat. The effects of drugs on single identified units were
analysed off-line as described previously.
4.3. RESULTS
All units studied responded to capsaicin (l-10|ig i.a.), adapted slowly to a noxious
mechanical stimulus, and were identified as C-fibres by conduction velocity
(<2.5ms"l Berne and Levy, 1990). All arthritic animals were used between 14 and
21 days after adjuvant injection
4.3.1. Effect of close arterial injection of synthetic substance P on articular
nociceptors in normal rats
Comparison of pooled data from 5 animals for the three doses of substance P with
either; a) the effect of saline injection or b) the preinjection period showed that
substance P had no significant effect on the articular nociceptors on either
mechanically evoked or spontaneous activity (Figures 4.1 and 4.2).
Data are shown normalised to the pre-injection activity as absolute basal numbers
of action potentials in spontaneously active afferents, or those evoked by the
mechanical indent varied considerably between experiments (Raw mean basal counts
per minute (c.p.m.) for each graph are shown in the figure legends.). Mean activity
is calculated for the minute preceding drug injection, the first 15 seconds after
injection and in blocks of 1 minute thereafter.
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4.3.2, Effect of close arterial injection of substance P on spontaneous and
mechanically evoked activity in arthritic rats.
Neither mechanically evoked (Figure 4.3) nor spontaneous discharge (Figure 4.4)
recorded from joint nociceptors in arthritic rats was affected by substance P when
compared to either preinjection control activity, or saline injection. However, 1 unit
showed increased activity 2 minutes post-injection of l(ig substance P (Figure 4.5).
Data are shown normalised to the pre-injection activity for both spontaneous and
mechanically evoked activity due to inter-animal and intra-experimental variation.
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Figure 4.1. Mechanically evoked responses ofarticular nociceptors in normal rats
to a 2s indent repeated at inteiwals of 120s following saline and substance P
injection (i.a.). Arrow indicates Substance P injection (15s before stimulus 1). Plots
are means ± S.E.M. Mean basal evoked activity in c.p.m. (± S.E.M.) was 246 (48).
Figure 4.2
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Figure 4.2. Normalised spontaneous activity ofarticular nociceptors in normal rats
following substance P injection (i.a.; arrow at time 0). Values are means ±S.E.M.
Mean basal spontaneous activity in c.p.m. (+S.E.M.) was 58 (32)
4,3.3. Effects on single articular nociceptors
In the meaned values for spontaneous activity in arthritic rats., 2.25 minutes post-
injection, there appears to be a non-significant response to l|ig substance P. This is
due to the effect of one nociceptor which responded slightly to 0.1 jig SP and
dramatically to l(ig SP (Figure 4.5). This unit had a conduction velocity of 1.8ms"l.
Activity is again expressed as a percentage of the pre-injection control due to






















Figure 4.3. Mechanically evoked responses in arthritic rats in response to a 2s
mechanical indent before and after injection ofsubstance P (arrow). Values are
















1 1 -r- r
1 2 3
time after injection (min)
Figure 4.4. Effect ofi.a. injection ofsubstance P on spontaneous activity in
articular nociceptors in arthritic rats. Activity is shown as normalised means ±




Figure 4.5. Activity in a single nociceptor from an arthritic rat after injection of
saline or substance P (SP), normalised to pre-injection controls. Drug injection was
at time 0. Mean basal spontaneous activity in c.p.m. (± S.E.M)for the experiment
illustrated in Figure 4.5. was 12 (3).
4.4, DISCUSSION
In behavioural studies, Nakamura-Craig and colleagues have shown a peripheral
hyperalgesia induced by intraplantar injection of substance P or neurokinin A
(Nakamura-Craig and Smith, 1989; Nakamura-Craig and Gill, 1991). CGRP also
caused hyperalgesia but was significantly less potent than either of the neurokinins.
Mechanical hyperalgesia can be induced by repeated saline injections (Levine et al.,
1985a) and this hyperalgesic effect may not be specific to tachykinins although this
is unlikely as neurokinin antagonists prevented the hyperalgesia, and saline did not
have an effect in the studies reported by Nakamura-Craig and Gill (1991). These
studies have been supported in humans when substance P and neurokinin A caused
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significantly more cutaneous pain than saline placebo, whereas CGRP had no effect
(Pedersen-Bjergaard et al., 1991). From these data it was hypothesised that
substance P could act on nociceptors to sensitise them to other mediators, or could
directly excite them.
4.4.1, Effects on single articular afferents and criteria for inclusion in the analysis
In the course of these studies, one unit responded to the close arterial injection of
substance P. From earlier studies group III articular nociceptors were shown to be
sensitised to noxious movements by substance P (Herbert et al., 1987). In the
experiments presented here, substance P seemed to have a minor effect on
spontaneously, not mechanically-evoked activity in an arthritic rat. This effect may
be due to the fact that a conduction velocity of < 2.5ms"1 was used as the cut-off for
C-fibre categorisation whereas there is some overlap in conduction velocity of C-
and A3- fibres (Lawson and Waddell, 1991) resulting in the inclusion of a nociceptor
from a class of afferent which may be sensitive to substance P However the criteria
for classification in the analysis were defined before the experiments were performed
and as statistical analysis cannot be performed on the responses of a single
nociceptor, this unit was included in the data shown here. It seems therefore that the
criteria for inclusion in this analysis may not have been appropriate for this animal
preparation.
4.4.2. The effects of substance P on nociceptive afferents
The results presented here show that substance P does not have an effect on
unsensitised articular nociceptors in the normal rat, or on sensitised nociceptors in
inflammatory arthritis. In general, this agrees with reports from other workers who
have studied the direct effect of substance P on cutaneous A3 and C-fibre afferents.
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It is possible that substance P is exerting a tonic effect during inflammation, in
conjunction with the other mediators of inflammation in the periphery, and therefore
exogenous substance P would have no effect in established inflammation, or in the
normal animal, without other sensitising agents. Recent work by Asghar and
McQueen (unpublished) has not supported this. Administration of an NK1/NK2
antagonist FK224 (Fujisawa) has no effect on either the mechanically evoked or
spontaneous activity in articular nociceptors innervating inflamed joints, and
substance P does not potentiate the action of bradykinin on nociceptors in normal
animals (Asghar and McQueen, unpublished).
The vast majority of previous work has been performed on cutaneous nociceptors,
although substance P action on neuroma afferents has also been studied and found to
be non-existent on either A- or C-fibres (Devor et al., 1992). In a more
physiological situation, Fitzgerald and Lynn (1979) found that synthetic substance P
injected in greater amounts than in these studies (2-20flg), induced only weak
excitation of a small number of polymodal nociceptors in rat skin and did not
potentiate responses to noxious stimuli. More recent studies on cutaneous C-fibre
nociceptors in ex vivo conditions have shown no direct effect of substance P or of
substance P antagonists (Cohen and Perl, 1990), but a potentiation of the response to
an "inflammatory soup" containing bradykinin, 5-HT, histamine and prostaglandin
E2 (Kessler et al., 1992). In vivo, substance P did not excite testicular nociceptors in
the dog (Kumazawa and Mizumura, 1979), and in a study on the cat knee joint, it
sensitised only group III, but not group IV afferents to specifically noxious
movements of either normal or acutely inflamed joints (Herbert et al., 1987). In this
classification by conduction velocity used by Schmidt and colleagues, the group IV
units probably belong to the same population as those under study here, which were
also not responsive to substance P either in the normal or arthritic state.
99
An excitatory action for substance P on primary sensory neuronal perikarya in the
trigeminal ganglion has, however, been demonstrated (Spigelman and Puil, 1991).
This excitation, along with the behavioural effects of substance P on peripheral
hyperalgesia have suggested that substance P may excite primary afferents through
an autoreceptor. The published literature on the action of substance P on peripheral
terminals along with the data shown here, earlier in vitro work which showed no
effect of substance P on dialysed trigeminal neurons or DRG neurons in culture
(Krishtal and Pidoplichko, 1981; Nowak and MacDonald, 1982) and recent evidence
that primary afferent neurons do not express the NK1 receptor (Brown et al., 1993)
does not support this hypothesis.
4.5. SUMMARY
Neurokinins have strong excitatory actions on motoneurons, second order sensory
neurons in both the dorsal hom and trigeminal nucleus (Otsuka and Yoshioka, 1993),
and postganglionic sympathetic neurons (Dun and Karczmar, 1979). However it
would appear from these data and the literature that the predominant peripheral
function of neuropeptides in general, and substance P in particular is on the vascular
and immune systems (Section 1) rather than on autoreceptors directly on primary
afferent nociceptors. Some workers have shown weak facilitatory actions for
substance P on primary afferents; it may be that substance P only has effects on C-
fibre nociceptors in conjunction with a number of other inflammatory mediators
The behavioural effects of substance P and neurokinin A in peripheral hyperalgesia
may not be direct effects of substance P on nociceptors, particularly as primary
sensory neurons do not express NK1 receptors. Alternatively, this hyperalgesia may
be mediated via A3 afferents, some of which are also nociceptive and may be
sensitised to noxious stimuli by substance P (Herbert et al., 1987).
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4.6. CONCLUSION
Substance P does not have an excitatory action on C-fibre nociceptors in either the
normal or the arthritic rat (present data)but an effect on spontaneous activity in A3
mechanoreceptors in this adjuvant mediated monoarthritis in the rat cannot be
excluded.
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SECTION 5. NEUROPEPTIDE MESSENGER RNA EXPRESSION IN
MALE AND FEMALE RATS WITH MONO- AND BILATERAL
ARTHRITIS
5.1 INTRODUCTION
5.1.1. Primary afferent neuropeptides in experimental arthritis.
Neuropeptides in primary afferents and projection neurons in the spinal cord have
been extensively studied in inflammatory and arthritic states, principally as they
have been implicated in both mediation of neurogenic inflammation and the spinal
processing of nociceptive stimuli. Numerous studies have shown that neuropeptides
in primary afferent neurons increase in established inflammatory conditions
particularly substance P (Smith et ah; 1992; Colpaert et ah, 1983; Lembeck et ah,
1981), CGRP (Hanesch et ah, 1993; Smith et ah 1992; Kuraishi et ah, 1989) and
somatostatin (Ohno et ah, 1990)-although the latter has also been reported to remain
unchanged in arthritic rats (Smith et ah, 1992). Messenger RNA levels of species
encoding substance P and neurokinin A also increase in primary afferents following
peripheral noxious (Noguchi et ah, 1988), and inflammatory stimuli (Iadarola and
Draisci, 1988).
VIP shows very low or absent expression in DRG under basal conditions but its
expression is dramatically increased following nerve injury such as axotomy or
crush in the rat (Atkinson and Shehab, 1986; Nielsch and Keen, 1989). Primary
afferent VIP is not increased on nerve damage in primates (Zhang et ah, 1993)
highlighting inter-species variation. VIP expression has not previously been
investigated in experimental arthritis.
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5.1.2. Male/female differences in adiuvant-induced monoarthritis.
Many autoimmune conditions in humans are known to affect proportionally greater
numbers of females than males, notably so in systemic lupus erythematosus (Inman
et al., 1978). It has been hypothesised that this is due to an effect of oestrogens since
both pregnancy and oestrogen containing oral contraceptives exacerbate the
condition (Mund et al., 1963; Jungers et al., 1982). The susceptibility to rheumatoid
arthritis is also greater in females than males; UK statistics show a 3:1 female to
male prevalence ratio and a 2.5:1 incidence ratio (Hazes and Silman, 1990), but the
hormonal influences in this condition are much less clear cut. It has been suggested
recently that, in humans, androgen levels may be more important in reducing
susceptibility to RA, than oestrogens in increasing risk (James, 1993), which would
account for the amelioration of disease severity often seen in the third trimester of
pregnancy (Hazes, 1991) when androgen levels are increased due to production in
the corpus luteum, placenta and foetal gonads and adrenal (James, 1993).
The situation in rodents is also complex. For example, inbred female LEW/N rats
are more susceptible to streptococcal cell wall arthritis than are males (Wilder et al.,
1982). In adjuvant arthritis, oestradiol has been shown to reduce the incidence of the
disease in rats (Mueller and Kappas, 1964) but pregnancy causes no improvement in
the disease process, in contrast to the situation in patients with rheumatoid arthritis
(Mathers and Russell, 1990; Unger et al., 1983). In gonadectomised animals
exogenous androgens were shown to eliminate glycosaminoglycan breakdown
whereas this was exacerbated by oestradiol administration (Steward and Bayley,
1992). However in the initial studies on adjuvant arthritis in rats, Pearson and Wood
(1959) found no sex differences in the incidence of polyarthritis. Holmdahl et al.
(1986) showed that female sex hormones will reduce the severity of arthritis induced
by Type II collagen in mice and that female mice were much less susceptible to
arthritis than male or oophorectomised female mice. In view of this conflicting data
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it was of interest to investigate the male/female differences in reaction to adjuvant in
the modified model of adjuvant disease used throughout the studies presented here.
5.1.3. Aim of the experiments
The role of the primary afferent in inflammatory conditions has been widely studied
in terms of the effector function of C-fibres. As neuropeptides are released both
centrally and peripherally, thorough study of the precise role of neuropeptide-
containing primary afferents in inflammatory arthritis is highly desirable. Studies of
peptide levels, while valuable, still leave the question of whether observed changes
are due to increased production, altered transport and/or metabolism, unanswered.
Studies involving animal models of chronic inflammation, for example, polyarthritis
in rats, are complicated by severe and widespread systemic disease. Different
neuropeptides may also have changing roles in the models of acute and chronic
inflammation routinely used. Therefore neuropeptide messenger RNA expression
has been investigated during the development of monoarthritis in DRG of male and
in established arthritis in both male and female rats to determine whether changes in
peptide are reflected in changes in the level ofmRNA. In addition, the primary
afferent neuropeptide response in symmetrical disease in male rats- has been
determined to elucidate the possible role of peptidergic primary afferents in the
contralateral spread of arthritis.
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5.2. MATERIALS AND METHODS
5.2.1, Neuropeptide mRNA expression in DRG
Monoarthritis was induced in female or male Wistar rats (7 weeks of age) and
bilateral arthritis in male rats as detailed in Section 2, i.e. by the subdermal injection
of either 150fig or 250|ig M.tub. around the left "ankle" joint. The appearance and
circumference of both ankle joints was recorded at intervals to assess inflammation
as detailed in section 2.2.
Monoarthritic male animals (n=3-5 per time point) were killed by decapitation at
various times after adjuvant injection (as outlined in the Results) in order to study
responses in the acute and chronic stages of inflammation. Monoarthritic females
and symmetrically arthritic males were monitored throughout development of
arthritis and were killed by decapitation fifteen days after adjuvant injection. Both
left and right fifth lumber (L5) DRG (which innervate the tarsal joint via the sensory
component of the sciatic nerve) were rapidly dissected from all animals, snap frozen
and stored at -80°C. Control L5 DRG from untreated animals (n=10) and animals
injected with filter-sterilised paraffin oil (n=3) were similarly taken. Sections were
hybridised with riboprobes complementary to all four neuropeptide mRNAs as
detailed in Section 2.4. Sections were then exposed to nuclear emulsion for two
weeks, developed and counterstained Expression of mRNA was estimated by
counting silver grains overlying neuronal cell bodies of less than 30 |im diameter
either by eye or using computerised image analysis.
5.2.2. Quantification of in situ hybridisation results
Initial in situ grain counts were determined by eye at x40 magnification under the
light microscope. Subsequent analysis was done using computerised image analysis
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designed by Seescan (Cambridge UK). These two methods of analysis were
subjected to linear regression analysis to determine the relationship between them.
Correlations were performed on silver grain counts from either cells expressing
neuropeptide mRNA or hippocampal cells expressing steroid receptor mRNA (the
latter counts were performed by Dr. J. Seekl). All in situ hybridisation data is
expressed as a percentage of the untreated control expression, calculated as
described in Section 2, however the mean (± S.E.M.) grain numbers for the control
groups are also given in the figure legends.
5.2.3. Statistics
Data were assessed by ANOVA followed by Dunnetts post hoc test. Inflammation
scores were compared using Wilcoxon's signed ranking test for paired data, and
Mann Whitney U test for unpaired data. The Null Hypothesis was rejected at the 5%
probability level. Values are shown as means ± standard error of the mean (S.E.M).
5.3 RESULTS
5.3.1.. Indices of inflammation during development of monoarthritis
Male and female rats show a significant difference in body weight at 7 weeks of age
and females tend not to increase in weight as rapidly as males, but development of
arthritis did not affect the normal gain in weight seen within each group. Animals
behaved normally with respect to grooming and exploratory behaviour throughout
development of arthritis, and showed only slight guarding of the injected limb. All
animals bore weight on the affected limb throughout the fifteen days of study.
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In both male and female groups of rats, all animals developed significant (p<0.01)
increases of the tibio-tarsal joint circumference ipsilateral to the side of adjuvant
injection (Figure 5.1). In no case was there involvement of the contralateral
(uninjected) joint. Although there were slight differences in the pattern of
development of joint swelling, overall there were no significant differences in
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Figure 5.1 Increase in left(injected) and right joints circumferences in
monoarthritic male andfemale rats during the development ofmonoarthritis.
Values are the difference between pre-injection joint circumference, and
circumferences on each day ofmeasurement post-injection, in mm ±SEM.
Overt signs of inflammation (redness, swelling) were also similar in the male and
female monoarthritic animals (Table 5.1).
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Left Right
Untreated controls 0 0
Female; monoarthritic 1.5 (1-3)* 0
Male; monoarthritic 3(1-3)** 0
Male; bilaterally arthritic 3(0-4) t 1 (0-4) t
Table 5.1 Inflammation scores in female and male monoarthric and bilaterally
arthritic rats. Values are median (range) and *p<0.05, **p<0.01 c.f. contralateral
limb (Wilcoxon signed rank test), tp<0.01 c.f. untreated controls (Mann Whitney U
test).
5.3.2. Quantification of neuropeptide messenger RNA levels.
Linear regression analysis of the two methods of determining the numbers of silver
grains in high density neuropeptide in situ hybridisation showed a strong positive
correlation between the two methods (Figure 5.2a). The ratio between eye and
machine grain counts was not 1:1, rather 1:4.9 (Equation 1). The linear regression
curve has the formula below:-
y = 4.9x -154 Equation 1
When low density grain counts by eye and computer were compared there was also
a strong positive correlation, with the linear regression curve represented by the
equation below:-
y = 0.8x + 4 Equation 2
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Figure 5.2. Linear regression curves for eye against computerised silver grain
counts:-
a) for high density silver grains (r-0.90, n=24, p<0.0001)
b)for low density silver grains (r-0.97, n=23, p<0.001)
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5.3.3. Neuropeptide messenger RNA expression during development of
monoarthritis
PPT mRNA in control L5 DRG was expressed in 22±1% of neurons. No change in
the proportion of neurons expressing PPT mRNA was seen at either 8 hours or 14
days (19± 1%) after FCA injection, in either left or right L5 DRG. Eight hours after
injection of adjuvant in male rats there was a significant increase (81±24% rise) in
PPT mRNA expression per neuron in L5 DRG innervating the injected joint, in
comparison with either the contralateral (uninjected) L5 DRG or control DRG. The
early induction of PPT mRNA expression in innervating L5 DRG neurons resolved
at 24 h, but recurred by 48 h and persisted until arthritis was evident at 14 days ; at
no time was there any increased expression in contralateral L5 DRG (Figure 5.3).
Expression of PPT mRNA in left and right DRG 8 hours after adjuvant injection is
also illustrated in Figure 5.6.
PPT mRNA levels were also significantly increased (42+13% rise) in L5 DRG from
female rats, fourteen days after adjuvant injection (Figure 5.4). This was not
significantly different from the increase in mRNA values in male animals (56±7%
rise; p>0.05). Contralateral L5 DRG PPT mRNA levels in females were not
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Figure 5.3. PPT mRNA expression during development ofmonoarthritis. Each
point is mean (n=3) ± SEM expressed as a percentage of control expression.
*p<0.05 compared with controls. Mean grain counts (±S.E.M..)for the control
group were 16832 left; 175±4, right.
CGRP mRNA was expressed in 37+3% of control DRG neurons, and there was no
significant change in the proportion of L5 DRG cells expressing CGRP mRNA at
the time of onset of chronic arthritis (day 14; 36±1%). As with PPT, the expression
of CGRP mRNA per neuron was significantly increased (44±6% rise) 8 hours after
FCA injection. CGRP mRNA levels remained significantly elevated up to and
including the time of development of chronic monoarthritis. These changes were
again limited to ipsilateral L5 DRG (Figure 5.5).
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Figure 5.4
Figure 5.4. Neuropeptide mRNA expression in DRG ofmonoarthricfemale rats.15
days after adjuvant injection Values are percentages ofuntreated controls and are
means ±SEM. *p<0.05 cf. control. Mean control grain counts were PPT, 179+29;
CGRP, 179+2; SS, 355±46.
Levels of CGRP mRNA in female rats also rose fourteen days post-injection
(24±3% ), and were significant when compared to contralateral mRNA levels
(Figure 5.4). The rise in females was significantly lower than CGRP mRNA values
in male rats (39±4%; p=0.02).
CGRP and PPT mRNA expression 8 hours and 14 days after unilateral adjuvant-



























Figure 5.5. CGRP mRNA expression in DRG ofmonoarthritic rats expressed as a
percentage of untreated controls. *p<0.05 compared to control value. (Means ±
SEM; n=3 per point). Mean control grain counts were 182±3, left; 193±5, right.
Somatostatin was the only neuropeptide mRNA species to show both ipsi- and
contralateral changes during the fourteen day time course of development of arthritis
in male rats. Ipsilateral mRNA expression was significantly reduced in the first 16
hours (-24+2%), returned to control values at 24 hours and was elevated when
arthritis is evident at 14 days (39+10%). Contralateral mRNA expression was
initially increased compared to controls at 24 hours (41±11%) and was reduced by 5
days remaining significantly lower when arthritis was evident at 14 days (-20±3%).
Ipsilateral and contralateral data are illustrated in Figure 5.6.
Somatostatin mRNA expression was also significantly increased in female rats
(147±16%) 14 days after adjuvant injection compared to controls (Figure 5.4) and to
the increase seen in males (39±10%; p=0.001). There were no contralateral changes
in SS mRNA expression in female rats in established arthritis.
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Left Right
Figure 5.6. Dark fieldphotomicrographs showing PPT mRNA (top) and CGRP
mRNA (bottom) expressing neurons in left and right L5 DRG taken 8 hours after
injection ofadjuvant around the left ankle joint. Note the increased density ofsilver
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Figure 5.7. Dark fieldphotomicrographs showing PPT mRNA (top) and CGRP
mRNA (bottom) expressing neurons in left and right L5 DRG taken 14 days after
injection ofadjuvant around the left ankle joint. Note the increased density ofsilver




Figure 5.8. Somatostatin mRNA expression in DRG ofmonoarthric rats. Values
shown are means ±S.E.M. *p<0.05 compared to controls (n=6 per point). Mean
control grain counts were left, 81±3; right 94±5.
5.3.4. Effect of paraffin oil injection on neuropeptide mRNA expression
Injection of sterile paraffin oil (vehicle) did not cause inflammation and there was
no change in CGRP mRNA expression eight hours after injection.
Injection of paraffin oil caused a significant decrease in PPT mRNA expression in
ipsilateral DRG neurons and did not affect contralateral expression (10412%
control) eight hours after injection. Injection of vehicle did not affect ipsilateral
somatostatin mRNA expression but caused a significant increase in contralateral
mRNA expression after eight hours. Neuropeptide mRNA levels after vehicle
injection are summarised in Table 5.2.
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Table 5.2. Neuropeptide messenger RNA expression in response to intradermal
injection of0.15ml sterile paraffin oil. PPT, CGRP and somatostatin mRNA
expression in L5 DRG (as a percentage ofexpression in untreated control rats) in
untreated control andparaffin oil injected rats, eight hours after injection.
(*p<0.05; n=3) Mean grain counts for control groups are PPT, 171±8 left, 17854
right; CGRP, 173±7 left, 197±5 right; SS, 81±5 left, 94±7 right.
5.3.5. Indices of inflammation during development of bilateral arthritis
Male rats injected with the higher dose of M.tub. showed a normal increase in
weight over the first fourteen days after adjuvant injection. There was a non¬
significant reduction in weight on development of symmetrical disease (see Figure
3.1). Rats also showed a rapid unilateral increase in left joint circumference (Figure
5.7) and inflammation score (Table 5.1) immediately after adjuvant injection which
was maintained throughout the development of inflammation. Fourteen days after
adjuvant injection, contralateral joint involvement was also apparent, evidenced by a




Figure 5.9. Increase in left (injected) and right (uninjected) ankle joint
circumferences during development ofbilateral arthritis in male rats. (Injection of
250pg M.tub. around left ankle joint) Points are calculated as the increase over
pre-injection measurement, in mm, and are means ±SEM. *p<0.05 cf. untreated
control.
5.3.6. Neuropeptide messenger RNA expression in bilateral arthritis
PPT and CGRP mRNA increased bilaterally - PPT (121±50% rise, left; 85±17%
rise, right) and CGRP (40±19% rise, left; 47±15% rise, right). SS mRNA increased
in left DRG neurons but was unchanged in right DRG compared to control values
(48±9% rise, left, 8+20% rise, right). The changes in neuropeptide gene expression
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right (uninjected) DRG
PPT CGRP Somatostatin
Figure 5.10. Neuropeptide mRNA expression in DRG ofbilaterally arthritic rats
(15 days after adjuvant injection)expressed as a percentage of untreated control
rats. Values are means ±SEM. *p<0.05, **p<0.01 cf. controls (n=5 per group).
Mean control grain counts were: PPT: 107±4; CGRP: 328537; SS 244±42.
Vasoactive intestinal peptide mRNA was only detected in the occasional cell in
control DRG but was always seen in positive control tissue taken from the
hypothalamic suprachiasmatic nucleus (Figure 5.11). No change in VIP mRNA
expression was detected during the development of arthritis. Injection of 0.15ml
vehicle did not induce expression of VIP.
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Figure 5.11. Lightfieldphotomicrograph showing VIP mRNA expression in control
section through the suprachiasmatic nucleus
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5.4. DISCUSSION
5.4.1. Neuropeptide messenger RNA expression in mono- and bilateral arthritis
5.4.1.1. PPT and CGRP mRNA expression in experimental arthritis
PPT and CGRP show similar changes in these experiments and hence will be
discussed together.
It has been shown that PPT and CGRP messenger RNA species show extremely
rapid and marked increases in individual cells innervating the inflamed joint. This
change in PPT and CGRP messenger RNA expression is confined to the DRG
ipsilateral to the inflammation, and does not occur in DRG containing neurons
innervating regions distant from the area of inflammation (LI), or in contralateral L5
DRG. PPT and CGRP show a biphasic increase in expression, with an initial peak at
around 8-16 hours, a trough at 24 hours and rising again as more chronic
inflammation appears with expression remaining raised at day 14. This increase in
expression of PPT per cell agrees with a previous study by Noguchi et al. (1988),
where cellular PPT expression was increased over the first 24 hours and returned to
control levels by 48 hours. This initial peak in expression also agrees with previous
work where PPT and CGRP mRNA were measured by Northern analysis in rat DRG
following bilateral hind limb inflammation induced by carrageenan (Iadarola and
Draisci, 1988). The changes they observed were confined to the early stages of the
inflammation, peaking at 2 hours, but their data did not go beyond twenty four
hours. It is therefore conceivable that the mRNA levels of both these neuropeptides
actually attain much higher levels even earlier than 8 hours; this early time period
was not examined in the experiments here as it was of interest to examine the
changes in both acute and chronic inflammation.
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In the present experiments the analysis was confined to neurons with cell bodies of
diameter <30|im. These neurons are thought to be involved in nociception; they
give rise to unmyelinated or thinly myelinated axons and are capsaicin-sensitive
(Nagy et al., 1992). Most SP-containing neurons are thought to belong to this subset
of primary afferents where they coexist with other neuropeptides particularly CGRP
(Skofitsch and Jacobowitz, 1985b). Therefore the results of Iadarola and Draisci
agree with those presented here on the change in PPT mRNA, as all the mRNA
present probably originated in this population of neurons. As regards the CGRP-
containing primary afferents, these are known to have both large and small perikarya
(Lee et ah, 1985) and the inclusion of mRNA levels in large neurons by using
Northern analysis may have obscured any changes in mRNA levels in small neurons
alone, which was the only population under study here. A more recent study
(Minami et ah, 1989) examining the expression of PPT, again by Northern analysis
showed that bilateral adjuvant-inflammation induces a 1.7 fold increase in PPT
expression in lumber DRG after 4 days, agreeing with the present data at 5 days,
which show a 140±4% increase.
It is clear from mRNA expression following injection of sterile paraffin oil that the
injection itself is not causing the initial increase in PPT and CGRP mRNA
expression, so it seems reasonable to conclude that it is attributable to the very rapid
inflammation which is induced by adjuvant injection. The mechanisms underlying
this early increase in mRNA expression are further investigated and discussed in
Section 7.
In bilateral arthritis, when contralateral inflammation is apparent, PPT and CGRP
mRNA increase in small primary afferent perikarya in both ipsi- and contralateral
DRG. This agrees with the results from monoarthritis and from previous studies
which demonstrated increased substance P and CGRP in DRG and peripheral nerves
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in response to inflammation (Donnerer et al., 1992) and arthritis (Colpaert et al.,
1983; Kuraishi et al., 1989). It is unclear whether induction of PPT and CGRP
mRNA expression initiates the contralateral spread of inflammation or is a
consequence of it, as mRNA expression was examined in animals with overt
contralateral disease. Both neuropeptide genes, however, show increases in
expression concurrent with the onset of bilateral disease, suggesting a close or causal
relationship between the spread of inflammation and the induction of synthesis of
these peptides. This assertion is supported by the previous data demonstrating
induction of both PPT and CGRP mRNA expression in innervating DRG within 8
hours of adjuvant injection, during the initial inflammatory response, many days
before histological arthritis becomes manifest.
The mechanism(s) underlying the contralateral induction of neuropeptide mRNA
expression are unclear. It may be that ipsilateral inflammation induces contralateral
mRNA changes through contralateral "sensitisation" of dorsal hom neurons.
Unilateral noxious or electrical stimulation induces contralateral expression of
immediate early gene/transcription factors in dorsal horn neurons, including the AP-
1 components c-fos and c-jun (Noguchi et al., 1991; Herdegen et al., 1991a) and the
nerve growth factor (NGF)-induced factor NGFI-A (also known as krox24 and
zif268; Herdegen et al., 1990). The number of expressing cells and the amount of
fos protein produced is increased on a subsequent contralateral stimulus (Leah et al.,
1992). Since AP-1 and other transcription factors may regulate PPT and CGRP gene
expression this mechanism of "molecular cross-talk" in the spinal cord may underlie
the contralateral increases in PPT and CGRP gene expression and provide a possible
basis for increased sensitivity of the symmetrical joint to inflammation and arthritis.
However, the exact neuronal pathways involved and the underlying molecular
mechanisms remain to be determined. The role of the primary afferent and other
neuronal systems is further examined and discussed in Section 7.
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5.4.1.2. Numbers of cells expressing PPT and CGRP mRNA.
In this study the criterion for a positive cell was a hybridisation signal overlying the
neuron of at least four times the background silver grain count. There was no
change in the numbers of DRG neurons expressing either PPT or CGRP mRNA
between untreated controls (22±1%, PPT; 37±3% CGRP) and in chronic arthritis
(19+1%, PPT; 36±1% CGRP). While there is variability in the literature regarding
the numbers of cells expressing Substance P/PPT or CGRP, most studies have found
that approximately 20% of DRG neurons express Substance P, and 40% express
CGRP. In a study examining both immunohistochemistry and in situ hybridisation
(Henken et al., 1988) there was no significant difference in the number of PPT/SP
positive cells assessed by either method.
Other workers have found increases in the numbers of PPT expressing cells
following peripheral noxious stimuli (Noguchi et ah, 1988) and adjuvant-induced
inflammation (Heppleman et ah, 1993), and CGRP immunoreactivity (Hanesch et
ah, 1993). In all of these studies the numbers of positive cells in control DRG are
rather lower than those found by other workers. In fact, Noguchi et al (1988) also
found many less cells expressing PPT in controls than they did in a subsequent study
one year later (Noguchi et ah, 1989). In particular the difference between the
numbers of CGRP positive cells in the study by Hanesch et ah (1993) and others
locating CGRP by immunohistochemistry or specific in situ hybridisation for either
a- or (3-CGRP is striking. It is unclear why these workers have identified such a low
number of positive cells in these studies; although differences in fixation technique
and tissue processing may account for this. Increases in the numbers of neurons
expressing a peptide detected by immunohistochemistry may be attributable to an
increase in individual cellular expression of PPT and CGRP mRNAs resulting in
increased detection of peptide following the onset of inflammation, in neurons which
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were initially below the detection limit of immunohistochemistry. This cannot
explain why changes in the number of neurons positive for PPT mRNA have also
been observed (Noguchi et al., 1988; Heppleman et ah, 1993); it is obvious that this
area requires further study.
In the only study to stringently quantify increases in DRG neuropeptide levels in
arthritis (Smith et ah, 1992), the increases in SP and CGRP were 33% and 200%
respectively. In the two studies which found increased numbers of cells expressing
PPT (Heppleman et ah, 1993) and CGRP immunoreactivity (Hanesch et ah, 1993)
also in adjuvant-induced monoarthritis, the numbers of cells increased by 16 and
17% respectively. In the case of CGRP particularly, this would not appear to be
sufficient to account for the large increase in peptide content. It is not possible to
explain why no change in the numbers of PPT and CGRP expressing neurons was
found in this study, however the aim of the studies presented here was not to
determine the numbers of neurons expressing any of the three neuropeptide mRNAs
which are usually expressed in DRG neurons, but to establish the mRNA changes in
individual neurons, which is a strength of the in situ hybridisation technique.
5.4.1.3. Somatostatin mRNA changes in mono- and bilateral arthritis.
Somatostatin is the only mRNA species under examination which shows
contralateral changes in the early stages of inflammation (Figure 5.8). In the first
twenty four hours the contralateral increase in mRNA expression appears to be due
to the injection itself, rather than any inflammatory response, as a similar effect is
seen on injection of paraffin oil (Table 5.2). In bilaterally arthritic animals
somatostatin mRNA does not show any contralateral change (Fig. 5.10) unlike PPT
and CGRP mRNA. As mRNA changes were examined immediately after the
appearance of contralateral inflammation, this suggests that increased somatostatin
biosynthesis is not an early event in the inflammatory arthritic process. Examination
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of mRNA later in the disease process may reveal a later change in messenger RNA
expression as somatostatin has been shown to increase in DRG of bilaterally arthritic
rats (Ohno et al., 1990). However the studies in this thesis have been concerned with
the early events in the development of disease and the contralateral effects; therefore
the possibility of later changes in somatostatin expression remain to be determined.
The contralateral decrease in somatostatin mRNA expression in arthritis (day 14)
seen initially (Fig. 5.8) has not been reproducible in either bilaterally arthritic rats,
where contralateral somatostatin mRNA expression is not different from control
values, or in other monoarthritic male or female animals (see Section 7).
Somatostatin mRNA only shows reproducible contralateral changes in the early
stages of unilateral inflammation, which are attributable to the initial injection
stimulus as demonstrated by the injection of paraffin oil (Table 5.2). The role of
somatostatin in arthritis remains an enigma. In general, somatostatin is thought to
have inhibitory properties; it is known to inhibit the release of Substance P, for
example (Gazelius et al., 1981). However, it is also known to increase in primary
afferent neurons in bilateral arthritis (Ohno et al., 1990), although this is disputed
(Smith et al., 1992), and has been implicated in the central modulation of thermal
nociception (Morton et al., 1989).
The functional significance of the changes in somatostatin, both ipsilateral and
contralateral to inflammation are still unclear. The contralateral increase which
occurs so rapidly after an ipsilateral stimulus (injection) may be involved in the early
priming of the nervous system with regard to the contralateral activation of primary
afferents in established inflammation. Contralateral events following an ipsilateral
noxious stimulus occur within hours of the initial stimulus (Leah et al., 1992;
Herdegen et al., 1990; Herdegen et al., 1991b). Many hyperalgesic states show
contralateral effects (Thompson et al., 1993) and the contralateral increase in
somatostatin mRNA may be involved in the initiation of these, possibly involved in
an inhibitory role. It is unlikely that somatostatin has a direct role in the
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contralateral spread of arthritis in this model as it does not show any contralateral
change in the first day on which contralateral inflammation is apparent.
5.4.1,4. Vasoactive intestinal peptide in experimental arthritis.
VIP expression was detected in only occasional cells in the experiments described
in this Section and showed no change in expression in response to inflammation or
arthritis. It has been suggested that VIP expression can be regulated by electrical
activity in neurons (Agoston et al., 1991). However, these investigations were
performed in dissociated spinal cord cell cultures and VIP expression is known to be
dramatically altered unless culture conditions are strictly maintained. In cultures of
DRG neurons, depolarisation and cAMP accumulation are thought to regulate the
expression of VIP and it has been hypothesised that VIP could be an inducible
neurotransmitter in inflammatory conditions (Mulderry, 1993). In arthritic animals,
articular primary afferent activity is known to be increased early in the time course
of development of inflammation and previously silent afferents develop spontaneous
activity (Schaible and Schmidt, 1988). If afferent activity was involved in the
regulation of VIP expression in vivo, inflammation could be expected to induce
expression of the mRNA. The results presented here suggest that VIP expression is
not induced by neuronal depolarisation in vivo and has no role in this model of
inflammatory arthritis. It is known that there is no neuronal damage in adjuvant
induced arthritis in the rat (Guilbaud et al., 1985); the results on VIP expression
support this data, as VIP expression is induced in rat primary afferent neurons by
axotomy or crush injury (Atkinson and Shehab, 1986; Nielsch and Keen, 1989).
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5.4.2. Male/ female differences in adjuvant-induced monoarthritis
These results show that there are no differences in the susceptibility or disease
progression in male or female animals in a mild adjuvant-mediated monoarthritis.
Monoarthritis in females follows the same course as that seen in males with a
sustained increase in left joint circumference of 9-11mm throughout the fifteen days
of study.
These results agree with those of Pearson and Wood (1959) who used both male
and female animals in their initial description of adjuvant arthritis and found no sex
dependence on either incidence or severity of the disease. Indeed in subsequent
studies on the passive transfer of adjuvant disease only female animals were used
(Pearson and Wood, 1964). Sex-linked mechanisms are known to affect a variety of
immunological conditions in a variable manner and experimental models of
autoimmune conditions often show non-uniform influences of sex hormones
(Schuurs and Verheul, 1989). Systemic lupus erythematosus shows a profound
female dominance, as testosterone suppresses both development of disease and
autoantibody production (Steinberg et al., 1979). Some models of inflammatory
arthritis have been shown to have some dependence upon sex hormones, but
different models show differing male/female susceptibilities. Collagen-induced
arthritis in the mouse has been clearly shown to be more severe in male and
oophorectomised female mice (Holmdahl et ah, 1986), whereas streptococcal cell
wall-induced arthritis is more severe in female rats; with the less severe disease in
males being dependent upon male testicular hormones (Allen et ah, 1983), and
androgens inhibit cartilage breakdown in the mouse air pouch model (Da Silva et ah,
1993; Steward and Bayley, 1992). In adjuvant disease, oestradiol will reduce the
incidence of joint disease if administered to either male or female rats (Mueller et ah,
1964). Studies of adjuvant disease related to pregnancy in the rat have also shown
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that female hormonal levels can have a beneficial effect on the disease if animals are
pregnant prior to induction, but no protective effect if pregnant animals are made
arthritic (Mathers and Russell, 1990). In humans, there is a definite female
preponderance in both prevalence and incidence of rheumatoid arthritis (RA) (Hazes
and Silman, 1990) and pregnancy usually causes a remission in the severity of RA
with a 'relapse' after birth. The data in humans also shows that pregnancy has a
protective effect against the onset of RA, both during pregnancy and for three
months thereafter (Silman et al., 1992).
The reasons for the disparity in the influence of sex hormones in RA and adjuvant
arthritis is unclear. It has been hypothesised recently that the female predisposition
to RA is due to low androgen levels and not high oestrogen levels (James, 1993),
particularly as men with RA also show low levels of androgens (Spector et al., 1989;
Spector et al., 1988). However, adjuvant arthritis in the rat and RA do not share the
same pathogenesis although they do show similar pathophysiology (Rainsford,
1982), and therefore it may be inappropriate to extend the "androgen theory" to the
experimental animal. Adjuvant arthritis in rats is primarily T-cell mediated (Chang,
1984) and this could explain why exogenous oestrogens will suppress adjuvant
arthritis (Mueller et al., 1964) in both sexes, since female sex hormones have a
suppressive effect on T-cell mediated functions (Kappas et al., 1963; Stimson and
Hunter, 1980) so removing this important component of the pathogenesis of the
disease. While many autoimmune diseases in humans and animals show varying
dependence upon sex hormones adjuvant arthritis has not been shown to be more
severe in either sex, merely susceptible to exogenous steroid hormones,
consequently, it is not surprising that there is not a male/female difference in the rats
in this study.
129
5.4.3. Expression of in situ hybridisation results
All results shown are expressed as a percentage of the basal expression of
messenger RNAs in untreated, normal animals. This is due to the interexperimental
variability inherent in the isotopic in situ hybridisation technique. If all parameters
such as hybridisation, washing temperatures and times, and exposure times are
strictly maintained, there is usually a difference in the specific activity to which the
riboprobes are labelled due to template length or activity of the RNA polymerase,
which will introduce variation in the numbers of silver grains in the final processed
section. Even in cases where all parameters are as closely maintained as possible,
there is usually some variation in the absolute grain numbers in control animals. The
in situ hybridisation technique as described here, is semi-quantitative in nature
because without standards for specific radioisotopic activities the absolute grain
numbers overlying any particular cell can not be related to any finite value for the
amount of messenger RNA. Therefore the grain count is a representation which
must always be compared to a standard, i.e. the expression in untreated control
DRG. For these reasons, all data are expressed as a percentage of the untreated
controls which are always included in each hybridisation.
5.4.4. Human versus computer image analysis of in situ hybridisation silver grain
numbers.
The selection of cells which were analysed in these experiments was perhaps the
point at which a degree of subjectivity could have been introduced. In those studies
analysed by direct visual counting of silver grains (neuropeptide mRNA expression
in the development of monoarthritis, section 5) four cells were counted from each
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DRG section, along with four areas of background. This number was primarily
determined as that which could give a representation of the level of expression
without becoming too arduous in the time required to count the silver grains. In all
subsequent experiments, when grain counting was computer-aided, more cells per
section were counted, as time limits again would allow. An attempt was made in all
the analysis to select cells which showed neither the lowest nor highest hybridisation
signal. Obviously this method of the selection of neurons form analysis could
introduce some sampling bias; however this was substantially eliminated by coding
all slides when sections were cut, and only breaking the code as to experimental
group after all in situ silver grain counting was completed. Unfortunately there is no
option on the computer software to facilitate the random selection of cells for
analysis by the computer itself. This would be a superior method of analysis as
sampling bias would be eliminated; however due to the coding of slides it is unlikely
that sampling bias introduced a large error in any of the studies presented in this
thesis.
The analysis programs used for counting high and low density silver grains are
different in the method in which the images are processed and this is reflected in the
different correlations between eye and machine counts (Figure 5.2a and b). Low
density counts identify only individual silver grains, and this is extremely useful in
the quantification of mRNAs which are not highly expressed such as transcription
factors (see Section 8). However this method of counting grains cannot be applied
to more highly expressed mRNAs such as the neuropeptides under study here. This
analysis routine cannot give accurate grain counts in neuropeptide in situ
hybridisation due to the clumping of silver grains, which is illustrated in Figures 5.6,
5.7 and below. Therefore the software designed for high density grain counts must
be used for quantitation of neuropeptide mRNA expression.
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Figure 5.12. Dark fieldphotomicrograph showing neurons expressing PPT mRNA
showing the density ofsilver grains overlying individual neurons. Original
magnification x20.
A high density grain count is calculated in two stages. Firstly all single grains are
counted, then clumps are detected and the number of grains calculated by dividing
the total area of clumped grains overlying any cell by a constant representing the
average silver grain size in the particular experiment. Totals are then calculated by
simple addition. Thus the computer uses defined rules to calculate the number of
silver grains in a clump, rather than an arbitrary determination as occurs when
counting by eye. This is of value as the computerised technique is consequently
more objective in the determination of numbers of grains Equation 1 shows that in
high density silver grain counting, the computerised image analysis system appears
to detect nearly five times the number of silver grains detected by eye, indicated by
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the x value. This could indicate either that the machine is 5 times more sensitive in
detecting silver grains than the human eye, or that a multiplication error has
somehow been introduced into the analysis software. On investigation, the latter
was found to be true, as the constant representing the average grain size was found to
be four times less than the actual grain size. However, this does not introduce a error
into the final data analysis as all in situ hybridisation results are always expressed as
a ratio of the basal mRNA expression in controls (Section 5.4.3.) which negates any
multiplication error introduced by the analysis software. This fault has been
eliminated in an updated version of the software.
Therefore this image analysis software represents a more objective and reproducible
method of determining silver grain numbers than direct visual counting, particularly
in situations where silver grain numbers are high.
5.5. CONCLUSIONS
This model of adjuvant arthritis in the rat shows equal disease patterns and severity
in both male and female animals, agreeing with other studies on adjuvant-induced
polyarthritis.
The numbers of primary afferent neurons expressing neuropeptides under
conditions of noxious stimulation and inflammation is still in dispute. Further
studies with rigorous and methodical methods of neuronal counting need to be
performed.
Neuropeptide mRNAs in primary afferent neurons show distinct, rapid changes in
response to developing arthritis and in the bilaterally arthritic animal. It is suggested
that PPT and CGRP encoded proteins may play a role in the contralateral spread of
arthritis in this model; this is discussed further in Section 6.
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SECTION 6 THE ROLE OF CAPSAICLN-SENSITIVE PRIMARY
AFFERENTS AND NEUROPEPTIDE mRNA EXPRESSION IN THE
SPREAD OF EXPERIMENTAL ARTHRITIS
6.1. INTRODUCTION
The effects of capsaicin systemically administered to the neonate on nociceptive
thresholds, inflammatory responses and, in particular, arthritis, is still in dispute. As
outlined in Section 1, the effects of either neonatal or perineural capsaicin in adults,
on thermal and mechanical nociceptive thresholds are equivocal, with authors
reporting both increased and unchanged values in both types of nociceptive test. All
workers, however, report decreased sensitivity to noxious chemical stimuli in
capsaicin-treated animals (Fitzgerald, 1983).
6.1.1. The peripheral sensory nervous system in articular inflammation
In recent years there have been investigations to determine the extent to which the
peripheral, central and sympathetic nervous systems contribute to the development
of inflammation and hyperalgesia. Joints are known to be innervated by capsaicin-
sensitive afferents (He et al., 1988), and both mechanical and chemical nociceptive
stimuli can be inhibited by close arterial injection of capsaicin (He et ah, 1990).
Investigations of capsaicin treatment on the development of inflammatory
hyperalgesia have shown that polyarthritic rats treated with capsaicin as neonates
(which ablates 90% of C-fibre afferents) show normal ambulatory and rearing
behaviours when compared with vehicle-treated controls (Hara et ah, 1984; Bartho et
ah, 1990). In a study of the decreased nociceptive thresholds seen in rats with
adjuvant arthritis (Hara et ah, 1984), neonatal capsaicin was shown to attenuate
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decreases in thermal nociceptive thresholds (tested by the hot plate, but not in tail
flick tests), chemical nociception tested by the formalin test and also in mechanical
nociceptive tests. Development of a neuropathic thermal hyperalgesia is also
prevented by neonatal capsaicin administration (Meller et al., 1992).
In rat adjuvant polyarthritis, both Hara and colleagues (1984) and Cervero and
Plenderleith (1987) failed to show an amelioration of the joint swelling in animals
treated with capsaicin at birth. Only Levine and colleagues (1986) have shown a
significant reduction in joint inflammation, assessed by radiography, in animals
treated neonatally with capsaicin. Colpaeit and colleagues (1983) showed that
capsaicin treatment of the adult rat (either before or after adjuvant injection), which
is a more restricted lesion than neonatal capsaicin, resulted in a reversal of the
decreased weight gain seen in arthritis, and an attenuation of the joint swelling
occurred in these animals. In a first attempt using a more confined nerve lesion,
Courtright and Kuzell (1965) showed that peripheral axotomy attenuated the severity
of adjuvant-induced arthritis in the rat. Levine et al. (1985a) showed that perineural
capsaicin will inhibit "reflex neurogenic inflammation", an effect they described of
contralateral paw swelling following ipsilateral paw injury and intra-articular
capsaicin will also reduce the severity of antigen-induced arthritis (Inman et al.,
1989). These latter studies therefore supported the findings of Courtright and Kuzell
that disruption of the peripheral sensory system could attenuate joint injury.
6.1.2, The effects of capsaicin on neuropeptides
The effects of both systemic and perineural capsaicin on the neuropeptides in
primary afferents has been outlined in Section 1. Capsaicin has acute effects on
primary afferents resulting in release of neuropeptides into the spinal cord and in the
periphery, and these effects can be blocked using ruthenium red (Amann et al., 1990;
Ohkubo et al., 1993), leaving other responses e.g. activation by mechanical or
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chemical stimuli unaffected. Ruthenium red will block the capsaicin-induced release
of peptides from peripheral terminals but does not affect release stimulated by
bradykinin or potassium depolarisation (Holzer, 1991). Systemic administration of
capsaicin to neonatal and adult rats results in a depletion of the primary afferent
neuropeptides substance P, somatostatin (Gamse et al., 1981), and CGRP (Kashiba
et al., 1990) but not neurotensin (a peptide not found in primary afferent neurons) in
DRG, peripheral nerve, dorsal roots and dorsal spinal cord. The effect of capsaicin
on primary afferent neuropeptides appears to be mediated through nerve growth
factor (NGF) as the neurotoxic effects of capsaicin on neuronal death and substance
P content can be blocked by NGF (Otten et al., 1983), and perineural capsaicin is
known to block retrograde transport of NGF which regulates substance P production
(Miller et al., 1982; Lindsay and Harmar, 1989).
6.1.3. The sympathetic nervous system in inflammation
Evidence is accumulating that the postganglionic sympathetic nervous system
contributes to inflammation, and particularly may influence the severity of joint
injury in experimental and clinical arthritis. Reflex sympathetic dystrophy is a
disease characterised by increased sympathetic activity which is associated with
bilateral joint inflammation (Kozin et al., 1976). It was proposed by Levine and
colleagues (1986) and Fitzgerald (1989) that the PGSN contributed to the joint injury
seen in experimental arthritis through reflex sensory activation of PGSN via the
sensory afferents and preganglionic sympathetic neurons located in the ventral hom
of the spinal cord. However, there are conflicting reports on the relative
contributions of sensory afferents and sympathetic efferents in, for example, joint
inflammation (Lam and Ferrell, 1991; Green et al., 1993a), and on the effects of the
inflammatory mediator bradykinin (Green et al., 1993b; Koltzenburg et al., 1992).
Unfortunately, systemic sympathectomy using guanethidine, while reducing
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peripheral noradrenaline and joint damage (Levine et al., 1986; Green et al., 1993a),
also significantly reduces the numbers of both substance P and CGRP
immunoreactive neurones in both the trigeminal and dorsal root ganglia (Mione et
al., 1992) and cannot be considered as a "clean" sympathetic lesion. A large number
of workers is attempting to clarify this situation.
It was also suggested by Levine et al., (1986) that distant hyperalgesic effects were
also dependent on the postganglionic sympathetic nervous system. This suggestion
was extended by Kidd and colleagues (1989b) in a hypothesis that a contralateral
sensitisation of nociceptors occurring through contralateral activation of the
preganglionic sympathetic nervous system could underlie the symmetrical spread in
experimental and clinical arthritis. Further, it has been proposed that neurogenic
plasma extravasation is dependent upon the postganglionic sympathetic neuron
(Gonzales et al., 1991). In a recent study of bradykinin-induced plasma
extravasation in the rat knee joint, Green and colleagues (1993b) found no evidence
for the release of noradrenaline in the contralateral joint, whereas bilateral changes in
sensory neuropeptide release have been observed during acute monoarthritis
(Bileviciute et al., 1993), further supporting a fundamental role for sensory afferents
in mediating contralateral effects of inflammation.
6.1.4. Aims of the studies
The experimental protocols used here, involving the neurotoxin capsaicin were
designed to examine the role of the unmyelinated sensory afferents in the mechanism
underlying contralateral spread of arthritis. The effect of neonatal and perineural
capsaicin on the maintenance and spread of arthritis in a modified model of
adjuvant-arthritis has been examined. The role of primary afferent neuropeptides in
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this spread has also been determined by assessing neuropeptide mRNA expression in
DRG innervating the inflamed joints by in situ hybridisation.
6.2. MATERIALS AND METHODS
6.2.1. Neonatal capsaicin treatment
Neonatal rats were injected with either 50mg/kg capsaicin solution or vehicle
subcutaneously on postnatal day 2, under 4% halothane anaesthesia. Capsaicin
solution was obviously exerting an immediate effect as pups showed signs of
respiratory disturbance and hypoxia. After recovery animals were left for seven
weeks before induction of either mono- or bilateral arthritis by injection ofM. tub.
suspension around the left tarsal joint as described in section 2.
6.2.2. Perineural capsaicin treatment
Sciatic nerves were exposed in the mid thigh region and capsaicin solution applied
directly to the nerve under halothane anaesthesia (1.5% capsaicin for 15 minutes as
described in detail in Section 2.4.1). Sciatic nerve exposure was used as a control
for surgical exposure of the nerve, since the vehicle is known to exert direct effects
upon axon conduction (Wall and Fitzgerald, 1981; Petsche et al., 1983). Following
perineural capsaicin treatment, animals were allowed to recover for two weeks
before induction of bilateral arthritis by intradermal injection of 250pg M. tub.
around the left ankle joint, under halothane anaesthesia. Animals with capsaicin
directly applied to either left or right sciatic nerves will be referred to as CAPL and
CAPR respectively.
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6.2.3. Monitoring of progress of arthritis
Weights, joint swelling and inflammation were monitored for fifteen days, when the
animals were killed by decapitation and L5 DRG taken and processed for
neuropeptide mRNA in situ hybridisation. Parallel sections from neonatally treated
animals were also processed for substance P immunohistochemistry (Section 2).
Ixft and right tarsal joints were removed by section of the tibia and fibula, post-fixed
in 10% formal saline, decalcified in Gooding and Stewart's solution, and processed
for histological examination. Joint sections were scored blind for signs of
inflammation/arthritis.
6.2.4. Efficacy of the perineural capsaicin treatments
The efficacy of perineural capsaicin treatment was determined by
radioimmunoassay of L4/5 DRG neuropeptides. A group of CAPL animals were
killed before induction of arthritis, L4/5 DRG taken and substance P, CGRP and
somatostatin content assayed as described in Section 2
6.2.5. Expression of in situ hybridisation data
All neuropeptide mRNA levels are expressed as a percentage of the basal
expression in untreated control animals as described in Section 5.4.3. Data were
compared by ANOVA followed by Dunnetts post hoc test
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6.3. RESULTS
6.3.1. Neonatal capsaicin treatment
6.3.1.1. Effect of capsaicin on the development of arthritis
Induction of monoarthritis in either capsaicin or vehicle treated rats did not affect
the normal weight gain (Figure 6.1) in rats of this age (see also figure 3.1 for normal
weight gain in untreated rats).
Figure 6.1
0 1 3 7 9 11 14
day after injection
Figure 6.1. Mean body weight ofmonoarthritic rats treated neonatally with either
capsaicin or vehicle (n-4 per group)
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The groups of rats in which arthritis was induced for the study of bilateral disease
showed significant differences in weight before arthritis was induced (230 ± 4g
capsaicin; 286 ± 8g vehicle). If changes in weight are compared, vehicle treated rats
showed a significant attenuation of the normal increase in weight with the onset of
bilateral arthritis (day 14) compared to capsaicin treated rats (Figure 6.2). Increases
in weight plotted in Figure 6.2 are calculated from the difference between the
measured value on each day minus the preinjection value for each animal.
Figure 6.2
0 2 4 6 8 10 12 14 16 18
day after injection
Figure 6.2. Increase in weight during development ofarthritis in capsaicin and
vehicle treated bilaterally arthritic rats (n=9 vehicle; 6 capsaicin).
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Neonatal capsaicin slightly attenuated but did not significantly affect left joint
swelling in either mono- or bilaterally arthritic rats (Figures 6.3 and 6.4), and slightly
delayed, but did not prevent right joint swelling in bilateral arthritis (Figure 6.4).
This was obviously not a function of weight gain as capsaicin slightly attenuated
joint swelling, but maintained the increase in weight in these animals.
day after injection
Figure 6.3. Increase in left (upper) and right (lower) joint circumferences in
monoarthritic rats treated on postnatal day 2 with either capsaicin or vehicle. There
were no significant differences between capsaicin and vehicle treated groups (n=4).
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day after injection
Figure 6.4. Increase in left (upper), and right (lower) joint circumference in
bilaterally arthritic rats treated neonatally with either capsaicin or vehicle.
(*p<0.05; n-6 capsaicin; 9 vehicle).
Histological assessment of right and left joints from bilaterally arthritic animals
showed no difference in the degree of arthritis 17 days after adjuvant injection,
between capsaicin or vehicle treated animals (Table 6.1). These animals showed the
same features of joint inflammation as those illustrated in Section 3.
Table 6.1. Histological scores for capsaicin and vehicle treated bilaterally arthritic
rats (day 17). Values shown are medians (range)
Left Right
Capsaicin 3 (2-4) 3 (0-4)
Vehicle 4 (3-4) 4 (2-4)
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6.3.1.2. Neuropeptide mRNA expression in monoarthritic rats
It can be seen from Table 6.2 that in vehicle treated animals the usual rise in all
three neuropeptide mRNAs is seen in ipsilateral, but not contralateral L5 DRG. In
animals treated on postnatal day 2 with 50mg/kg capsaicin, in the remaining
neuropeptide expressing cells, only somatostatin mRNA shows a significant
decrease in expression compared to untreated control values. PPT and CGRP
mRNA expression in this population of cells is not significantly different from that
in untreated control animals, and do not exhibit the usual rise in these neuropeptides
seen during monoarthritis (Section 5). The changes in left (injected side) DRG
mRNA expression are additionally illustrated in Figure 6.5.
Table 6.2. Expression of neuropeptide mRNAs in monoarthritic rats tday 15 after
adjuvant injection) treated at postnatal day 2 with either capsaicin or vehicle.
*denotes significantly differentfrom control values (untreated animals) p<0.05; n-
4 per group. Mean ±S.E.M. control grain counts were; PPT, 108±12; CGRP,
135±20; SS, 157±10.
PPT CGRP Somatostatin




Capsaicin 146±48 153+27 124±29 77±12 4515* 2413*
Vehicle 622±195* 122±18 226+18* 110±26 212120* 114115
144
Figure 6.5. Expression ofPPT, CGRP and somatostatin in left DRGfrom
untreated control animals , and animals treated neonatally with either capsaicin or
vehicle, 15 days after adjuvant injection. Neonatal capsaicin treatment prevented






6.3.1.3. Expression of neuropeptide mRNAs in bilaterally arthritic rats
Treatment of neonatal rats with vehicle, again does not affect the expression of the
three neuropeptide mRNAs in bilateral arthritis, as would be predicted from the
changes observed in vehicle treated monoarthritic rats, as all show the usual rises in
both left and right L5 DRG (PPT and CGRP) or only left L5 DRG (somatostatin). In
animals treated neonatally with capsaicin, the usual rise in mRNA seen in both L5
DRG in bilateral arthritis was attenuated and expression of PPT mRNA in the
remaining cells did not show any significant differences from untreated controls.
CGRP mRNA expression was significantly lower in right DRG from capsaicin-
treated animals than in untreated controls. Expression of somatostatin mRNA was
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also significantly reduced and indeed was not detectable in animals treated
neonatally with capsaicin. The neuropeptide mRNA changes are detailed in Table
6.3 and Figure 6.6.
Table 6.3. Expression ofPPT, CGRP and somatostatin mRNAs in L5 DRG of
bilaterally arthritic rats treated on postnatal day 2 with either capsaicin or vehicle,
17 days after adjuvant injection. *p<0.05 compared to untreated control values;
n=6 capsaicin, 9 vehicle; ND no detectable expressing cells Mean ±S.E.M. control
grain counts were; PPT, 121324; CGRP, 2S4±71; SS, 244±84
PPT CGRP Somatostatin




Capsaicin 94±14 70±5 121±16 64±4* ND ND
Vehicle 221±50* 185±17* 135±7* 133±10* 212+20* 135+29
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Figure 6.6. Neuropeptide mRNA expression 17 days after adjuvant injection n DRG
from rats treated neonatally with either capsaicin or vehicle. ND = not detectable.



































6.3.1.4. Substance P immunoreactivitv in DRG from caosaicin-treated animals
It can be clearly seen from Figure 6.7 that substance P immunoreactivity is present
in both vehicle and capsaicin treated arthritis animals compared to the control
without primary antibody. This indicates that the remaining neurons which express
PPT mRNA are still capable of substance P-like protein translation.
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c) d)
Figure 6.7. Lightfield photomicrographs ofDRG neurons expressing substance P-
like immunoreactivity from a) control; b) capsaicin and c) vehicle treated rats. A
control section was incubated without the primary antibody (d).
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6.3.2. Perineural capsaicin treatment
6.3.2.1. Efficacy of perineural capsaicin lesions: effects on DRG neuropeptide
Content
CAPL caused a significant reduction in L4-5 DRG content of substance P, CGRP
and somatostatin, only on the treated side, in otherwise normal animals. Substance P
showed the greatest decrease (62% fall compared with untreated controls), CGRP
fell by 37% and somatostatin by 35%. Contralateral neuropeptide content was not
significantly different from control values. (Table 6.4). Neuropeptide content is
expressed as pg/ganglion as small lengths of peripheral nerve or dorsal root are often
left attached to DRG on dissection and may bias expression by weight.
Table 6.4. Neuropeptide content ofL4/5 DRG in normal and CAPL animals.
Values are pg/ganglion ±SEM (*p<0.05, paired and unpaired t test compared to
control or contralateral; n=5 per group).
Substance P CGRP Somatostatin
Control CAPL Control CAPL Control CAPL
Left 186126 70124* 11781110 748175* 4612 3013*
Right 192132 16419 11711116 1217139 4613 4012
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6.3.2.2. Effect of perineural capsaicin on animal behaviour
No animal showed any abnormal motor effects or infection following capsaicin
application to the sciatic nerve. None of the surgical interventions significantly




Figure 6.8. Increase in weight ofbilaterally arthritic, CAPL, CAPR and arthritic
rats following sciatic nerve exposure during development ofarthritis. (n=10
bilateral arthritis; 9 CAPL; 4 CAPR; 5 nerve exposure).
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6.3.2.3. Effect of perineural capsaicin on left and right joint inflammation
Bilaterally arthritic animals showed a rapid and sustained increase in left ankle joint
circumference immediately after adjuvant injection (Figure 6.8) and subsequent
involvement of the right ankle joint involvement after 14 days, evidenced by a
significant increase in joint circumference (Figure 6.10) as detailed in section 5.
Rats with bilateral arthritis showed no significant differences in either left or right




Figure 6.9. Increase in left joint circumferences in bilaterally arthritic and sciatic
nerve exposed, CAPL and CAPR rats. (*p<0.05 CAPL ; fp<0.05 CAPR vs either
bilateral arthritis or nerve exposure).n values are as in Figure 6.8.
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6.3.2.3A. Capsaicin application to the left sciatic nerve (CAPL)
CAPL significantly reduced both left (Figure 6.9) and right (Figure 6.10) joint
swelling when compared to animals with bilateral arthritis and sciatic nerve
exposure.
The reduction in joint swelling for the right ankle was accompanied by a reduction







Figure 6.10. Increase in right joint circumferences in bilaterally arthritic and
sciatic nerve exposed, CAPL and CAPR rats. (*p<0.05 CAPL ; fp<0.05 CAPR vs
either bilateral arthritis or nerve exposure).n values are as in Figure 6.8.
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Table 6.5. Inflammation scores for right and left joints from bilaterally arthritic,
CAPL and CAPR rats. Inflammation scores for right joints before day 14 are all
zero. Values shown are median (range).
Bilaterally arthritic CAPL CAPR
Day Left Right Left Right Left Right
14 3 (0-4) 0.5 (0-2) 2(1-3) 0 2(1-3) 0
15 3 (0-4) 1 (0-3) 1.5(1-3) 0 2(1-3) 0(0-1)
6.3.2.3B. Capsaicin application to the right sciatic nerve (CAPRI
CAPR, surprisingly, also caused a significant reduction in both left joint swelling
compared to bilaterally arthritic rats only on days 11 and 14 (Figure 6.9). There is
some evidence that unilateral nerve lesions can affect the normal functioning of the
contralateral nerve and this is discussed in section 6.4.2.2. There was also a
significant attenuation of right joint swelling (Figure 6.10) reflected in lower
histological and inflammation scores of the right joint (Tables 6.5 and 6.6).
Table 6.6. Histological scores (as defined in Section 2) of left and right tarsal joints
in bilaterally arthritic, CAPL and CAPR animals, 15 days after adjuvant injection.
Values shown are median (range). (*p<0.05 vs bilaterally arthritic animals; n=5
bilat. 4, CAPL and CAPR)
Left Right
Bilaterally arthritic 3 (2-4) 2 (2-4)
CAPL 2.5 (1-4) 1.5 (1-2)
CAPR 2.5(1-4) 0.5 (0-2)*
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6.3.2.4. Effect of perineural capsaicin on neuropeptide mRNA expression
Neuropeptide mRNA expression in animals with bilateral arthritis has been
described in Section 5 and is summarised in Table 6.7; briefly mRNA expression of
PPT and CGRP, but not somatostatin was increased in both left and right L5 DRG
neurons when compared to untreated controls. VIP mRNA was not detected in any
section of DRG from either untreated, control arthritic or capsaicin-treated arthritic
animals, but was always detected in positive control sections of the hypothalamic
suprachiasmatic nucleus.
6.3.2.4A. Animals with CAPL and arthritis
CAPL caused a significant reduction in PPT, CGRP and somatostatin mRNA levels
compared to bilaterally arthritic rats, in the remaining left L5 DRG neurons capable
of expressing these neuropeptides (also associated with a small, but significant
attenuation in joint swelling). CAPL also prevented the rise in neuronal PPT mRNA
expression in contralateral (right) L5 DRG, but did not affect the rise in CGRP
mRNA seen in L5 DRG of bilaterally arthritic animals. Somatostatin mRNA
expression remained at control levels in right DRG neurons (Table 6.7).
6.3.2.4B. Animals with CAPR and arthritis
CAPR prevented the rise in PPT and CGRP mRNA expression seen in right L5
DRG neurons in symmetrically arthritic animals, and did not alter somatostatin
mRNA expression. This was associated with a reduction in right joint swelling.
CAPR also prevented the rise of CGRP and somatostatin mRNA expression in left
L5 DRG. However, the elevation of PPT mRNA expression in the left DRG (the
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side injected with adjuvant) was maintained (Table 6.7), as was inflammation and
arthritis, although joint swelling was non-significantly reduced. Neuropeptide















































Figure 6.11. Neuropeptide mRNA expression in DRG ofbilaterally arthritic,
CAPL and CAPR animals 15 days after injection ofadjuvant. *p<0.05, fp<0.01 cf.
untreated controls. n=5 per group.
Figure 6.12. Dark field photomicrographs ofPPT mRNA in L5 DRGfrom
a) control, b) and c) left and right DRG from a bilaterally arthritic rat, d) and e)
left and right DRG from CAPL rat. PPT mRNA represented by silver grain density
is increased in both left and rightDRG in the bilaterally arthritic rat. Note decrease
in left, and no increase in right silver grain density in CAPL animal.
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Table 6.7. Neuropeptide mRNA expression in DRG ofbilaterally arthritic, CAPL
and CAPR animals 15 days after injection ofadjuvant. (*p<0.05, fp<0.01 cf.
untreated controls). ND = no detectable expressing cells. Mean ±S.E.M.. control
grain counts were; PPT, 10734; CGRP, 328±37; SS, 244342.
P]PT CGRP Somatostatin
Left Right Left Right Left Right
Control 100±8 100±11 IOC1110
Bilateral
arthritis
219±48t 190±20t 140±20* 147115+ 14819* 108120
CAPL 34+6* 105±4 4916+ 19615+ ND 7014
CAPR 174±13* 88+19 105±6 83111 71113 108120
6.4. DISCUSSION
It has been proposed that the sensory and sympathetic nervous systems interact to
mediate the spread of inflammation and arthritis (Kidd et al., 1989b). The present
results have shown that a specific neurotoxic lesion of polymodal nociceptors will
significantly attenuate the spread of arthritis, whereas neonatal destruction of
unmyelinated primary afferents will not. The implication, and possible significance
of these results is discussed below.
6.4.1. Neonatal capsaicin
The results obtained may appear to be surprising in view of the general acceptance
that systemic capsaicin attenuates the severity of adjuvant-induced arthritis
(Fitzgerald, 1989; Kidd et al., 1989b; Levine et al., 1986). These results show that
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destruction of ~90% of C-fibre afferents has only mild effects on the initial, left
inflammatory focus and a slight delaying effect on the contralateral spread. As
mentioned in the introduction, only Levine and colleagues (1986) have shown a
reduction in disease severity of adjuvant arthritis in rats treated neonatally with
capsaicin. At first assessment, this could be due to the differences in the method of
determining the disease severity; Levine and colleagues used radiographic analysis
of the joints, whereas other workers who have found no reduction in severity
assessed the disease by measurement of joint swelling (Hara et al., 1984; Cervero
and Plenderleith, 1987). In the current experiments, the severity of arthritis has been
assessed both by joint swelling, and histological examination (which correlate
strongly with each other; Section 3), and there was no difference between groups of
animals treated with capsaicin or vehicle.
6.4.1.1. Effects of neonatal capsaicin on the development of related structures
It is now recognised that the central nervous system is not hard-wired and may
show both functional and morphological plasticity in response to nerve injury
(Woolf, 1993). It is well documented that neonatal treatment with capsaicin results
in disorganised somatotopic representations in both the spinal cord of rats, and the
whisker barrel representations in the mouse (Wall et al., 1982c). These animals also
show changes in physiological responses such as expanded receptive fields (Wall et
al., 1982a) and morphological changes in the innervation of the dorsal horn (Jancso
et al. 1977).
Following the destruction of the central terminals of the unmyelinated primary
afferents in the substantia gelatinosa of the dorsal horn by capsaicin, there is
reinnervation of the substantia gelatinosa by the remaining primary afferents. Nagy
and Hunt, (1983), used anterograde labelling techniques to confirm that there was a
considerable loss of inputs, but also showed that there was a reorganisation of
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primary afferents involving reinnervation of lamina II (Rexed, 1952) in particular.
The methodology used in this study did not identify the functional modality of the
fibres which were seen to reinnervate structures within the spinal cord following the
destruction of the unmyelinated fibres by capsaicin. Subsequent studies attempted to
identify the invading afferents in lamina II on the basis of the terminal arborisation
patterns as hair follicle afferents (Rethelyi et al., 1986; Beal and Knight, 1987), and
this was confirmed by physiological studies (Shortland et al., 1990). Rethelyi et al.
(1986) found terminals corresponding to hair follicle afferents in the lateral aspect of
the dorsal horn, with functionally unidentified sprouting fibres of different terminal
arborisation pattern in the medial aspect of the dorsal horn. These authors suggest
that these may be slowly or rapidly adapting mechanoreceptors, or Pacinian
corpuscle afferents innervating glabrous skin on the foot. Furthermore, it is apparent
that the chronic afferent denervation caused by neonatal capsaicin causes an increase
in sympathetic innervation density and transmitter content. It has been suggested
that this may be caused by increased availability of growth factors due to lack of
competition from the sensory nervous system (Holzer, 1991).
6.4.1.2. Primary afferent neuropeptides following neonatal capsaicin
administration: role in adjuvant arthritis
It has been shown that in vehicle-treated animals, the neuropeptide mRNAs under
study show the same changes as those described previously in bilaterally arthritic
rats, namely bilateral increases in PPT and CGRP mRNA and unilateral increase in
somatostatin mRNA expression. Capsaicin-treated rats, however, do not show
significant changes in PPT mRNA expression, when compared to normal untreated
controls. Individual cellular expression of CGRP was significantly lower than
untreated controls only in right DRG. Neonatal capsaicin, while destroying the vast
majority of unmyelinated primary afferents, does not remove all neuropeptide
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expressing neurons although the numbers of neurons expressing substance P, CGRP
and somatostatin are known to be markedly reduced in number (Holzer, 1991) and
neurons expressing somatostatin mRNA were undetectable in this study. It is
conceivable that the neurons in capsaicin-treated animals, in which neuropeptide
mRNA expression was examined are a different population to those in untreated
controls, and show lowered basal levels of mRNA expression that those in untreated
animals. Capsaicin-sensitive neurons are thought to be those primarily involved in
the mediation of neurogenic inflammation but capsaicin-resistant neurons, which
also contain neuropeptides, may well be found to possess efferent functions (Holzer,
1988). It must also be borne in mind that neonatal capsaicin does not result in a total
lack of capsaicin-sensitive afferents in the adult; whether this is a result of
development at a later stage, or escape from the neurotoxin at the time of injection is
unknown (Holzer, 1991). The relative proportions of C-fibre modalities in adults
treated as neonates is also not significantly different from vehicle treated animals,
and these primary afferents show normal function suggesting a degree of recovery in
the adult animal (Holzer, 1991). The effects of neonatal capsaicin treatment on
primary afferent neuropeptide gene expression is unknown. Decreases in the amount
of peptides in DRG following capsaicin have been measured by radioimmunoassay
and it is unknown whether these changes are attributable to decreased numbers of
neurons or decreased expression in individual cells or a combination of both (Gamse
et al., 1981; Wimalawansa, 1992). This complicates the interpretation of the data
shown here as it is unknown whether the neuropeptide mRNA levels in arthritic
capsaicin-treated rats could have been increased from a lower level, to control values
in response to adjuvant injection. This possiblity is supported by the finding that
CGRP mRNA expression in bilaterally arthritic rats is significantly lower than that
in untreated controls. It is a likely explanation for somatostatin mRNA-expressing
neurons as while these were undectectable in the group of animals used for study of
bilateral arthritis, the levels in monoarthritic animals were significantly lower than
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untreated controls (Table 6.2). In order to be able to fully appreciate the
implications of the mRNA levels presented here they would be better compared to
capsaicin-treated, non-arthritic controls rather than the totally untreated animals
used. This control group was not included initially as the experiment was designed
to assess the effect of neonatal capsaicin on adult arthritis, rather than the actions of
capsaicin per se. However the exclusion of this group limits the interpretation which
may be placed on the data obtained.
There may be some intra-spinal compensation for the loss of primary afferent-
derived substance P as evidenced by the increase in PPT mRNA in spinal cord
(Sivam and Krause, 1992). There is also some evidence to indicate that there may be
recovery of the CGRP- and FRAP-positive primary afferents, and substance P-
positive intraspinal neurons at six weeks of age (Hammond and Ruda, 1991). While
the neurons found to be expressing PPT and CGRP do not increase their expression
in arthritis in capsaicin treated animals, it is known that dorsal horn neurons in adult
rats treated neonatally with capsaicin are supersensitive to tachykinins (Salt and Hill,
1983). This could indicate that while the absolute amount of translated neuropeptide
are no different from control levels, the sensitivity of the dorsal horn to release of
these peptides is increased, thereby maintaining the stimulatory effect. In addition to
this, as somatostatin mRNA is decreased or completely abolished in these animals
and somatostatin is known to inhibit the release of substance P from primary afferent
terminals (Brodin et al., 1981; Gazelius et al., 1981), the loss of inhibition of release
may also potentiate the action of PPT-derived neurpeptides on dorsal horn neurons.
The evidence discussed above indicates that the morphological and functional
changes seen after neonatal capsaicin treatment can profoundly alter both the normal
physiology of the spinal cord and its reactions in pathophysiological conditions. The
effect of this lesion in regulating the spread of inflammation cannot be clearly
defined until the reorganisation of the dorsal horn and its primary afferent input are
more thoroughly understood. Therefore it is impossible to draw any firm
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conclusions on the function of capsaicin-sensitive primary afferents in inflammatory
arthritis using this lesion especially as the effects of capsaicin treatment on basal
neuropeptide mRNA expression were not studied..
6.4.2. Perineural capsaicin
Perineural capsaicin has time-dependent effects on the afferent nerve. Initially,
perineural capsaicin stimulates the afferents, for example resulting in decreased heart
rate and mean arterial blood pressure if the vagal nerve is treated (Buck and Burkes,
1986) or release of neuropeptides into the dorsal horn from a cutaneous sensory
nerve (Zhao et al., 1992), followed by a reversible conduction block (Wall and
Fitzgerald, 1981). The long term effects of perineural capsaicin are a permanent 70-
80% reduction in functional polymodal nociceptors after two weeks (Pini and Lynn,
1990) and an abolition of neurogenic inflammation (Jancso et al., 1980). This is
similar to the lesion caused by systemic administration in the adult which seems to
be restricted to a sub-population of small primary sensory neurons consisting of
approximately 15-18% of the total cell population (Lynn, 1990; Jancso, 1992) and
therefore these are much more specific lesions than that caused by neonatal
administration. Systemic administration in the adult rat has been shown to attenuate
AA (Colpaert et al., 1983).
The importance of primary afferents in arthritis has been attributed by various
authors to the neuropeptides contained in these primary afferents, which are also
known to be transported to (Harmar and Keen, 1982), and released in the periphery
(Diez Guerra et al., 1988). The neuropeptide changes and possible functions in
inflammatory arthritis has been outlined in Sections 1 and 5
These results show increases in specific neuropeptide mRNA expression in
innervating DRG on development of bilateral arthritis, i.e. both ipsilateral to the
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initial inflammatory focus and contralaterally. Perineural capsaicin lesions of the
sciatic nerve inhibited spread of arthritis and attenuated the arthritis on the side of
immune stimulant injection in this model. These lesions also resulted in a reduction
in primary afferent neuropeptide mRNA expression, suggesting an association
between arthritis, its spread and induction of DRG neuropeptide mRNA expression,
particularly that encoding PPT.
The possible mechanisms and significance of the bilateral increases in PPT and
CGRP mRNAs have been discussed in Section 5.
6.4.2.1. Effects of capsaicin treatment of the left sciatic nerve fCAPLh
The results presented here show that perineural capsaicin will reduce the ipsilateral
(injected side) swelling by only -50%. As the histological features of arthritis are
similar in the left joints of all bilaterally arthritic and CAPL animals in this
experiment, this implies that the local, profound immune stimulation caused by
adjuvant (Freund and Lipton, 1955) may largely override a smaller, but still
significant modulating effect of primary afferent neuropeptides on peripheral
oedema and vascular effects. This assumption is supported by the observation that
substance P and CGRP can cause oedema formation and vascular effects (Gamse
and Saria, 1985; Brain and Williams, 1985). Substance P has, however been
implicated in the mediation of arthritic damage; infusion of the peptide into joints
will result in a greater degree of joint damage in adjuvant arthritis (Levine et al.,
1984). Also, as PPT mRNA was studied, the importance of the second protein
translated from this mRNA, neurokinin A (NKA) should not be overlooked. While
under cell culture conditions the relative quantities of substance P and NKA
translated from the PPT-A gene are approximately equal (MacDonald et al., 1989), it
is not known whether treatment with capsaicin will alter the post-transcriptional
processing of these neuropeptides. Recent evidence suggests that NKA has an
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important spinal function in nociceptive processes (Fleetwood-Walker et al., 1993;
Wiesenfeld-Hallin, 1993), and it is also known to be released from peripheral nerve
terminals (Diez Guerra et al., 1988).
Importantly CAPL completely blocks the contralateral spread of arthritis,
suggesting that distant spread of inflammation is mediated by capsaicin-sensitive
components of the peripheral nervous system. PPT mRNA in contralateral DRG
was expressed at control (non-arthritis) levels, whereas CGRP mRNA expression
was elevated to levels associated with arthritis, although overt spread of
inflammation and arthritis were prevented. This could indicate that some other
mechanism, other than the capsaicin-sensitive primary afferents (e.g. the sympathetic
nervous system which is unaffected by perineural capsaicin; Cervero and McRitchie,
1982), was functioning to activate the contralateral neurons expressing CGRP
mRNA. As this effect on CGRP mRNA was associated with a significant
attenuation of contralateral joint inflammation, this would support the contention
that sympathetic efferent activation of nociceptors is not of major importance in the
spread of inflammation. These data further suggest that peptides encoded by the
PPT gene - e.g. substance P and neurokinin A (MacDonald et al., 1989) - may be of
greater importance than CGRP in mediating the contralateral spread of arthritis, as
suggested by the pro-arthritic effects of substance P demonstrated by Levine et al.
(1984).
6.4.2,2, Effect of capsaicin treatment of the right sciatic nerve (CAPRI
CAPR had a significant effect on swelling of the left joint at two points in the time
of the experiment but this was not reflected in the degree of arthritis assessed
histologically. This agrees with the results obtained by Levine and colleagues
(1985a) in a study of "reflex neurogenic inflammation". This was essentially a study
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of contralateral hyperalgesia and swelling following minor ipsilateral paw injury,
rather than a defined inflammatory lesion, where the authors investigated the effect
of perineural capsaicin on small increases in ipsi- and contralateral paw thickness (0-
3% change). In Levine's study, perineural capsaicin treatment of the nerves in the
uninjured limb also produced a decrease in the contralateral injured paw
hyperalgesiai agreeing with the results presented here that perineural capsaicin can
have effects contralateral to the lesion in itself. This effect is unlikely to be due to a
systemic effect of the locally applied neurotoxin. Capsaicin applied perineurally for
a longer period (30 minutes) than that used in the studies discussed here is absorbed
into the circulation, but in amounts too small to exert a neurotoxic effect on distant
tissues (Holzer, 1991).
The effects of CAPR on the spread of arthritis from the initial left focus to involve
the right hind limb further emphasises the importance of capsaicin-sensitive primary
afferents in the mediation of this spread. CAPR completely prevented the
contralateral spread of arthritis and the induction of CGRP and PPT mRNAs in the
right L5 DRG. CAPR also markedly attenuated the increase in CGRP mRNA in left
DRG in the face of the continuing local inflammation. By contrast, the increase in
PPT mRNA ipsilateral to adjuvant injection was maintained, as was arthritis, further
indicating the likely importance of this gene and its products in neurogenic
inflammation.
6.4.2.3. Neuropeptide mRNA changes in DRG contralateral to the capsaicin
application: mechanisms through which perineural capsaicin exerts distant effects
CAPR has distant effects on the neuropeptide mRNAs in left DRG, preventing the
rise in PPT and somatostatin mRNAs. The mechanism(s) underpinning the different
changes in neuropeptide mRNA expression contralateral to the capsaicin lesion with
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CAPL and CAPR are unknown. Contralateral effects may reflect the subsequent
state of activation (i.e. presence or absence of adjuvant) of the respective sciatic
nerves. Others have shown that nerve injury suppresses neurogenic vasodilation and
plasma extravasation in response to antidromic stimulation in nerves contralateral to
an injury (Allnatt et al., 1990). If polymodal nociceptors are destroyed using
perineural capsaicin before the nerve section, the contralateral impairment of
neurogenic inflammation is no longer seen (Stephen Lisney, personal
communication) suggesting that the contralateral effects observed in this model of
injury and regeneration are also mediated through capsaicin-sensitive polymodal
nociceptors.
The neurotoxic effect of perineural capsaicin can be reversed by NGF (Otten et al.,
1983) and NGF is known to regulate spinal cord conductivity in the adult rat (Lewin
et al., 1992c). Following perineural capsaicin application, transganglionic
degeneration of primary afferents is apparent within 14 days (Jancso G, 1992), and
this treatment alters afferent inputs to dorsal horn neurons both ipsilateral and
contralateral to the injury (Fitzgerald 1982). Thus, there may be plastic changes
within the dorsal horn resulting in altered primary afferent reactions to inflammation.
It is conceivable that a similar process to that seen after neonatal capsaicin, of
sprouting of non-injured primary afferent terminals and synaptic reorganisation in
the dorsal horn could occur following perineural capsaicin application, although to a
lesser extent, particularly since morphological changes indicative of neuronal
plasticity have been noted within hours of damage (Goshgarian et al., 1989).
Furthermore, the increase in neuronal activity seen during inflammation will itself
induce plastic changes in the spinal cord (Dubner and Ruda, 1992). Clearly the
summation of these effects, together with more direct capsaicin-mediated actions on
neuropeptide mRNA expression and their regulation by transcription factors, are
difficult to predict but might well combine to explain the discordant increases in
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primary afferent neuropeptide mRNA expression that were found after CAPL and
CAPR.
While the results from the perineural capsaicin experiments do not disprove an
involvement of sympathetic efferents in the contralateral spread of arthritis in this
model, they are more strongly indicative of a fundamental role for the peripheral
sensory system. The problem inherent in using the "end point" of contralateral
disease to attribute fundamental importance to either the sympathetic and sensory
nervous systems in the spread of inflammation is that, if the activation of nociceptors
and PGSN is sequential as proposed by Kidd and associates (1989b), then lesion of
either system would, inevitably result in an attenuation of the arthritis. The sequence
of events at a spinal level, and whether either dorsal horn sensory neurons or
preganglionic sympathetic neurons are involved, needs to be determined so that
effect of lesions on neuronal activation can be precisely pinpointed with respect to
both time, and the system involved.
Capsaicin-sensitive primary afferents and their central connections are involved in
the maintenance of arthritis and are necessary for the distant spread of inflammation
in our attenuated model of adjuvant arthritis. Contralateral inflammation is
associated with a concurrent increase in PPT and CGRP, but not somatostatin
mRNA expression, or induction of VIP expression, suggesting that specific
neuropeptide products may be involved in the mediation of contralateral spread of
arthritis in this model. Neuropeptides translated from the preprotachykinin gene




Neonatal capsaicin and the destruction of unmyelinated afferents does not affect the
contralateral spread of arthritis. This may reflect an increased sensitivity of dorsal
horn neurons to primary afferent neuropeptides, decreased inhibition of release of
substance P by somatostatin, or some recovery of primary afferents. The lesion may
also allow the sympathetic nervous system to assume a greater importance than
under normal circumstances.
Perineural capsaicin treatment, a more selective lesion, suggests that capsaicin-
sensitive components in the peripheral nervous system are of fundamental
importance in the mediation of the spread of arthritis seen in this modified model of
adjuvant arthritis in the rat.
Neuropeptides encoded by PPT and CGRP mRNAs expressed in these capsaicin-
sensitive neurons are also of importance in the spread of arthritis. PPT encoded
peptides may be of more importance than CGRP, although a synergistic relationship
is more probable.
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SECTION 7. IN VIVO REGULATION OF NEUROPEPTIDE mRNA
EXPRESSION
7.1. INTRODUCTION
Very little is known about the in vivo regulation of sensory neuropeptides
particularly in DRG neurons. Much of the work investigating the expression of
neuropeptide genes, particularly PPT and CGRP has concentrated on the alternative
splicing seen in these genes and the tissue specificity of expression. However, it is
still unknown why only limited populations of DRG neurons express particular
neuropeptides, although the neuropeptide phenotype of DRG neurons appears to be
already determined at birth, at least in the case of VIP (Mulderry, 1993). In the
chick embryo, the majority of DRG neurons express substance P and it appears that
both central and target derived factors act to suppress PPT expression in neurons
which are not "destined" to express this gene in the adult (Barakat-Walker et al.,
1991). It has not yet been determined what these factors may be.
7.1.1 Regulation of sensory neuropeptides by glucocorticoids
Circulating honnones such as glucocorticoids and sex steroids are known to
regulate the expression of various genes through direct interaction with DNA
sequences in the 5' flanking portions of target genes. Regulation can also occur at
several other levels; it is known that adrenalectomy increases the axonal transport of
substance P and, conversely, increased (exogenous) corticosterone levels increase
the axonal transport of somatostatin (MacLean, 1987) in the vagus nerve.
Glucocorticoids also regulate neuropeptide expression in other areas of the central
and peripheral nervous systems such as in brain and sympathetic neurons. It is
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probable, however that different regulatory mechanisms are important in different
tissues.
The neuropeptides substance P and Leu-enkephalin are both expressed in rat
striatum and both preproenkephalin (PPE) and PPT have been shown to be regulated
by circulating glucocorticoids. Adrenalectomy results in a decrease in both PPT and
PPE mRNA expression which can be reversed by corticosterone administration,
although increasing corticosterone levels by restraint stress does not affect PPT
mRNA expression. This suggests that maintenance of PPT mRNA expression
requires at least basal corticosterone levels. Although PPE shows diurnal variation
paralleling that of corticosterone, this is not seen with PPT (Chao and McEwan,
1991). In cultured sympathetic neurons, glucocorticoids inhibit the stimulation of
PPT mRNA caused by the inflammatory mediator IL-1 {3 (Kessler and Freidin, 1991).
Rat VIP gene expression is also regulated in the intact hypothalamus by exogenous
corticosterone and oestrogen (Gozes, 1988). It is difficult, however, to extrapolate
data obtained under culture conditions to the in vivo situation as DRG ganglion cells
lose both central and peripheral targets, and different regulatory mechanisms may act
in the CNS and the PNS. Sensory neurons, particularly, are thought to be dependent
on centrally and peripherally derived factors for maintenance of phenotype (see
Section 1.9); therefore data obtained under culture conditions must be treated with
caution. In vivo, DRG neuropeptides have recently been shown to be regulated by
glucocorticoids. Adrenalectomy caused increases in ganglionic content of substance
P and CGRP and a decrease in somatostatin, effects which were abolished by
dexamethasone administration (Smith et al., 1991). Rat DRG neurons express both
mineralocorticoid and glucocorticoid receptors (J.R. Seckl, personal communication)
and it is therefore possible that these changes in peptide content are mediated at the
level of transcription. However, assessment of neuropeptide content of whole
ganglia may disguise changes in subpopulations of neurons, and changes in peptide
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content may reflect regulation at the level of post-translational processing rather than
transcription.
Glucocorticoids may affect the inflammatory process in ways other than directly via
modulation of gene expression. Synthetic glucocorticoids inhibit the expression of
the cycloxygenase 2 gene, an inducible form of the enzyme thought to be a major
mediator of inflammation (O'Banion et al., 1992), and are also known to have potent
anti-inflammatory effects on the immune system and neuronal excitability (Joels and
de Kloet, 1992).
7.1.2. Nerve growth factor
The dependence of adult DRG neurons on NGF for the maintained expression of
certain neuropeptides, particularly substance P and CGRP has been outlined in
Section 1.8. It has been suggested that NGF may exert its effects on neuropeptide
gene expression in the adult either directly (Gilchrist et al., 1991), via the cAMP or
Ca2+/phosphatidylinositol pathways (Kageyama et al., 1991) or via inducible
transcription factors (Section 8). It is possible that glucocorticoids and NGF effects
may interact in the regulation of gene expression as dexamethasone is known to
repress both c-fos expression (Yin and Howells, 1992), c-jun DNA binding (Yang-
Yen et al., 1990) {transcription factors known to be NGF-inducible} and NGF-
receptor mRNA induction by NGF (Foreman et al., 1992).
7.1.3. Regulation of neuropeptide gene expression by other mechanisms
As mentioned in Section 4, various inflammatory mediators are known to act on
peripheral nociceptive afferents to both activate and sensitise them. This results in
ongoing spontaneous activity in many nociceptors and increased response to usually
innocuous stimuli. Depolarisation with 40mM K+ has been shown to increase the
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expression of VIP and PPT in DRG cultures (Mulderry, 1993b), VIP in spinal cord
cultures (Agoston et al., 1991), and intra-hippocampal injection of the excitotoxin
kainic acid increases PPT mRNA ipsilateral to the injection site (Brene et al., 1992).
7.1.4. Aims of the study
It was of interest to determine whether adrenalectomy would potentiate the
increases in PPT and CGRP mRNA expression seen in arthritic rats, in view of the
effects seen on adrenalectomy at the level of peptide expression, and thereby alter
the severity of arthritis. Also, as nociceptive afferents are known to have increased
spontaneous activity in arthritic rats, the effect of blocking action potential
conduction to the DRG on neuropeptide mRNA expression has also been studied.
1.2. MATERIALS AND METHODS
7.2.1. Adrenalectomy and induction of arthritis
Animals were surgically adrenalectomised under halothane anaesthesia (Section
2.5.1) and allowed to recover for three days from surgery before induction of either
mono- or bilateral arthritis as previously described. Monitoring of weight and joint
swelling was performed as before. Fifteen days after adjuvant injection animals
were killed by decapitation, and trunk blood and DRG collected. In situ
hybridisation for PPT, CGRP and somatostatin mRNA expression was performed on
sections of DRG as described previously.
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7.2,2, Blockage of action potential conduction
Action potential conduction in the left sciatic nerve was blocked by direct injection
of 2% lidocaine (Sigma) solution in sterile saline without surgical incision or
exposure of the nerve. Only animals exhibiting complete motor paralysis of the left
hind limb were then injected with 150|ig M.tub. around the left tibio-tarsal joint.
Animals were killed by decapitation 8 hours later and DRG processed for in situ
hybridisation for PPT, CGRP and somatostatin mRNA expression as described
previously.
7.3. RESULTS
7.3.1. Assessment of inflammation
7.3.1.1. Effect of adrenalectomy on indices of joint swelling and inflammation
Adrenalectomised animals had no circulating corticosterone as determined by
corticosterone radioimmunoassay (< 20 nmol/L). Sham operated rats were found to
have circulating corticosterone levels equivalent to those previously found in mono-
or bilaterally arthritic rats (section 3) (886 ± 682 nmol/L morning corticosterone
levels for sham operated arthritic rats; n=5). One ADX rat in the monoarthritis
group was found to have detectable corticosterone levels and was therefore excluded
from the data analysis. Adrenalectomised (ADX) monoarthritic rats showed the








Figure 7.1. Left and right joint circumferences from ADX and sham operated rats
during the development ofmonoarthritis. (Means ±S.E.M. n=4 ADX; 5 sham)
Figure 7.2
day after injection
Figure 72. Weight gain during development ofmonoarthritis in ADX and sham
operated rats. Groups showed significantly different initial mean weights (206±5g,
ADX; 229±8g, sham) but the gain in weight was not significantly different between







Joint swelling in bilaterally arthritic rats also showed no significant differences
between ADX and sham operated rats, although there was a tendency for the left
swelling to be greater in ADX rats (Figure 7.3) and right swelling to be slightly less.
As in the monoarthritic group, the sham and ADX groups had significantly different
body weights before induction of arthritis (200± 4 g, ADX; 238± 8 g, sham; means ±
S.E.M.) and when the gain in weight over the 15 day period was compared, ADX
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day after injection
Figure 73. Increase in left and right joint circumferences in bilaterally arthritic
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day after injection
Figure 7.4. Mean increase in body weight ofbilaterally arthritic ADX and sham
operated rats during development ofarthritis. *p<0.05 compared to sham operated
group (Means ±S.E.M. n=5 per group).
7.3.2. Neuropeptide mRNA expression
7.3.2,1. Effect of adrenalectomy on neuropeptide mRNA expression
Although adrenalectomy did not significantly affect the degree of arthritis, it did
have subtle effects upon PPT and CGRP mRNA expression. Somatostatin mRNA
expression was examined in only bilaterally arthritic animals (as this mRNA shows
unilateral increases in expression in both mono- and bilateral arthritis [Section 5])
and was unaffected by adrenalectomy (Figure 7.5). As expression in right DRG
from monoarthritic animals is not significantly different from untreated controls, all
results were nomtalised to the expression in right DRG from monoarthritic sham






n *p<0.05 vs control
Figure 7.5. Somatostatin mRNA expression in DRG from ADX or sham operated
bilaterally arthritic rats 14 days after adjuvant injection. Values are means ±
S.E.M.; n-5 per group. There were no significant differences between ADX and
sham animals. Mean ±S.E.M. control grain counts were 184±24
PPT mRNA was increased in left (injected side) DRG neurons in monoarthritic, and
both left and right DRG in bilaterally arthritic, sham operated animals as observed
previously (Section 5). In ADX monoarthritic rats, PPT mRNA expression was not
different from sham operated rats; however bilaterally arthritic ADX rats showed a
significant PPT mRNA increase in left (injected) DRG and no increase in right DRG





















n=4 ADX; 5 sham
sham adx
Figure 7.6A PPT mRNA expression in monoarthritic ADX and sham operated rats
(day 14). Adrenalectomy does not significantly affect the expression ofPPT mRNA.



















1 *p<0.05 vs control
#p<0.05 ADX vs sham
n=5 per group
Figure 7.6B PPT mRNA expression in bilaterally arthritic ADX and sham operated
rats, (day 15) Adrenalectomy does not affect the left (injected side) PPT mRNA
expression but attenuates the increase in right PPT mRNA expression usually seen in
bilaterally arthritic rats. Values are means ±S.E.M. Mean control grain counts
were 466+38
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CGRP mRNA expression in sham operated rats was as previously observed in
untreated mono- and bilaterally arthritic rats, increased ipsilaterally in monoarthritis
and bilaterally in bilateral arthritis. In ADX monoarthritic rats, CGRP mRNA
expression was not significantly different from sham operated rats (Figure 7.7A).
Bilaterally arthritic ADX rats showed significantly increased expression in left DRG
neurons over sham operated rats. Right CGRP mRNA expression was also
increased in bilaterally arthritic ADX rats, but this was not significantly different





















n=4 ADX; 5 sham
Figure 7.7A. CGRP mRNA expression in DRGfrom monoarthritic ADX or sham
operated rats (day 14). Left (injected side) mRNA expression is significantly raised










"• #p<0.01 vs sham/control
n=5 per group
Figure 7.7B. CGRP mRNA expression in DRG from bilaterally arthritic ADX or
sham operated rats; (day 15). Sham operated rats show bilateral increases in
CGRP mRNA expression. ADX rats show significantly increased left (injected) side
CGRP mRNA levels compared to sham animals. Expression in right DRG is
significantly raised compared to controls but not sham animals. Values are means ±
1.3.2.2. Effect of local anaesthetic nerve block on neuropeptide mRNA expression
Expression of PPT, CGRP and somatostatin mRNA in left DRG from rats subjected
to local anaesthetic block of the left sciatic nerve, and injected with 150|ig M.tub.
was not significantly different from untreated controls (Figure 7.8). Thus lidocaine
nerve block prevented the changes in PPT, CGRP and somatostatin mRNA
expression seen eight hours after adjuvant injection described in Section 5. This
indicates that action potential conduction to the cell body may, in part, regulate the
increase in PPT and CGRP mRNA and the decrease in somatostatin mRNA at this
S.E.M
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time after adjuvant injection. The increase in PPT mRNA was totally prevented
whereas CGRP showed only a partial reduction and somatostatin mRNA expression
showed a non-significant rise (Table 7.1). This suggests that the increased neuronal
activity seen in primary afferents innervating inflamed joints differentially regulates
neuropeptide gene expression in DRG neurons.
Table 7.1. Neuropeptide mRNA levels in left DRG 8 hours after adjuvant injection
with and without nerve block with 2% lidocaine solution. Values shown are means ±
S.E.M. *p<0.05 cf. controls.
PPT CGRP Somatostatin
Control 100±7 100±13 100±21
Adjuvant 181±24* 144±6* 81±8*












Figure 7.8. Effect of lidocaine nerve block on expression ofPPT, CGRP and
somatostatin mRNAs 8 hours after adjuvant injection. Lidocaine ne?~ve block
inhibited the rise in PPT, CGRP mRNA and the fall in somatostatin mRNA. Values
are means ±S.E.M. n-5 per group. Mean control grain counts were; PPT, 179±13;
CGRP, 445±51; SS, 355±65.
1.4. DISCUSSION
7.4.1, Effect of adrenalectomy on signs of inflammation
Adrenalectomy only significantly affected the weight gain in bilaterally arthritic
animals and did not have profound effects upon joint circumferences of either mono-
or bilaterally arthritic rats. Although the degree of arthritis, as assessed by
measurement of the joint circumference was not significantly affected by
adrenalectomy, the general well-being of the animals as reflected in the normal
weight gain seen over this period of time, was affected in bilaterally arthritic
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animals. As monoarthritic rats continued to gain weight normally this loss of weight
may be indicative of the systemic consequences of the lack of an hypothalamo-
pituitary-adrenal response to the slightly more severe inflammation, in combination
with the effects of adrenalectomy itself on normal weight gain.
These results are in contrast to those obtained by Sarlis et al., (1992) who found that
adrenalectomy significantly affected the degree of polyarthritis in rats assessed by
paw volume, to the extent of causing increased mortality in the animals. However it
must be remembered that the model used in the studies discussed here is not
identical to the polyarthritis used by Sarlis, and even bilateral arthritis cannot be
directly compared to the polyarthritic model. Animals with polyarthritis are already
systemically ill and therefore it is not surprising that adrenalectomy, which is known
to attenuate the body's response to severe illness, would exacerbate their condition.
The model used in the studies outlined in this thesis generally shows no systemic
effects, and this is the only situation in which a significant drop in body weight has
been observed using this model.
7.4.2. Effect of adrenalectomy on neuropeptide mRNA expression
In view of the lack of effect of adrenalectomy on the degree of arthritis, it was
surprising that the intervention had significant effects on both PPT and CGRP
mRNA expression. However, the raised morning corticosterone levels in these
arthritic rats might be expected to have some effect in terms of the genes regulated
by circulating corticosteroids. The only study examining the in vivo regulation of
neuropeptides in DRG showed that adrenalectomy increased substance P and CGRP
and decreased somatostatin in DRG (Smith et al., 1991). It has been hypothesised
that adrenalectomy would further potentiate the increases in PPT and CGRP mRNA
expression seen in inflammation and thereby potentiate the arthritis. This, however,
only occurs in the case of CGRP mRNA in left but not right DRG. PPT mRNA
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shows the normal increase in left DRG of bilaterally arthritic rats, but does not
increase in right DRG despite continued contralateral arthritis. The lack of
contralateral increase in PPT mRNA is associated with a slight, non-significant
reduction in right joint swelling, which may again support a role for the peptides
translated from the PPT gene in the contralateral effects seen in this model of
arthritis. However the effects of adrenalectomy on these neuropeptide mRNAs
occur in the face of ongoing inflammation, which is unaffected by the surgical
intervention. It would therefore appear that while adrenalectomy does have subtle
effects on the expression of PPT and CGRP mRNAs, the high circulating
corticosteroids in arthritic animals have minor importance in the modulation of the
disease in this model.
7.4.3. The influence of neural activity on neuropeptide mRNA expression
Depolarisation is known to increase PPT mRNA expression in cell culture
(Mulderry, 1993b). However, VIP is also increased on depolarisation (Mulderry,
1993b) and yet is unaltered in experimental arthritis in vivo (Section 5) when
primary afferents are known to become spontaneously active within hours of the
onset of inflammation (Schaible and Schmidt, 1985). This illustrates the danger of
extrapolation of data obtained in culture systems to the in vivo situation.
As only animals showing complete motor paralysis were used in this study,
unmyelinated afferent conduction was definitely blocked as the action of local
anaesthetics is dependent upon fibre diameter, with fibres mediating painful stimuli
being affected first and those with large myelinated fibres affected last and
recovering most rapidly. Nerve blocks were performed directly, ("blind") to avoid
any possible gene induction due to surgical exposure of the nerve. It was possible to
determine in which animals a successful block had been achieved as motor paralysis
was evident; injection of sterile saline as a control was unsatisfactory as there was no
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method of determining that the solution had been delivered around the sciatic nerve,
so untreated animals were used as a control in these studies as in all other
experiments on neuropeptide mRNA expression
In view of the data presented in this section, it seems that action potential
conduction to the soma of unmyelinated primary afferents may be responsible, in
part, for the changes in mRNA expression seen during the first 8 hours after adjuvant
injection.
7.5. SUMMARY
Adrenalectomy had no significant effect on overt parameters of arthritis in either
mono- or bilaterally arthritic rats, but did affect the normal weight gain in bilaterally
arthritic animals. Alterations in neuropeptide mRNA in arthritic adrenalectomised
rats exert only subtle effects on the inflammatory process.
Primary afferent activity developing within hours of the onset of inflammation may
mediate the changes in neuropeptide mRNA seen eight hours after adjuvant
injection, suggesting that immune stimulation or circulating humoral mediators alone
are insufficient for early neuropeptide mRNA induction.
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SECTION 8. THE POSSIBLE ROLE OF TRANSCRIPTION FACTORS IN
THE REGULATION OF NEUROPEPTIDE mRNA EXPRESSION DURING
INFLAMMATION
8.1. INTRODUCTION
As shown in Section 5, during the acute inflammation seen following adjuvant
injection, (3-PPT, a-CGRP and somatostatin show very early changes in mRNA
expression. The expression of these genes is known to be under the control of a
number of different factors, including nerve growth factor (see Section 1.8) electrical
activity, glucocorticoids and cAMP as has been discussed in Sections 1 and 7.
Analysis of the 5' flanking DNA from both the PPT, somatostatin and VIP genes has
shown multiple transcription factor recognition, or consensus, sequences including
those for the transcription factors studied here (see below).
8.1.1. Immediate early genes
Immediate early genes are a group of genes, the expression of which is normally at
extremely low or undetectable levels, but which can be activated within minutes by
the addition of a growth factor in culture or following a physiological or
pharmacological stimulus. Their expression is usually transient, peaking within
minutes, and as these genes have a short half-life, shortly becoming undetectable
once more. Many of these genes were initially characterised in the rat
pheochromocytoma cell line (PC 12) as being inducible following NGF- stimulated
cell differentiation. Members of this family of factors include the fos and jun
families which interact to form the AP-1 complex, and an NGF-inducible (NGFI)
family. Many of these immediate early genes encode transcription factors, which
together with their tightly controlled expression strongly suggests that they are
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involved in the regulation of so called late response genes in response to external
stimuli (Sheng and Greenberg, 1990).
8.1.2. The AP-1 complex: fos and jun
Fos and jun are the two most widely studied members of a family of immediate
early genes which are the cellular correlates of viral oncogenes. Transcriptional
activation of fos usually occurs within 5 minutes of stimulation and continues for 15-
20 minutes causing a peak mRNA level at 30-45 minutes post-stimulation (Morgan
and Curran, 1991). Other members of this family are fos-related antigens (fra) 1 and
2 (Cohen and Curran, 1988; Nishina et al., 1990), jun B (Ryder et ah, 1988), and jun
D (Ryder et ah, 1989) among others. These two groups of nuclear proteins dimerise
through a "leucine zipper" dimerization domain in each protein. This consists of an
a-helical structure with 4 leucine residues spaced 7 amino acids apart such that all
the leucines are aligned along one face of the helix. The leucine zipper domain is
also required for required for DNA binding (Mitchell and Tjian, 1989). Fos-Jun,
Fra-Jun and Jun-Jun dimers also require a highly conserved basic region for DNA
binding; all the dimers forming the AP-1 complex recognise the AP-1 consensus
sequence 5'-TGACTCA-3' (Mitchell and Tjian, 1989). Fos-Jun dimers are more
stable than Jun-Jun dimers and have a greater DNA binding affinity (Morgan and
Curran, 1991). ATF/CREB (activating transcription/cyclic AMP responsive element
binding proteins), the transcription factors first identified as leucine zipper proteins,
which respond to intracellular cAMP also dimerise with the Fos/Jun family. This
cross-family interaction results in an altered DNA binding specificity for the AP-1
and ATF/CRE binding sites (Hai and Curran, 1991). Regulation by cAMP is of
importance as PPT, somatostatin and VIP genes all have an active cAMP response
element in their 5' flanking DNA sequences (Chapman et al., 1993; Lamperti et al.,
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1991; Tsukada et al., 1987), and cAMP is thought to mediate the hyperalgesia
actions of eicosanoids (Taiwo et al., 1989).
8.1.3. Other nerve growth factor inducible transcription factors
On the discovery that NGF could induce the expression of the fos/jun family in
PC12 cells, other workers investigated the induction of further genes by nerve
growth factor. Milbrandt and colleagues have isolated two genes, NGFI-A (also
known as krox-24, zif268, egr-1 and TIS-8 (see Morgan and Curran 1991 for refs.)),
a "zinc-finger" protein (Milbrandt, 1987) recognising the concensus sequence
5' -GCGGGGGGCG- 3', and NGFI-B (nurr77, N10, TIS-1), which belongs to the
steroid receptor superfamily (Milbrandt, 1988). The 5' flanking region of the NGFI-
A gene has been shown to possess an NGF-responsive element (Changelian et al.,
1989). Other genes are also known to be induced by NGF in PC12 cells but they
will not be discussed here.
8.1.4. Activator protein-2 (A.P-21
Transcription factor AP-2 is expressed developmentally in tissues of neural crest
origin such as dorsal root ganglia (Mitchell et al., 1991). AP-2, which also exists as
a dimer (Williams and Tjian, 1991a) recognises the specific DNA sequence 5'-
GCCN3GGC-3' and requires an amino-terminal proline-rich sequence in order to
stimulate transcription (Williams and Tjian, 1991b). The presence of AP-2 site
confers cAMP inducibility on a gene (Mitchell and Tjian, 1989).
8.1.5. Transcription factors and neuropeptide genes
Many neuropeptides have been shown to have AP-1 binding sites within their
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promoter regions and in PPT, somatostatin and VIP these have been found to be
active (Quinn, 1992; Goodman, 1990). AP-2 sites have been identified in the 5'
flanking regions of a number of genes, and have been shown to be active in
regulation of expression of the human growth hormone and proenkephalin genes
(Courtois et al., 1990; Goodman, 1990), the rat TNF-(33 gene (Lafyatis et al., 1990)
and human immunodeficiency virus 1 (Muchardt et ah, 1992). The PPT promoter
has two non-consensus AP-2 sites at positions -78 and -564 of the 5' flanking
sequence; it is still unknown whether these are active. There are also several AP-2
sites after the transcription start site of the PPT gene.
8.1.6. Aim of the experiments
These experiments were designed to determine whether any of the transcription
factors described above were expressed in small DRG neurons in the early response
to peripheral inflammation, and if so, whether their expression could be associated
with any of the neuropeptide mRNAs which show changes in this condition.
8.2. MATERIALS AND METHODS
Adjuvant-inflammation was induced as described in Section 2. Animals were
killed by decapitation at intervals of 30 minutes, 1, 2, 4 and 8 hours after adjuvant
injection, left and right L5 DRG dissected, rapidly frozen and processed for in situ
hybridisation. Complementary RNA probes for c-jun, NGFI-A, -B and AP-2
mRNAs were used. Expression of mRNAs was determined using computer-aided
image analysis and expressed as a percentage of the basal expression in untreated
control animals. Positive control sections of normal rat hippocampus were used to
ascertain the efficacy of hybridisation.
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For c-jurt, a specific probe was subcloned from the full length cDNA as outlined in
Section 2. Similar brain sections were also hybridised with a specific jun D cRNA
probe and the differential distributions in brain compared to those in the literature.
The c-jun cDNA probe was also hybridised to a Northern blot of whole brain total
RNA to check specificity.
8.3. RESULTS
8.3.1. Specificity of the c-jun probe
The c-jun cDNA probe hybridised to two bands of approximately 2.6-2.7 and 3.4kb
in length on a Northern blot of total brain mRNA as previously described (Figure
8.1; Ryder et ah, 1988). These two transcripts are thought to represent primary
unspliced (3.4kb) and mature (2.6-2.7kb) transcripts. A comparison of the
distributions of jun-c and jun D in rat brain at the level of the hippocampus by in situ
hybridisation revealed a differential distribution of the mRNAs recognised by these
two probes which agreed closely with that previously published (Mellstrom et ah,
1991), with basal c-jun expression being very low, if not undetectable in all areas of
normal brain except hippocampus, and jun D being much more widely expressed in
hippocampus, cortex, and many thalamic and hypothalamic nucleii as shown in
Figure 8.2.
Figure 8.1. Northern blot








Figure 8.2. Autoradiographs ofcoronal rat brain sections through anterior
hippocampus hybridised with A) c-jun cRNA probe and B) jun D cRNA showing the
differential distributions of these transcription factors in brain.
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8.3.2, Expression of transcription factors in positive control sections
All other transcription factors studied were basally expressed in normal
hippocampus agreeing with the previous literature for NGFI-A and -B (Figures 8.3
and 8.4). AP-2 was also found to be basally expressed at low levels in hippocampus
and this represents the first description of this expression (Figure 8.5).
8.3.3. Expression of NGFI-A. -B and c-iun in DRG neurons
NGFI-A, NGFI-B and c-jun mRNAs were not expressed in either DRG neurons
from normal animals, or at any point following adjuvant injection.
8.3.4. Expression of AP-2 in DRG neurons
AP-2 mRNA was constitutively expressed in all DRG neurons irrespective of size.
When expression of AP-2 mRNA was assessed in DRG neurons of diameter less
than 30p.m in normal animals, it was found to be similar to the basal expression of
AP-2 mRNA in control hippocampus CA1 neurons. In DRG neurons in animals
with adjuvant injection, the expression of AP-2 mRNA was found to be altered in
left (injected side) DRG while not significantly different from controls in right
(uninjected side) DRG. The changes in expression of AP-2 mRNA following
adjuvant injection are shown in Figures 8.6 and 8.7.
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Figure 8.3. Basal expression ofNGFI-A mRNA in rat hippocampus. NGFI-A
mRNA is shown in hippocampus byfilm autoradiography (top) and
microautoradiography (bottom) showing higher silver grain density overlying the









Figure 8.4. Basal expression ofNGFI-B mRNA in rat hippocampus. NGFI-B
mRNA is shown in hippocampus byfilm autoradiography (top) and
microautoradiography (bottom) showing higher silver grain density overlying the
CA1 region of the hippocampus.
Figure 8.5. Basal expression ofAP-2 mRNA in rat hippocampus. AP-2 mRNA is
shown in hippocampus byfilm autoradiography (top) andmicroautoradiography
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Figure 8.6. Expression ofAP-2 mRNA during the first eight hours after adjuvant
injection around the left tibio-tarsal joint. AP-2 mRNA shows a significant
reduction in expression after 30 minutes and a significant increase in expression
after 1 hour, returning to control values at 2 hours. Mean control grain counts were
30±5 per small cell (diameter <30pm).
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Figure 8.7. Dark fieldphotomicrographs showing expression ofAP2 mRNA in
DRG neurons from control (left) and adjuvant injected rats (1 hour; right). Original
magnification x40.
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The populations of small DRG neurons expressing AP2 mRNA in DRG from
control rats and 1 hour after adjuvant injection are illustrated in Figure 8.8. It can be
seen that the majority of DRG neurons in control DRG express very low amounts of
AP2 mRNA (open bars). One hour after ipsilateral adjuvant injection, this
population is altered, showing a reduction in the numbers of cells expressing low
amounts of AP2 mRNA and the appearance many more cells expressing much











silver grains per cell
Figure 8.8. Populations ofsmall DRG neurons expressing AP2 mRNA in control
DRG and 1 hour after ipsilateral adjuvant injection.
198
8.4. DISCUSSION
8.4.1. Expression of c-jun
The subclone for c-jun, taken from the 3' untranslated region of the c-jun cDNA
was hybridised to both normal brain sections and total rat brain mRNA Northern
blot. On the basis of the differential distributions of c-jun and jun D assessed by in
situ hybridisation, this probe appears to be specific for c-jun mRNA; however this
still needs to be confirmed by Northern blot analysis of total brain mRNA for jun D
and jun B, to confirm that cross-hybridisation is not occurring within members of the
jun family. It has been shown here that c-jun mRNA as detected with this probe is
not expressed under basal conditions or during the development of inflammation
agreeing with previous workers who failed to show induction of c-fos or c-jun
mRNA or immunoreactivity following noxious thermal or electrical nerve
stimulation (Jenkins and Hunt, 1991). A low basal level of Jun-like
immunoreactivity has been seen in DRG (<5% cells), although no c-jun mRNA was
evident, c-jun mRNA has been shown to be induced in DRG neurons on axotomy
(Jenkins and Hunt, 1991) where it does not act as a typical immediate early gene, but
shows long term increases in both mRNA and protein expression over the seven
days of this study. The increase in c-jun on axotomy has suggested a role in axonal
regeneration as it is not expressed in situations where axonal growth was prevented
(Jenkins et ah, 1993). Axotomised sensory and motoneurons show increased
expression of galanin and CGRP respectively, which are both colocalised with c-Jun
protein under these conditions (Herdegen et ah, 1993). This is suggestive of a role
for c-jun in the regulation of these peptides. However, CGRP in motoneurons is also
increased following axonal transport blockade with vinblastine (Katoh et ah, 1992)
suggesting that at least in motoneurons retrograde transport of some factor acts as a
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repressor of CGRP expression. This indicates that the regulation of CGRP in
motoneurons is distinct from sensory neurons and therefore c-jun may not influence
CGRP expression in sensory neurons as indicated by the results presented here.
However, PPT and somatostatin are known to have active AP-1 sites in their 5'
flanking regions (Quinn, 1991; Goodman, 1990) and therefore may be regulated by
AP-1 in DRG. Only one member of the jun family has been examined here, further
experiments to examine the expression of jun D and jun B need to be undertaken.
Also, while c-fos does not appear to be expressed in DRG either basally or on
electrical stimulation of unmyelinated afferent fibres (Hunt et al., 1987), fos-related
antigens may be important in PPT gene regulation under culture conditions (J.
Quinn, personal communication). Therefore further experiments to study the
expression of fra-1 and fra-2 will also be undertaken. Alternatively it is conceivable
that nerve growth factor may be exerting a direct effect on neuropeptide genes to
increase expression, as peripheral NGF levels are known to be increased in
inflammatory conditions (Andreev et al., 1993) and sciatic nerve NGF content
increases in adjuvant-induced inflammation.
8.4.2, Expression of NGF-induced transcription factors on noxious stimulation
The majority of studies investigating the expression of immediate early genes,
particularly those which constitute the AP-1 complex, have looked at the response of
dorsal horn neurons to noxious peripheral stimulation. In primary sensory neurons,
NGFI-A expression has been examined following noxious thermal stimulation and
mRNA expression was not found in DRG neurons either before or after stimulation
(Jenkins and Hunt, 1991) agreeing with the results presented here. NGFI-B
expression has not been studied in primary afferents during noxious stimulation or
inflammation, but from these results it would appear to be unimportant in primary
afferent responses to nociceptive stimulation.
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In spinal cord, expression of numerous immediate early genes has been
demonstrated by either in situ hybridisation or immunohistochemistry, including c-
fos (Hunt et al., 1987), c-jun, NGFI-A (Herdegen et ah, 1991a) and NGFI-B (Wisden
et ah, 1990). Induction of these genes is seen in superficial dorsal horn laminae on
noxious thermal (Wisden et al., 1990) electrical (Herdegen et al., 1991a; Herdegen et
al., 1990; Hunt et al., 1987) visceral (DeLeo et al., 1991) surgical (Herdegen et al.,
1991b) and arthritic stimuli (Abbadie and Besson, 1992). Electrical stimulation of
the sciatic nerve also induces NGFI-A-immunoreactivity in various areas of the brain
especially in the parabrachial nucleus, the dorsal hypothalamic nucleus, the lateral
habenular nucleus and the amygdala (Herdegen et ah, 1990). The expression of Jun
B, Jun D and Fos B is sequential following a noxious stimulus suggesting
differential gene regulation dependent upon the genes expressed either immediately
on stimulation or some hours afterwards (Herdegen et ah, 1991a). c-fos expression
has been implicated in the regulation of spinal expression of dynorphin, as fos has
been colocalised with preprodynorphin mRNA in dorsal horn neurons during
inflammation (Noguchi et ah, 1991), and a functional AP-1 site has been
demonstrated in the prodynorphin promoter (Naranjo et ah, 1991). The
transactivation of the prodynorphin gene appears to be under the control of the
descending serotonergic raphe fibres (Lucas et ah, 1993).
In the majority of cases the changes seen in dorsal horn immediate early gene
expression are ipsilateral to the stimulus (Wisden et ah, 1990). However, a priming
contralateral stimulus will potentiate both ipsi- and contralateral expression of fos-
immunoreactivity to a subsequent stimulus (Leah et ah, 1992), and late (4-8 hours
after stimulation) contralateral expression of c-fos, NGFI-A, c-jun and jun D has
been observed after C-fibre stimulation (Herdegen et ah, 1991a; 1991b;).
Contralateral expression of jun B and c-fos was in a precise mirror image location to
the area showing the heaviest expression on the stimulated side (Herdegen et ah,
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1991b). The contralateral activation of dorsal horn neurons may reflect, in part, a
mechanism through which neurally mediated contralateral spread of inflammation
may occur (see Section 6).
8.4.3. AP-2 mRNA expression
This transcription factor was the only one studied here to show a change in small
DRG neurons. The expression of AP-2 mRNA was constitutively low (-30
grains/cell), but this showed a 100% increase in expression after one hour, returning
to control levels within 2 hours. The PPT promoter contains two putative non-
consensus AP-2 binding sites at positions -78 and -564. AP-2, as an enhancer acts in
a position-independent manner (Goodman, 1990), however it remains to be
determined whether either of these sites do bind AP-2 and are active. It is also of
interest to determine whether AP2 mRNA expression increases in neuropeptide-
containing neurons or a different population. Colocalisation studies are planned to
address this issue. This study also revealed basal expression of AP-2 in rat
hippocampus which has not been described previously.
It must be remembered that these results are preliminary and require further work in
order to verify the role of transcription factors in the regulation of these
neuropeptides. Other members constituting the AP-1 complex need to be studied to
determine their possible roles, and the activity (if any) of the AP-2 sites on the PPT
promoter require further study. It is also entirely possible that the changes in AP-2
mRNA levels observed are entirely coincidental and may have no bearing on the
changes in neuropeptide gene expression seen in this model of adjuvant-induced
inflammation. Nevertheless it is intriguing that changes in AP2 and PPT and CGRP
mRNAs all occur in small DRG neurons ipsilateral to the stimulus.
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SECTION 9. DISCUSSION
9.1. The immune system and adjuvant-induced arthritis
This thesis has dealt exclusively with the possible nervous system involvement in
experimental arthritis, as suggested by observations in both the experimental animal
and in clinical rheumatoid arthritis. It is a common oversight of the study of
inflammatory processes to ignore any possible contribution of any other system,
particularly the immune system. While the data presented here are strongly
suggestive of a fundamental role for the peripheral sensory nervous system and the
neuropeptides expressed therein in this condition, it is not intended to imply that
there is not a large immune component in this disease. Rather, this would suggest an
extremely close relationship between the immune and sensory nervous systems in
inflammatory processes. The arthritogenicity of Mycobacterium has been attributed
to activation of T-cell subtypes which cross-react with articular tissues, thus causing
joint destruction and amplification of a local immune response (Wooley, 1991).
This could arise by a failure to clonally delete self-reactive T-cell populations during
thymus development, giving rise to susceptible strains of animals, which do indeed
exist (see Section 3). It seems clear that in monoarthritis, the contribution of the
nervous system to the maintenance of joint swelling and destruction, while evident
(Section 6), is minor compared to that of the immune reaction caused by the local
injection of adjuvant. The immune system is of obvious importance in the initiation
of classical adjuvant disease, as immunosuppressants will prevent the development
of arthritis (Wooley, 1991). It would therefore appear that an intimate reaction
between the immune and nervous systems is probably of great importance in the
spread of disease.
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9.2. Contralateral spread of arthritis
In passive transfer experiments, labelled T cells sensitised to Mycobacterium
tuberculosis were injected into naive animals and their tendency to migrate to joints
was examined. Labelled cells were found to be more numerous in the joints of rats
injected with cells taken from arthritic rats rather than from controls. However it has
proved notoriously difficult to initiate adjuvant arthritis by passive transfer, requiring
the use of extremely large numbers of activated cells taken from spleen and not
thymus, and the use of a highly inbred strain of rat (Pearson and Wood, 1964).
Passive transfer was not possible under any other circumstances, particularly in
immunologically normal outbred strains such as that used routinely in the studies
presented here. Also, an immunological basis cannot fully explain the precise
symmetrical nature of the arthritis in the modified model used throughout these
studies as it would be expected that if establishment of arthritis was purely
dependent on the production of a T-cell subset sensitised to articular tissues, then
other joints would all have equal disease susceptibility, which is not the case. Thus
it would appear that the initiation (and spread as these are concurrent in the classical
model) of arthritis is not wholly dependent upon immunological phenomena, and
requires the participation of an additional system. However, it could suggest that,
due to an intimate interaction between the nervous and immune systems, the
initiation of overt arthritis could be critically dependent upon both systems. The
presence of an articular T-cell reaction could induce susceptibility in a joint, and
whether overt arthritis would develop would then depend on the state of activation of
the peripheral nervous system and whether, for example, neuropeptides were
released into the joint thereby stimulating the initiation of arthritis. Evidence
supporting this hypothesis exists in both the clinical and experimental situations, as
hemiplegic patients with rheumatoid arthritis can show sparing of the paralysed limb
when assessed clinically, but concurrently show very mild histological inflammation
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of the "unaffected" denervated symmetrical joint (Veale et al., 1993). As has already
been mentioned, a "mild" stimulus of intra-articular injection of inert spheres results
in contralateral synovial inflammatory infiltration (Kidd et al., 1989a).
The histological studies presented here do not disprove this hypothesis; light
microscopic examination of the joints was performed and sections were scored on
the presence or absence of a marked inflammatory infiltrate or actual destruction of
synovium or bone. It would be difficult to resolve whether an extremely mild
inflammatory infiltrate was present without using markers for these cells and
accurately quantitating numbers in experimental and control joints.
The results shown here and the evidence from the literature strongly suggest that,
even if there is a dependence on the immune system for the initiation of
monoarthritis in this model, there is a fundamental requirement for the peripheral
nervous system, particularly tire capsaicin-sensitive primary afferent, in the
maintenance, and more importantly, the spread of arthritis. This would explain the
precise topographical spread of arthritis seen in both this experimental model and
clinical rheumatoid arthritis.
9.3. The role of primary afferent neuropeptides
The aim of the experiments reported in this thesis was to further elucidate the role
of the peptidergic primary afferent in experimental arthritis. Studies of neuropeptide
levels in DRG suggested that increased central and peripheral release of these
neuropeptides in arthritis may be due to increased production of particularly
substance P and CGRP within the primary afferent neuron. However, studies of
absolute neuropeptide quantity per ganglion are complicated by the fact that this
gives no indication of any change in peptide degradation or rate of axonal transport,
both of which could affect the steady state levels of ganglionic neuropeptide. The
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results presented here, however, support the hypothesis that peptide increases are due
to increased transcription of the genes studied, in response to peripheral
inflammation, but cannot conclusively prove this due to limitations of the in situ
hybridisation technique. This method of analysing mRNA levels, while extremely
powerful in its ability to precisely localise study to a single population of cells,
measures steady state mRNA and therefore also gives no indication of possible
changes in mRNA stability, which could also result in apparently increased mRNA
levels. While it is unlikely that this is indeed the case, as accumulating evidence
from many laboratories supports the data presented here, it is a disadvantage of the
in situ hybridisation technique which must be remembered. Future use of intron-
specific probes to localise and quantitate unspliced RNA transcripts could resolve
this.
It has not been ascertained whether the changes in mRNA reported here are a
consequence of the inflammation, an initiating event or even merely coincidental. In
the case of the changes observed in monoarthritis, it is likely that the observed
events (among many others) result from the peripheral excitation and sensitisation of
the primary afferents by the inflammatory stimulus of the injection of adjuvant. This
is supported by the result obtained on local anaesthetic nerve block, which clearly
inhibited the rise in PPT mRNA and partially blocked the rise in CGRP mRNA, both
of which are seen within the first eight hours of the onset of inflammation.
While it has been shown here that contralateral spread of arthritis in this modified
model of adjuvant arthritis is critically dependent on the capsaicin-sensitive afferents
innervating the joint, it is also evident that the neuropeptides, particularly those
translated from the PPT-A and CGRP genes are also of importance. The bilateral
changes observed in PPT and CGRP mRNAs in bilateral disease are evident when
disease has become symmetrical. Further studies on the time course of bilateral
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changes need to be undertaken to determine how contralateral changes are related to
the onset of contralateral disease.
It is unlikely that neuropeptides released in the periphery have significant effects on
the primary afferent terminals themselves and therefore the neuropeptides produced
in primary afferents probably have two main functions; modulation of a) the immune
and vascular systems in the periphery and b) the activity of spinal cord neurons. If
the hypothesis, outlined above, that the peptidergic primary afferent is crucial for the
initiation and maintenance of contralateral arthritis is correct, it could be assumed
that while contralateral primary afferent activity may not be increased, the
neuropeptide transport to the periphery may be. In addition to determining the
relationship of onset of inflammation and increased neuropeptide production, it is
also of interest to establish whether there is indeed an increased transport of pro¬
inflammatory neuropeptides in nerves innervating arthritic joints both ipsilateral and
contralateral to the adjuvant injection site.
9.4. The central nervous system
All the studies presented in this thesis have concentrated upon the primary afferent
in arthritis and have somewhat neglected the central nervous system, particularly the
spinal cord. It is obvious from the work of other laboratories that the spinal cord has
a major role in the processing of nociceptive information, but it obviously also
affects the contralateral spread of arthritis as seen in this model. Studies are planned
which should determine whether contralateral neuronal activation occurs through the
sensory or sympathetic nervous systems, using neuroanatomical labelling of
activated neurons by examining immediate early gene expression as discussed in
Section 8.
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Furthermore, it is of interest to ascertain whether it is indeed increased release of
neuropeptides in the dorsal hom which mediate the contralateral spread of arthritis.
Further studies are planned which will utilise intrathecal neutralisation of
neuropeptides using either immunological or antagonist approaches, to determine the
importance of release of these neuropeptides in this condition.
9.5. The relevance of the observations to arthritis.
The joints from rats with adjuvant-induced arthritis show, in addition to joint
involvement, both gross and histological evidence of dermal inflammation. It is
impossible to state conclusively that all the neurons showing changes in
neuropeptide content (Smith et al., 1992) or mRNAs (present data) innervate
articular structures. Indeed some evidence exists that the observations of
neuropeptide mRNA levels presented here may be common to all inflammatory
states rather than specific to arthritis (Nahin and Byers, 1992). It is likely that the
apparent relationship between peptidergic afferents and spread of disease is arthritis-
specific; there are no reports of, for instance, dermal inflammation spontaneously
involving a symmetrical site. One method of overcoming this problem of the
specificity of the changes to the disease state would be to retrogradely label neurons
innervating the joint by intra-articular injection of a tracer which was specific for
either capsaicin-sensitive neurons (Nagy et al., 1992) or unmyelinated afferents.
This would enable mRNA changes only in identified articular afferents to be studied.
However, this regime would probably require the development of another model
using a different joint, probably the knee, as intra-articular injection into the tibio-
tarsal joint is notoriously difficult due to both the small size of the joint and its
complex nature which results in there being no large defined joint space into which
to inject drugs etc.
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9.6. The regulation of primary afferent neuropeptide gene expression in vivo
As already stated, gene regulation is usually studied under culture conditions as this
facilitates dissection of the regulatory mechanisms. The studies presented here on
glucocorticoid regulation of the neuropeptides under investigation highlights the
problems of addressing this in vivo, as this pharmacological manipulation can have
profound effects upon the whole animal which may affect the gene under study by
some complex mechanism not directly attributable to the manipulation itself. It
seems from the literature that cAMP may be of importance in the regulation of these
genes in inflammation, as many hyperalgesic states particularly those involving
arachadonic acid metabolites seem to be cAMP-dependent.
Possible regulation by transcription factors has, so far proved inconclusive. While
AP-2 mRNA was altered in small DRG neurons it remains to be determined whether
this effect is a) specific to these peptidergic neurons or generally in DRG neurons
during inflammation, b) whether AP-2 expression is correlated in any way with any
of the neuropeptides under study here or whether it is involved in the regulation of
additional genes and c) whether the putative AP-2 sites in the PPT promoter region
are active.
Therefore there are numerous studies which need to be performed in order to reach
any definite conclusions on the in vivo regulation of these neuropeptide genes.
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SECTION 10. CONCLUSIONS
A novel model of adjuvant-induced inflammatory arthritis which can be easily
manipulated to produce either monoarthritis or disease involving both tibio-tarsal
joints has been characterised for the study of peptidergic primary afferent
involvement in inflammatory arthritis.
Using this model it has been determined that synthetic substance P has no
significant role in the activation or sensitisation of unmyelinated articular
nociceptors in this condition.
The primary afferent neuropeptide gene responses to inflammation have been
examined, and it has been shown that the mRNAs encoding PPT and CGRP in DRG
neurons show extremely large, rapid rises in expression in response to adjuvant-
induced monoarthritis. Bilateral arthritis is also associated with bilateral rises in
expression of these mRNAs in DRG. Somatostatin mRNA is also increased in
mono- and bilateral arthritis but only in DRG ipsilateral to the initial adjuvant
injection. VIP appears to have no role in inflammation as induction of this mRNA
was never seen.
Specific neurotoxic lesions of capsaicin-sensitive primary afferents have defined a
fundamental role for this component of the peripheral sensory nervous system and
the neuropeptides expressed therein in the contralateral spread of arthritis seen in this
model.
Preliminary investigations on the in vivo regulation of these neuropeptides during
inflammation have indicated that the mechanisms underlying the changes seen are
extremely complex, but are in part determined by the interaction of the effects of
changes in neuronal activity, circulating corticosteroids, and may be mediated
through certain transcription factors.
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Neuropeptides in dorsal root ganglia (DRG) have been implicated in the pathogenesis of pain and neurogenic inflammation in experimental and
clinical arthritis. Recently we demonstrated increased levels of substance P (SP) and calcitonin gene-related peptide (CGRP) confined to
innervating DRG in adjuvant-mediated monoarthritis. We have now investigated whether changes in peptide content are reflected in altered
neuropeptide gene expression and the time course involved. Using in situ hybridization we found marked increases in expression of
/3-preprotachykinin (PPT; 81 + 24% rise) and a-CGRP (44 + 6% rise) mRNAs in innervating (ipsilateral L5) DRG neurones only. These increases
occured at the onset of acute inflammation (8 h) and persisted until chronic arthritis developed after 14 days. There were no changes in the
proportion of DRG neurones expressing PPT or CGRP mRNAs. Messenger RNA encoding vasoactive intestinal polypeptide (VIP) was not
induced. These data suggest that increased synthesis of PPT and CGRP peptides in DRG may play a role in the pathogenesis both of
adjuvant-mediated acute inflammation and chronic arthritis.
INTRODUCTION
Much evidence suggests a role for the nervous sys¬
tem in the pathogenesis and maintenance of experi¬
mental and clinical arthritis. Joints are innervated by
primary afferents whose cell bodies are located in
dorsal root ganglia (DRG). These neurones synthesize
a variety of neuropeptide neurotransmitters, many of
which have been implicated in nociception and neuro¬
genic inflammation. Section of primary afferents or
neonatal treatment with capsaicin (which destroys 90%
of unmyelinated primary afferents) attenuates the
severity of adjuvant arthritis14,5, reducing joint swelling
and raising nocioceptive thresholds to normal levels. In
both experimental and clinical arthritis the synovial
innervation and synovial fluid neuropeptide concentra¬
tions are altered20'27'26'43. Furthermore denervation (e.g.
due to hemiplegia or poliomyelitis) protects joints from
rheumatoid arthritis42'8.
Of DRG neuropeptides thought important in arthri¬
tis, much emphasis has been placed on the role of the
tachykinins, particularly substance P (SP) which medi¬
ates the flare and wheal reaction in neurogenic inflam¬
mation, and calcitonin gene-related peptide (CGRP),
with which SP is colocalised in a subpopulation of
DRG neurones15'40. SP is translated from all tran¬
scripts of the preprotachykinin (PPT) A gene, some of
which also encode neurokinin A12. SP-immunoreactive
fibres project from DRG to both the dorsal horn and
synovium, and SP causes plasma extravasation on pe¬
ripheral release in the skin7. Following development of
arthritis tachykinin levels are increased in primary af¬
ferents and DRG neurones innervating affected
joints21'41. SP is released in the dorsal horn in pol-
yarthritic rats and, when administered intrathecally,
elicits a behavioural response suggestive of pain38'39.
Infusion of SP into knee joints leads to increased
inflammation and joint destruction2'.
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CGRP is expressed in DRG neurones and is thought
to modulate the actions of SP. CGRP levels also in¬
crease in DRG and spinal dorsal horn after adjuvant
injection15,18'30'41. Intrathecal administration of CGRP
lowers nociceptive thresholds to mechanical stimuli
and enhances release of SP. Immunoneutralisation of
endogenous CGRP, either intrathecally or systemically,
attenuates hyperalgesia and inflammation in arthri¬
tis19'24. CGRP is also a potent vasodilator4'25 and may
contribute to the peripheral changes seen in neuro¬
genic inflammation both directly and by potentiating
SP-mediated increases in capillary permeability6.
A number of previous investigations have demon¬
strated increased DRG content of neuropeptides in
adjuvant-mediated polyarthritis, but their interpreta¬
tion is complicated by the severe and widespread sys¬
temic disease in these models35'36. We have recently
developed a rat model of mild adjuvant monoarthritis
with inflammation and arthritis confined to one joint
and no obvious systemic disturbance9'41. Using this
model, we found increased SP and CGRP content in
innervating DRG, but not in other ipsilateral or any
contralateral (unaffected) DRG, suggesting the peptide
content changes were specific for the affected joint.
However, the radioimmunoassay methods employed in
this and other studies are unable to distinguish whether
increased synthesis, decreased axonal transport and/or
peripheral release underlie the increase in DRG pep¬
tide levels. We have therefore examined expression of
mRNA encoding sensory neuropeptides in DRG in
monoarthritis. In addition we have examined DRG
expression of mRNA encoding vasoactive intestinal
peptide (VIP). VIP shows very low or absent expres¬
sion in DRG under basal conditions but its expression
is dramatically increased following axotomy, crush in¬
jury or even electrical activation3'15'31'29'1. As VIP is
known to modulate the actions of SP on the vascula¬
ture in neurogenic inflammation in skin16,we investi¬
gated its biosynthesis in experimental monoarthritis.
chronic inflammatory changes are seen after injection of Freund's
incomplete adjuvant41).
Synthesis of radiolabeled cRNA probes
Probes were transcribed in vitro from plasmid constucts contain¬
ing cDNAs encoding jSPPT (441 bp full-length cDNA cloned in
pGEM3;12), a-CGRP (450 bp fragment encoding the 3' untranslated
sequence cloned into pSP64;2) and VIP (350 bp EcoRI fragment in
pSP64). ^S-labelled cRNA antisense probes were transcribed in
vitro using SP6 polymerase (Gibco BRL, UK), [35-S]UTP (800
Ci/mmol, Amersham Int., UK) and unlabelled UTP to a specific
activity of 3-5 X 108Ci/mmol.
In situ hybridisation
Sections were postfixed in 4% paraformaldehyde in 0.1 M phos¬
phate buffered saline solution for 10 min and rinsed three times in
2XSSC. All solutions were treated with diethylpyrocarbonate
(0.02%). 35S-labelled cRNA probes were denatured by heating at
70°C and added to hybridisation mix (50% deionised formamide, 0.6
M NaCl, 10 mM Tris-Cl (pH 7.5), 0.02% Ficoll, 0.02% poly¬
vinylpyrrolidone, 0.1% BSA, 1 mM EDTA, 0.1 mg denatured salmon
sperm DNA, 0.05 mg/ml total yeast RNA, 0.05 mg/ml yeast tRNA,
10% dextran sulphate and 10 mM dithiothreitol) to give 10X
106counts/ml. Hybridisation mix (70 /ul) was added to each slide
which was then coverslipped and sealed with DPX. Hybridisation
was carried out overnight in sealed humid chambers at 50°C. After
hybridisation slides were soaked in 2 X SSC to remove coverslips,
rinsed in 2XSSC and treated with RNase A (30 /xg/ml) for 60 min
at 37°C. Washes consisted of 2XSSC at room temperature and
0.1 x SSC at 50°C for 60 min. Sections were then dehydrated in
graded ethanols in 0.3 M sodium acetate, air dried and dipped in K5
nuclear emulsion (Ilford, UK). Sections were exposed at 4°C for 2
weeks, developed and counterstained with haematoxylin and eosin.
Control sections were pretreated with RNase A (100 /ug/ml) for 60
min at 37°C prior to hybridisation. Expression of mRNA was esti¬
mated by counting silver grains overlying neuronal cell bodies of less
than 30 /xm diameter. For each animal, four representative cells in
each of three separate sections of each DRG were counted. Left L5
DRG from animals injected with FCA were compared to L5 DRG
from (i) the contralateral side and (ii) untreated controls. The
percentage of neurones expressing each mRNA in the various treat¬
ment groups was also estimated.
Statistics
Data were assessed by ANOVA followed by paired or unpaired
Student's /-tests, as appropriate. Significance was defined as P <
0.05. Values are means + S.E.M.
MATERIALS AND METHODS
Induction of arthritis
Monoarthritis was induced in male Wistar rats (200-250 g) by a
total intradermal injection of 0.15 ml Freund's Complete Adjuvant
(FCA; 1 mg/ml, Sigma) at two sites around the left tarsal joint,
under halothane anaesthesia, and the animals allowed to recover41.
The appearance and circumference of both ankle joints was recorded
at intervals to assess inflammation. At various times after FCA
injection, animals (n = 3-5 per time point) were killed by decapita¬
tion and both left and right L5 DRG (which innervate the tarsal joint
via the sensory component of the sciatic nerve) and the left L[ DRG
(non-sciatic distribution) were rapidly dissected, snap frozen and
stored at -80°C. Sections (10 /xm) were thaw-mounted on gelatin
and poly-L-lysine-coated slides and stored at -80°C. Control L5
DRG from untreated animals (n = 10) and animals treated with











Fig. 1. Expression of /3-PPT mRNA in left (arthritic) and right
(control) rat L5 DRG neurones during development of adjuvant
monoarthritis. Values are expressed as % control mean +S.E.M.
* P < 0.05 compared with control and right DRG.
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RESULTS
Injection of adjuvant resulted in the rapid induction
of unilateral inflammation (redness and swelling) within
24 h. This persisited for 4-5 days followed by some
resolution, until swelling recurred with signs of chronic
monoarthritis at 14 days. No changes in circumference
or appearance were observed in the contralateral limb,
other joints or in untreated animals. Animals were not
severely affected by the arthritis although they tended
to favour the affected limb.
In control L5 DRG PPT mRNA was expressed in
22 ± 1% of neurones. No change in the proportion of
neurones (diameter < 30yum) expressing PPT mRNA
was seen at either 8 h or 14 days (19 + 1%) after FCA
injection, in either left or right L5 DRG. Eight hours
after injection of FCA there was a significant increase
(81 ± 24% rise) in PPT mRNA expression per neurone
in L5 DRG innervating the injected joint, compared to
either the contralateral (uninjected) L5 DRG, non-in¬
nervating L, (94 + 6% of control Lx) DRG or controls
(Figs. 1 and 2A,C). The early induction of PPT mRNA
expression in innervating L5 DRG neurones resolved
at 24 h, but recurred by 48 h and persisted until
Fig. 2. Dark-field photomicrograph (magnification X 360) showing cells expressing /3-PPT mRNA in rat L5 DRG neurones. A: left (injected side)
DRG; 8 h after adjuvant injection. B: left (injected side) DRG; 14 days after adjuvant injection. C: right (contralalteral) DRG; 8 h after adjuvant
injection. D: right (contralateral) DRG; 14 days after adjuvant injection. Note increased density of silver grains (white) over injected side (left)




















Fig. 3. Expression of a-CGRP mRNA in left (arthritic) and right
(control) rat L5 DRG neurones against time after adjuvant injection.
Values are expressed as % control mean + S.E.M. * P< 0.05 com¬
pared with control and right DRG.
arthritis was evident at 14 days (Figs. 1 and 2B,D); at
no time was there any increased expression in the
ipsilateral L, or contralateral L5 DRG.
CGRP mRNA was expressed in 37 + 3% of control
DRG and there was no significant change in the pro¬
portion of L5 DRG cells expressing CGRP mRNA at
the time of onset of chronic arthritis (day 14; 36 ± 1%).
As with PPT, the expression of CGRP mRNA per
neurone was significantly increased (44 + 6% rise), 8 h
after FCA injection (Figs. 3 and 4A,C). CGRP mRNA
levels remained significantly elevated up to and includ¬
ing the time of development of chronic monoarthritis
(Figs. 3 and 4B,D). These changes were limited to
ipsilateral L5 DRG.
Fig. 4. Dark-field photomicrograph (magnification X360) showing cells expressing a-CGRP mRNA in rat L5 DRG neurones. A: left (injected
side) DRG; 8 h after adjuvant injection. B: left (injected side) DRG; 14 days after adjuvant injection. C: right (contralateral) DRG; 8 h after
adjuvant injection. D: right (contralateral) DRG; 14 days after adjuvant injection. Note increased density of silver grains (white) over injected
side (left) DRG neurones at both time points.
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Injection of paraffin oil (vehicle) caused no increase
no obvious inflammation and no change in either PPT
mRNA or CGRP mRNA expression, 8 h after injec¬
tion.
At no point during the development of monoarthri¬
tis was expression of VIP mRNA detected either in
innervating or contralateral L5 DRG.
DISCUSSION
These results demonstrate that within 8 h of unilat¬
eral injection of a low-dose of adjuvant around the
ankle joint there is marked induction of PPT and
CGRP mRNA expression in innervating L5 DRG neu¬
rones. This increase in mRNA expression is due di¬
rectly to the action of FCA as vehicle injection alone
produced no such change. The increased gene expres¬
sion in treated animals persists at least until chronic
monoarthritis is established (14 days), but no induction
of VIP mRNA expression is found.
Previous studies of neuropeptide gene expression in
DRG have shown induction of PPT mRNAs 4 days
after bilateral hindpaw injection of adjuvant28 and
within 3 h of unilateral noxious stimulation (formalin
injection) of the hindpaw34, although the latter largely
represented an increased proportion of DRG neurones
expressing PPT mRNA rather than any induction in
mRNA expression per neurone. Early (~ 16 h) induc¬
tion of CGRP mRNA has been shown11 in motor
neurones after axotomy (which causes decreased CGRP
mRNA expression in DRG;32). We now show rapid
(< 8 h) induction of PPT mRNA expression localised
to innervating DRG, without alteration in the propor¬
tion of expressing neurones. The discrepancy between
our findings and those of Noguchi et al.34 may relate to
the rather low proportion of neurones expressing PPT
mRNA in control DRG (~ 11%) in the previous study,
whereas we and others13 find ~ 20% of DRG neu¬
rones express PPT mRNA. Alternatively, the more
noxious formalin stimulus might recruit an additional
population of neurones to express PPT peptides. In
parallel with the early induction of PPT mRNA we
also found CGRP mRNA induction within 8 h; again
this represented an increase in expression per neurone
rather than any change in the proportion of neurones
expressing the a-CGRP gene. Our data on the propor¬
tion of neurones expressing a-CGRP agree closely
with previous studies32.
Increased neuropeptide gene expression was limited
to DRG innervating the affected joint, consistent with
our previous radioimmunoassay data41. These data do
not support recent suggestions that unilateral inflam¬
mation per se induces both gross and microscopic
contralateral inflammation of neurogenic origin17'22.
Furthermore, the increased SP- and CGRP-Iike im-
munoreactive content of innervating DRG that we
have previously demonstrated in monoarthritis41 is
likely to be due, in large part, to induction of biosyn¬
thesis of these neuropeptides, although alterations in
peptide degradation and/or axonal transport may also
occur.
Studies on the time course of articular primary
afferent activity during acute arthritis have shown an
early induction of resting discharge and response to
movement in group III and IV afferents and previously
quiescent fibres become responsive within 2-3 h37.
Thus electrophysiological evidence shows primary af¬
ferents become sensitized rapidly following injection of
adjuvant. We found PPT and CGRP gene induction in
innervating DRG within 8 h of adjuvant administra¬
tion. Given the substantial pre-existing pools of both
CGRP and PPT mRNAs in DRG it is likely that the
injection of adjuvant leads directly (i.e. via increased
sensory neuronal activity) to induction of expression of
the respective genes. It seems unlikely that the changes
in neuropeptide gene expression observed are medi¬
ated via humoral or other systemic factors secondary to
adjuvant injection as (i) the model used here is very
mild in comparison to many other polyarthritic models
and systemic illness is not a feature at any stage and (ii)
gene induction was limited to the innervating DRG.
This is suggestive of a causal relationship between the
mRNA changes and the inflammatory process. Expres¬
sion of both peptide mRNAs fell at 24 h, when inflam¬
mation is still marked, but thereafter remained ele¬
vated until 14 days, at which time histological evidence
of monoarthritis becomes manifest (ref. 9 and Donald¬
son et al., in preparation). Therefore the early changes
in PPT and CGRP gene expression cannot be at¬
tributable to arthritis, and are most probably associ¬
ated initially with the inflammation seen around the
joint within 24 h of injection, when histological evi¬
dence of inflammation is also seen (L. Donaldson et
al., unpublished observations).
VIP modulates the actions of SP on the vasculature
in cutaneous neurogenic inflammation15 and is thought
to be involved in the reorganisation or regeneration of
peripheral nerves as its expression is greatly increased
following axotomy33. We found little or no VIP mRNA
expression in control DRG neurones, confirming previ¬
ous data15'33. Furthermore, we did not find any induc¬
tion of VIP expression in innervating or contralateral
DRG at any stage following adjuvant injection. Thus,
although it has been suggested that electrical activity
per se induces VIP gene expression in some neurones',
since electrical activity increases in sensory afferents,
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and previously quiescent afferents are activated, during
arthritis10 it is unlikely that this is regulating VIP gene
expression in DRG neurones.
In conclusion, we show for the first time that the
response of SP and CGRP mRNAs to low dose adju¬
vant injection is rapid, marked, specific to the DRG
innervating the joint and maintained throughout the
development of monoarthritis. There is no evidence to
support the involvement of VIP in experimental
monoarthritis. It follows from the effects on SP and
CGRP mRNA shown here that peptide translation
may be increased equally rapidly and maintained
throughout the course of the disease, suggesting a role
for these peptides in the pathogenesis and mainte¬
nance of experimental inflammation and arthritis.
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Much evidence suggests an important role for the nervous system in the pathogenesis of peripheral inflammatory conditions
such as arthritis. The classical adjuvant-induced arthritis model in the rat is a severe condition in which polyarthritis is
accompanied by widespread systemic disease, complicating the interpretation of data. We have developed an adjuvant-induced
arthritis of the tibio-tarsal joint in the rat, using a low dose of Freund's adjuvant administered locally. Initial inflammation is
followed, after 14 days, by chronic monoarthritis which is maintained without generalised effects or loss of use of the limb until at
least 30 days postinjection. A higher dose of adjuvant produces contralateral inflammation and arthritis, but only after 14 days, and
without the complicating effects seen in classical adjuvant disease. Indirect measures of arthritis (joint circumference, inflammation
score and nociceptive threshold) correlate closely with the histological state of the joint, supporting the use of these indices. This
model can be easily exploited by alteration of adjuvant dose, to determine the roles of the nervous system in the pathogenesis,
maintenance and symmetrical spread of inflammatory arthritis.
Introduction
Studies of the cutaneous 'triple response' to
injury by Lewis (1942) originally demonstrated
the important role of the nervous system in the
pathogenesis of peripheral inflammation. Since
then much interest has focused on the mecha¬
nisms underlying such neurogenic inflammation,
generating a plethora of studies at anatomical,
biochemical, neurophysiological and, more re¬
cently, molecular biological levels.
One of the most frequently exploited models
of neurogenic inflammation is adjuvant-induced
Correspondence: Lucy F. Donaldson, University of Edinburgh,
Department of Medicine, Western General Hospital, Edin¬
burgh EH4 2XU, UK.
arthritis in the rat which involves severe pol¬
yarthritis of the tarsal, carpal, phalangeal and
spinal joints, accompanied by lesions to the eyes,
ears, nose, skin and genitals as well as anorexia
and profound weight loss (Pearson and Wood,
1959; Rainsford, 1982). Many studies have
demonstrated changes in peripheral and spinal
neuronal function and neurotransmitter concen¬
trations in this model (Kuraishi et ah, 1989; Ohno
et al., 1990; Guilbaud, 1991). However, the
widespread and severe disease induced makes it
difficult to attribute changes observed to the neu-
rogenic/arthritic processes per se. Moreover, the
disease process is erratic with a remitting and
relapsing course. Clearly, adaptations of this
model which limit disease severity would be of
interest not only to reduce animal discomfort but
also to demonstrate effects specific to arthritis.
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Unilateral injection of a low dose of adjuvant
into rat footpad has been used by other re¬
searchers to investigate changes in central
(Guilbaud et al., 1985; Hylden et al., 1989) and
peripheral sensory neuronal function (Bartho et
al., 1990) and spinal cord gene expression (Minami
et al., 1989) in response to peripheral inflamma¬
tion. However, since apparently small alterations
in the dose and route of administration of adju¬
vant appear to produce major differences in the
extent of the inflammation produced, we have
investigated the effect of increasing doses of
heat-killed Mycobacterium tuberculosis on inflam¬
mation and the histological appearance of the
joint in this model. The relationship between
indirect measures of inflammation, such as joint
swelling and nociceptive threshold, and the histo¬
logical appearance of the joint has also been
investigated to determine whether use of these
common indices is valid.
Materials and methods
Male Wistar rats (200-250 g) were allocated to
groups (n = 5/group). Animals, under halothane
anaesthesia, were injected subdermally with ei¬
ther paraffin oil vehicle or Freund's complete
adjuvant containing 50 /xg, 150 ixg or 250 /xg
attenuated M. tuberculosis (MAFF, UK) sus¬
pended in 0.05 ml of paraffin oil, divided between
two injection sites around the left tarsal joint.
Controls were untreated. Before induction of
arthritis and twice weekly thereafter, the animals
were weighed, their left and right tarsal joint
circumferences measured, and left tarsal joints
scored for inflammation and response to a mild
noxious stimulus. Nociceptive threshold was de¬
termined by the pressure required to elicit limb
withdrawal and was measured either subjectively
and scored 0-3 (0 = intense pressure, 3 = slight
pressure), or objectively using a pressure gauge
and scored 0-8 based on a meter reading (0 = very
slight pressure, 8 = intense pressure). Index of
inflammation, 0 = normal, 1 = mild redness, 2 =
moderate redness and swelling, 3 = severe swell¬
ing/lesions over the joint. All measurements were
performed blind to treatment by the same experi¬
enced operator.
Preliminary histological studies demonstrated
chronic monoarthritis 14 days after adjuvant in¬
jection. Therefore, 15 days after injection, ani¬
mals were deeply anaesthetised with sodium pen¬
tobarbitone (60 mg/kg i.p.) and perfused through
the descending aorta with heparinised saline (500
U/kg, 10 ml) followed by 10% formal saline
(— 50 ml) until the hind limbs were fixed. Both
hind limbs were removed and decalcified in
Gooding and Stewart's solution (15% formic acid,
5% formaldehyde in distilled water) for 2 weeks.
Tissues were blocked in gelatin and sections (20
/j,m) cut by cryostat, mounted and counterstained
with haematoxylin and eosin. Each section was
scored blind for the presence and degree of joint
inflammation, assessed on the following histologi¬
cal features; inflammatory cell infiltrate, synovial
proliferation, articular cartilage breakdown and
new bone formation and classified as: 0 = normal,
1 = subdermal inflammation, 2 = mild, 3 = mod¬
erate and 4 = severe joint inflammation; scores
^ 3 were taken as indicative of arthritis.
Statistical analysis of joint circumferences was
by ANOVA followed by post-hoc Dunnett's test.
Spearman's rank correlation coefficient was used
to determine correlations between the histologi¬
cal arthritis and gross measures of inflammation.
Values are means + SEM. Significance was set at
P < 0.05.
Results
During development of inflammation, animals
showed little or no apparent discomfort and loco¬
motor activity was near normal, with only occa¬
sional guarding of the affected limb. Only in the
group receiving the highest dose of M. tuberculo¬
sis (250 /Xg) was the left hind limb not used for
walking, and then only at 14 days postinjection.
The normal gain in weight was not affected by
any treatment (data not shown). Animals injected
with M. tuberculosis showed a dose-related in¬
crease in left (injected) joint circumference, red¬
ness and swelling, and histological inflammation
score. Injection of 50 /xg M. tuberculosis or paraf¬
fin oil alone caused slight, non-significant in¬














Fig. 1. Effect of dose of adjuvant injected around the left
tarsal joint on (A) left (ipsilateral) and (B) right (contralateral)
tarsal joint circumference (mm). * P < 0.01 compared with
circumference before injection, untreated and paraffin in¬
jected control groups (Dunnett's).
remained constant for 15 days. By contrast, injec¬
tion of 150 jag or 250 ixg M. tuberculosis caused
acute inflammation and significant swelling of the
left tarsal joint within 24 h, reaching an initial
peak 4 days postinjection (P < 0.01). This initial
swelling partially resolved at day 5 (although re¬
maining significantly swollen compared to con¬
trols), but increased again 14 days postinjection
(Fig. 1A).
Animals receiving the 250 /xg dose showed
redness and swelling of the contralateral tarsal
joint at 14 days postinjection (Fig. IB). Those
receiving 250 /xg also showed mild forepaw
swelling, nose and eye inflammation and visceral
lesions. Only animals injected with 250 ixg of M.
tuberculosis showed a statistically significant in¬
crease in contralateral (right) joint circumference
after 14 days (P < 0.01) (Fig. IB).
Animals receiving no treatment, paraffin, or 50
ix g M. tuberculosis showed no histological evi¬
dence of arthritis of the left tarsal joint, although
an inflammatory infiltrate in overlying subcuta¬
neous tissues was evident in the latter group.
Histological features of arthritis were seen in the
left tarsal joints of the animals receiving 150 and
250 ixg M. tuberculosis. Animals receiving 250 ixg
showed a significant arthritis of the contralateral
tarsal joint. There was a significant correlation
(Spearman rank correlation coefficient) between
the histological score and (i) the increase in joint
circumference (n = 37, r = 0.71, P < 0.0005) (Fig.
2A) and (ii) the inflammation score (n = 25,
r = 0.86, P < 0.0005) (Fig. 2B). The response
to a subjectively scored mild noxious stimulus
(squeeze) did not correlate significantly with joint
histology (n = 23, r = 0.36, P > 0.05; not shown),
whereas when this parameter was subsequently
assessed objectively, a highly significant correla¬
tion was seen (n = 30, r= -0.699, P < 0.0001)
(Fig. 2C).
Discussion
Most models of inflammatory arthritis involve
lesions in multiple joints, including spontaneous
arthritis in MRL/lpr mice, arthritis induced by
antigens (adjuvant, streptococcal cell wall, type-II
collagen) or by overproduction of tumour necro¬
sis factor in transgenic mice (Keffer et ah, 1991);
all tend to exhibit similar incidences, time courses
and immune reactions to the antigen involved
(Magilavy, 1990). Very few models of chronic
monoarthritis have been described; indeed the
validity of monoarthritic models has been ques¬
tioned since many human arthritides are noted
for their symmetry (Kozin et ah, 1976) which is a
diagnostic criterion for rheumatoid arthritis in
the United States (Mitchell and Fries, 1982).
Nevertheless, monoarthritic models have yielded
much useful data on mechanisms specific to the
arthritic/inflammatory process and its spread,
and clinical inflammation and arthritis may be
asymmetrical or confined to a single joint.
We now demonstrate a rat model of arthritis
in which the induction and, more particularly,
spread of arthritis is dependent on the dose of
adjuvant used; vehicle and sub-threshold doses of
adjuvant produce only minimal local inflamma¬
tion without arthritis, intermediate doses of adju¬
vant (150 fig M. tuberculosis) cause a rapid initial
local inflammatory response which is followed,
after 2 weeks, by histological evidence of chronic
monoarthritis, and higher doses (^250 /u.g M.
tuberculosis) result in much more widespread in¬
flammation. These increases in dose of M. tuber¬
culosis lead to localised initial inflammation fol¬
lowed by bilateral or more widespread arthritis by
14 days, suggesting that when unilateral neural
activation exceeds a 'threshold', contralateral
nerves are excited and may exert efferent as well
as afferent effects sufficient to induce inflamma¬
tory and destructive changes. This model might
be used to define the respective roles of neural
and immune systems in the development and
spread of inflammatory arthritis. Thus, use of the
higher (250 jug) dose will allow study of the role
of neuropeptide genes and their products in sym¬
metrically spreading disease, away from the site
of local immune stimulation. Similarly, the effects
of lesions (chemical, physical) or pharmacological
manipulation of peripheral nerves on the devel¬
opment and spread of arthritis can be investi¬
gated. The contribution of neurogenic inflamma¬
tion to the inflammatory state has been previ¬
ously investigated using total sympathectomy or
extensive surgical lesions (Levine et al., 1985,
1986), but our model has the advantage that more
specific lesions may be performed without com¬
promising the well-being of the animal, as inflam¬
mation and manipulations can be confined to a
single limb. We have previously demonstrated
that adjuvant injection (150 /j.g dose) causes very
early (8 h) and sustained increases in expression
of genes encoding specific sensory neuropeptides
in dorsal root ganglia innervating the affected
joint, but not the contralateral side, in this
monoarthritis (Donaldson et al., 1992). Further-
Fig. 2. Correlation curves (Spearman rank) for relationship
between histological score and (A) increase in joint circumfer¬
ence, (B) inflammation score and (C) pressure causing paw
withdrawal. (Several points are coincident.)
9
more, changes in the neurophysiology of primary
afferents (Guilbaud et ah, 1985), inflammatory
mediators and their effects on peripheral noci¬
ceptors (Grubb et ah, 1988), and neuropeptide
content of dorsal root ganglia (Hanesch et ah,
1992; Smith et ah, 1992) have been localised to
the affected side during both the initial inflam¬
mation and when chronic monoarthritis occurs.
Thus this model has produced data specific to the
pathogenesis and maintenance of the arthritic
state per se rather than more generalised inflam¬
mation.
In the assessment of chronic arthritis, limb or
joint swelling and/or response to noxious stimu¬
lus have been employed as indirect estimates of
disease state. However, the subjective nature of
these measures has been criticised (Rainsford,
1982). We now show that joint circumference,
indices of superficial inflammation and measure¬
ment of nociceptive threshold correlate closely
with the underlying arthritic histopathology, thus
validating their use.
In conclusion, we describe a model of adjuvant
arthritis which is easily manipulated to produce
either a monoarthritis or more extensive disease.
The severity of chronic arthritis is dose-depen¬
dent and higher doses of adjuvant cause dissemi¬
nation of disease, which then resembles an atten¬
uated form of the classical adjuvant polyarthritis
(Pearson and Wood, 1959). Ethically, this model
has the advantage of showing contralateral dis¬
ease spread without the more unpleasant effects
seen in classical adjuvant disease. The easy ma¬
nipulation of the arthritic state by alteration of
the injected dose of M. tuberculosis facilitates the
investigation of the pathogenesis of adjuvant-
mediated neurogenic inflammation and its spread.
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